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ABSTRACT 
 
Portal hypertension and Gastro-Oesophageal varices (GOV) can occur in early 
stage Primary Biliary Cirrhosis (PBC) and are associated with a poor prognosis. 
Screening with endoscopy however, is only recommended in advanced 
disease.  Transjugular-intrahepatic-portosystemic shunting (TIPS) is a life 
saving procedure in patients with decompensated portal hypertension. Serial 
TIPS patency checks using a venogram, in stable patients, offers a unique 
opportunity to sample portal venous blood, and in doing so to study the role of 
the human intestinal mucosa in bio-transforming essential nutrients. 
The aim of this work was to create a non invasive, inexpensive, externally 
validated screening tool to identify PBC patients with GOV and to use in-situ 
TIPS as a novel route of access to sample portal venous blood to define the 
exact site of bio-transformation of folates in humans. 
 A cross-sectional retrospective study of 330 PBC patients who underwent an 
OGD at Newcastle was used to create a predictive tool that was externally 
validated in PBC patients from Cambridge and Toronto. 48% of the Newcastle, 
31% of the Cambridge and 22% of the Toronto cohorts of PBC patients had 
GOV. 25% (95% CI 18–32%) of the Newcastle cohort had GOV diagnosed at 
an index variceal bleed. Of the others, 37% (95% CI 28–46%) bled after a 
median of 1.5 years (IQR 3.75). Transplant-free survival was significantly better 
in those without GOV vs. those with GOV (p <0.001), but similar in patients with 
GOV that bled and those that did not (p = 0.1). The NVP score (%Probability of 
GOV) = 1 / [1+exp ^ − (9.186 + 0.001 * alkaline phosphatase in IU − 
0.178*albumin in g/L − 0.015*platelet×109) was validated in external cohorts 
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(AUROC 0.86). Cost consequences analyses revealed the NVP score to be as 
accurate as, but more economical than using either OGD directly or other risk 
scores for screening.   
A prospective cross-over study of portal and peripheral venous labelled folate 
concentrations following oral dosing with physiological doses of stable-isotope-
labelled folic acid (FA) or 5-formyltetrahydrofolic acid (5-FTHF) in six subjects 
with a TIPS in situ was set up. At 15 minutes, a median 86% [range 60-88%] of 
labelled folate in the hepatic portal vein following a dose of FA was unmodified 
FA. In contrast, following a dose of 5-FTHF, only a median 3% [range 2-6%] of 
labelled folate in the portal vein was unmodified 5-FTHF; the rest being 
methylated to 5-MTHF, suggesting limited gut wall dihydrofolate reductase 
capacity and suggesting that the liver in humans, rather than the intestinal 
mucosa as previously thought, is the organ responsible for this process. 
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GENERAL INTRODUCTION 
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Chronic Liver Disease is the 5th largest cause of mortality in the UK. A large 
proportion of this mortality is attributable to the development of portal 
hypertension, a progressive complication of cirrhosis that causes life 
threatening complications such as bleeding from gastro-oesophageal varices 
(GOV), ascites and spontaneous bacterial peritonitis, hepatorenal syndrome 
and hepatic encephalopathy. Of these, the development of GOV is one of the 
most severe complications; bleeding from GOV associated with a mortality of 
around 20%. (N. Chalasani et al., 2003; Carbonell et al., 2004) Progressive liver 
disease ultimately results in decompensation and liver failure in cases where 
modifiable causal factors, such as alcohol, are not addressed adequately or 
when disease modifying interventions are ineffective. Identifying patients with 
chronic liver disease who are at risk of developing complications such as portal 
hypertension, end stage liver failure who would not respond to standard of care 
remains an area of intense research. Being able to address this challenge 
would result in improved outcomes by allowing early initiation of 
pharmacological therapy and where these fail, early consideration for liver 
transplantation leading to improved survival. 
Primary Biliary Cirrhosis (PBC) is a chronic liver disease of cholestatic aetiology 
which lends itself well to studying prediction models that aim to identify patients 
at risk of developing complications. Portal hypertension and GOV can develop 
early in PBC, independent of the presence of cirrhosis, (Nakanuma, 2003; Ali et 
al., 2011) and herald a poor prognosis. (Rydning et al., 1990; D.E.J. Jones et 
al., 2002b; Takeshita et al., 2003) Invasive screening of all PBC patients by 
means of Oesophageo – Gastro-duodenoscopy (OGD) is associated with risk, 
which is unnecessary in those who can be stratified as being unlikely to have 
GOV, in addition to being expensive. Current guidelines are unclear as to when 
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screening with an OGD should be initiated in early disease. A non invasive, cost 
effective, externally validated tool to predict the presence of GOV in patients 
with PBC, especially in early disease would have a beneficial impact outcome 
by allowing pharmacotherapy to be initiated to reduce the risk of bleeding. 
Finding such a tool remains a challenge and its creation would be an important 
development in the study of the evolution of portal hypertension in these 
patients. 
The liver plays an important role in the post absorptive metabolism of a number 
of macro and micronutrients as well as drugs and toxins. Accepted hypotheses 
about the bio availability and metabolic pathways of essential nutrients and 
vitamins in humans have often been derived using animal models or in vitro 
human cell culture studies. To study such pathways in humans would require 
portal venous blood sampling from human volunteers after the oral ingestion of 
the nutrient in question. Portal venous sampling, however, is only possible 
through trans-jugular or trans-hepatic routes which is invasive and associated 
with significant risk to the individual and therefore not ethically justifiable. 
Experimental animal models and in-vitro studies may not accurately replicate 
the human metabolic milieu and may not therefore reliably answer important yet 
basic questions about the exact site of biotransformation, exact bio availability 
or metabolic pathways of essential micro nutrients and vitamins in humans. 
In selected chronic liver disease patients who present with complications of 
portal hypertension such as bleeding from GOV not adequately treated with 
endotherapy or in those with refractory ascites, a transjugular intrahepatic stent 
shunt (TIPS) can be a life saving and quality of life improving procedure. A 
significant proportion of such patients have minimally progressive or non 
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progressive disease especially when the iterative aetiological factors (usually 
alcohol) have been adequately addressed. TIPS dysfunction secondary to stent 
occlusion remains a serious concern, especially in patients who have 
uncovered stent prosthesis. In an effort to detect occlusion early, most centres 
offering TIPS have follow up protocols that include regular TIPS patency checks 
as a part of the long term surveillance of such patients to ensure that clinical 
benefit is maintained. These patency checks can be undertaken by either an 
ultrasound doppler scan or a TIPS venogram. Following up well compensated 
patients with in-situ TIPS by means of a venogram offers a unique opportunity 
to access portal venous blood in humans and define metabolic pathways and 
the exact site of biotransformation of orally ingested tagged micronutrients or 
vitamins. Folic acid is one such vitamin where controversy about the exact site 
of biotransformation into bioactive folate metabolites is a hotly debated topic. 
Currently accepted wisdom, based on animal studies, is that the site of 
biotransformation is in the human small intestine. However, an increasing body 
of evidence suggests that the liver rather than the small intestine may be 
involved in the biotransformation of folic acid in humans.  Portal venous 
sampling in patients with in-situ TIPS who have ingested tagged stable folic acid 
offers an opportunity to study the exact site of biotransformation of this 
important vitamin in humans. 
This piece of work aims to rise up to the clinical challenge of predicting the 
presence of portal hypertension in patients with PBC and to utilise the 
opportunity presented at routine TIPS venography to answer important 
questions about the actual role of the human small intestine and liver in the 
metabolism of folic acid.  
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CHAPTER 1: NON INVASIVE PREDICTION OF PORTAL 
HYPERTENSION IN PBC 
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1.1 Introduction 
Current EASL and AASLD guidelines recommend screening with Oesophageo-
Gastro-Duodenoscopy (OGD) in advanced (Stage IV) disease although it is 
recognised that histology may underestimate disease severity and that the 
evidence regarding the selection of patients and timing of screening is 
contradictory especially in patients with early stage disease.  The default of 
indiscriminate screening is associated with increased cost and risk to patients. 
There is therefore a need to support the development of validated and more 
rational ways to stratify risk of developing GOV. Alternative triggers are 
therefore needed to decide when to screen for varices. These triggers should 
ideally be independent of histology in PBC as a liver biopsy is no longer needed 
to make the diagnosis. Several non-invasive tools based on laboratory 
parameters alone, or in combination with imaging, help identify patients with 
PBC and GOV appropriate for OGD screening. However, they have not been 
comprehensively validated outside the derivation cohort. It is also not clear if 
such approaches are cost effective. 
1.1.1 Portal Hypertension 
Portal hypertension can occur in the presence or absence of chronic liver 
disease. When it occurs in the setting of chronic liver disease, portal 
hypertension is usually associated with poor outcomes and is a poor prognostic 
marker in these patients. The most significant endpoints in the natural history of 
portal hypertension are the development of and bleeding from Gastro 
Oesophageal Varices (GOV), the occurrence of hepatic encephalopathy and 
the occurrence of hepatorenal syndrome. Understanding the development of 
portal hypertension requires an understanding of hepatic blood flow and portal 
vascular anatomy and the pathophysiological changes that occur with the 
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advent and progression of liver cirrhosis. Diagnostic modalities including non 
invasive and invasive techniques allow risk stratification and the initiation of 
prophylactic therapies which can reduce the risk of life threatening events and 
improve outcomes. 
Hepatic blood flow and portal vascular anatomy 
The liver is a highly vascular organ and receives about a quarter of the cardiac 
output per minute. About 2/3rd of the blood supplied to the liver is via the portal 
vein and the remainder via the hepatic artery. The portal vein receives blood 
from the splanchnic organs, omentum and the spleen and is formed by the 
confluence of the splenic vein and the superior mesenteric vein behind the neck 
of the pancreas. The liver therefore receives blood from the entire alimentary 
tract. The portal vein and the hepatic artery enter the liver at the porta hepatis 
which also serves as the exit portal for bile ducts and lymphatics. After repeated 
branching in the liver, terminal portal venules and hepatic arterioles supply 
hepatic sinusoids to form metabolic micro-hubs in the liver. Blood from the 
sinusoidal and inter sinusoidal spaces is collected by terminal hepatic or central 
venules which empty into larger hepatic veins and these finally empty into the 
inferior vena cava. The direction of blood flow in the portal vein in normal 
circumstances is towards the liver. When portal pressure increases low 
pressure collaterals located in anatomical areas of extra-hepatic portosystemic 
venular communication open up leading to the formation of varices. The 
anatomical sites of varix formation include the confluence of the oesophageal 
branches of the left gastric vein and the oesophageal veins, the superior rectal 
vein and the middle and inferior rectal veins, para umbilical veins and the 
superficial abdominal wall veins, retroperitoneal veins and some colonic veins, 
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the bare area of the liver and finally (and rarely) the ductus venosus between 
the left hepatic vein and the inferior vena cava. 
Definition of portal hypertension 
The term portal hypertension was first coined by Gilbert and Carnot in 1902. 
(Sandblom, 1993) The hepatic venous pressure gradient (HVPG) in the portal 
vein is normally between 1-5 mmHg. Any increase in this pressure is termed 
portal hypertension. Clinically significant portal hypertension leading to the 
development of GOV, however, usually occurs when the portal pressure is ≥10-
12 mmHg. (Garcia-Tsao et al., 1985; Groszmann et al., 2005) Depending on the 
cause of portal hypertension and the site of the pathological obstruction, portal 
hypertension may be classified (Table 1) as being pre-sinusoidal, sinusoidal or 
post- sinusoidal in origin. 
Table 1: Classification and causes of portal hypertension  
 
Type of Portal Hypertension 
 
Causes 
Pre sinusoidal 
Pre Hepatic 
Portal vein thrombosis, Splenic vein thrombosis (Left 
sided portal hypertension), Idiopathic tropical 
splenomegaly 
Hepatic 
Schistosomiasis, Nodular Regenerative Hyperplasia, 
Tuberculosis, Sarcoidosis, Amyloidosis, Polycystic 
liver disease, Infiltrative diseases such as 
myeloproliferative disorders and certain glycogen 
storage diseases 
Sinusoidal Hepatic 
Liver cirrhosis, Alcoholic hepatitis, Acute viral 
hepatitis, Acute fatty liver of pregnancy 
Post sinusoidal 
Hepatic Veno-occlusive liver disease 
Post Hepatic 
Budd Chiari Syndrome, Increased right sided 
cardiac pressure, Severe pulmonary hypertension 
and Infiltrating malignant diseases of the inferior 
vena cava and or hepatic veins 
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Measurement of portal pressure 
Portal venous pressure measurements were first reported by Thompson in 1937 
during laparotomy. (Sandblom, 1993) Direct measurement of portal venous 
pressure through transjugular or trans-hepatic portal venous catheterisation is 
possible but associated with significant risks and therefore not performed 
routinely. (Juan Rodes et al., 2007a) Indirect measurement of portal venous 
pressure can be carried out by measuring the pressure in the hepatic vein after 
wedging it, either by inflating a balloon or by advancing the tip of the catheter 
into a small branch of the hepatic vein, the former being the preferred method. 
This yields the Wedged Hepatic Venous Pressure (WHVP) which represents 
the pressure in the column of blood between the hepatic sinusoids and the 
wedge which represents the hepatic sinusoidal pressure. In the absence of liver 
pathology, this is lower than the portal pressure due to the equilibrating effect of 
inter sinusoidal communications. (Kumar et al., 2008) In cirrhosis, where the 
normal architecture of the liver is distorted, these connections are lost and in 
such cases, WHVP correlates with portal pressure. (Lin et al., 1989; Escorsell et 
al., 1999; Thalheimer et al., 2005) The portal pressure is most accurately 
expressed, however, as the Hepatic Venous Pressure Gradient (HVPG), which 
is the difference between the WHVP and the free hepatic venous pressure 
(FHVP). This is because measuring the HVPG eliminates any effects of raised 
intra abdominal pressure on the WHVP and the FHVP, as can be observed in 
ascites or after large volume paracentesis, resulting in erroneous results. (Juan 
Rodes et al., 2007a) A schematic showing the measurement of the HVPG using 
a balloon to act as a wedge using a radiologically guided pressure transducer 
and an example of the pressure tracing obtained whilst measuring HVPG is 
shown in Figure 1. 
10 
 
Figure 1: Measurement of HVPG 
 
C 
 
Figure 1A and 1B are schematic diagrams showing the use of a radiologically 
guided pressure transducer in the measurement of FHVP and WHVP in health 
and in sinusoidal disease respectively. Figure 1C shows a pressure transducer 
tracing from a typical balloon catheter. Abbreviations: IVC,Inferior Vena Cava; 
PVP, Portal Venous Pressure; WHVP, Wedged Hepatic Venous Pressure; 
HVPG, Hepatic Venous Pressure Gradient; FHVP, Free Hepatic Venous 
Pressure (Figure adapted from Parikh S. Dig Dis Sci 2009; 54: 1178–1183) 
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The measurement and recording of the WHVP, FHVP and the HVPG can help 
classify the cause of portal hypertension as pre-sinusoidal, sinusoidal or post 
sinusoidal (Figure 2). This classification is useful in pointing to the aetiology of 
portal hypertension and in doing so allowing appropriate management to be 
initiated. 
Figure 2: Identifying the site of portal hypertension using portal pressure 
studies 
 
Using free hepatic venous pressure (FHVP), wedged hepatic venous pressure 
(WHVP) and the hepatic venous pressure gradient measurements (HVPG) to 
identify the nature of pathology causing portal hypertension. (A) Pre-sinusoidal 
hypertension where FHVP and WHVP are not raised but HVPG is raised (B) 
Sinusoidal hypertension where WHVP is increased but not FHVP and (C) Post 
Sinusoidal hypertension where both FHVP and WHVP are raised.  
12 
 
1.1.2 Pathogenesis of portal hypertension 
The pressure in any vascular bed depends on its vascular resistance and the 
volume of blood flowing through it. In the context of hepatic portal circulation 
therefore, portal pressure is a product of the vascular resistance of the hepatic 
vascular bed and the volume of splanchnic blood received by it. Increased 
vascular resistance or increased blood flow or a combination of both factors (as 
is commonly encountered clinically) results in portal hypertension. Whereas the 
cause for pre sinusoidal and post sinusoidal portal hypertension is 
predominantly increased vascular resistance due to true pre or post sinusoidal 
anatomical obstruction to the flow of portal venous blood, the cause for cirrhotic 
(sinusoidal) portal hypertension is far more complex and includes both a 
mechanical structural component and a dynamic vasoactive component. 
Cirrhosis of the liver is a condition in which the liver undergoes architectural 
distortion due to the formation of nodules as a result of fibrosis. Nodular 
regeneration and vascular changes are associated with but not required to 
make the diagnosis of cirrhosis. The process of fibrosis is driven by iterative 
injury and ultimately leads to cirrhosis. When the aetiology causing the iterative 
injury is addressed by treatment (for example successful treatment of viral 
hepatitis or iron overload in haemachromatosis) or in the case of alcohol, by 
abstinence, there is increasing evidence that the fibrosis might regress. (J. 
Rodes et al., 2007b) The Child Pugh Turcotte Score and the Child Pugh Grade 
(Table 2) were initially used to stage the severity of liver disease in patients with 
cirrhosis. The Chid Pugh system, though useful, includes parameters that 
depend on clinical judgment of severity and hence include subjective 
components. The Model for End Stage Liver Disease (MELD) and the UK End 
Stage Liver Disease (UKELD) scores are regression based mathematical tools 
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that use lab parameters to predict outcome thereby eliminating subjectivity in 
staging and prognostic risk stratification. The MELD and UKELD are 
preferentially used to stage severity of liver disease especially with regards to 
prioritising liver transplantation listing. In addition to predicting outcome, in most 
cases, advancing scores correlate well with an increased risk of developing 
portal hypertension and GOV.  
Table 2: Child Pugh Scoring and Grade to stage liver cirrhosis 
 1 2 3 
Ascites None Mild Moderate to Severe 
Hepatic 
Encephalopathy 
None 
Grade I-II  
(or suppressed with 
medications 
Grade III-IV 
(refractory) 
Bilirubin (μmol/L) <34 34-50 >50 
Albumin (g/L) >35 28-35 <28 
INR <1.7 1.7-2.3 >2.3 
Child Pugh Grade = Sum of individual scores (Survival at 24 months): A = 5-6 points 
(85%); B = 7-9 points (57%); C= 10-15 points (35%) 
 
Structural distortion 
As mentioned above, the pathogenesis of portal hypertension in cirrhosis is a 
combination of increased vascular resistance and increased portal blood flow. 
The increased vascular resistance occurs as a result of both mechanical 
changes in hepatic vascular anatomy and a dynamic component that causes 
increased vascular tone. The mechanical component in cirrhosis is caused due 
to the distortion of the normal vascular architecture of the liver by progressive 
fibrosis and regenerative micro nodule formation leading to sinusoidal 
obliteration and increased anatomical vascular resistance. 
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Vasoactive mediators 
 A separate dynamic component (Shibayama and Nakata, 1985) contributing up 
to 30% of the pressure in cirrhotic portal hypertension (Bhathal and Grossman, 
1985) has been identified and is an ideal target for therapeutic interventions in 
portal hypertension. This “dynamic” component is caused by increase in hepatic 
vascular tone which is caused due to a disruption of the balance between 
vasodilator and vasoconstrictor substances in the portal circulation that are 
responsible for maintaining normal hepatic perfusion in health. Important 
vasoactive mediators involved in the pathogenesis of portal hypertension are 
shown in Table 3. (Maruyama and Yokosuka, 2012)  
Table 3: Vasoactive mediators involved in maintaining normal hepatic perfusion 
in health and in the development of portal hypertension in cirrhosis 
Vasodilators Vasoconstrictors 
Nitric Oxide Endothelin 
Carbon Monoxide Angiotensin II 
Glucagon Nor epinephrine 
Endocannabinoid Vasopressin 
Prostaglandins  
 
Nitric Oxide  
Amongst the various vasoactive mediators, Nitric oxide (NO) appears to be the 
most important mediator of portal hypertension. A powerful vasodilator, NO is 
produced from the amino acid L-arginine by endothelial NO synthase (eNOS). 
In rats, NO inhibition increases portal pressures and increases markedly the 
hepatic response to epinephrine. (Wiest and Groszmann, 1999) In cirrhosis 
hepatic NO induced vasorelaxation is impaired due to insufficient hepatic NO 
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production. (Gupta et al., 1998) This occurs despite normal expression of eNOS 
mRNA and normal levels of eNOS protein. Though the exact mechanism of 
reduction in NO production in cirrhosis is unclear, the decreased activity of 
hepatic eNOS may in part be due to increased expression of caveolin, as Akt (a 
serine threonine kinase)-induced phosphorylation of eNOS reverses inhibitory 
conformation of eNOS in association with caveolin-1. (Garcia-Cardena et al., 
1997; Maruyama and Yokosuka, 2012) This reduction in hepatic NO results in 
increased portal pressure through its direct effect on the vascular endothelium 
and also, to a degree its effect on the hepatic stellate cell (HSC). Under normal 
physiologic conditions, NO exerts paracrine effects on HSCs. However, in 
cirrhosis, when NO generation is impaired, along with concomitant HSC 
activation and changes in sinusoidal structure, portal pressures can increase 
significantly resulting in portal hypertension. (Langer et al., 2008) Not only is the 
intrahepatic NO production reduced in cirrhosis, there is also an increase in 
extrahepatic NO production resulting in splanchnic vasodilatation. (Pizcueta et 
al., 1992; Wiest and Groszmann, 1999) The increase in extrahepatic splanchnic 
NO production seen in cirrhosis is caused by increased expression and activity 
of splanchnic eNOS due to a combination of the effects of shear stress, the 
increase circulating vasoactive factors (e.g., endothelin, angiotensin II, 
vasopressin, and norepinephrine) and an over expression of the angiogenic 
factor vascular endothelial cell growth factor (VEGF). (Maruyama and 
Yokosuka, 2012) The increased intra hepatic resistance is unable to cope with 
increased portal venous blood flow brought about by splanchnic vasodilatation 
resulting in portal hypertension.  
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Carbon Monoxide 
Another important but less potent vasoactive mediator is carbon monoxide 
(CO). CO is a product of haeme group oxidation by haeme oxygenases. It is a 
smooth muscle relaxant. In cirrhosis its production in the liver is reduced leading 
to vasoconstriction whilst at the same time systemic production is increased 
causing increased cardiac output and a hyperdynamic circulation. (Tarquini et 
al., 2009; Maruyama and Yokosuka, 2012) 
Glucagon 
Glucagon is a humoral vasodilator which works by relaxing vascular smooth 
muscle by decreasing its sensitivity to endogenous vasoconstrictors, such as 
nor epinephrine, angiotensin II and vasopressin. (Wiest et al., 2001) Increased 
circulating insulin and glucagon levels are commonly observed in patients with 
cirrhosis as well as in animal models of portal hypertension. (Gomis et al., 1994) 
The role of glucagon in causing splanchnic hyperaemia provides a rationale for 
the use of somatostatin and its synthetic analogs in the treatment of portal 
hypertension. (Maruyama and Yokosuka, 2012)  
Endocannabinoids, Prostacyclins and other mediators 
The endogenous cannabinoid anandamide and activation of vascular 
cannabinoid CB1 receptors have been implicated in the development of portal 
hypertension in endotoxaemic cirrhotic patients. (Batkai et al., 2001) 
Prostacyclins and COX derived prostanoids including Thromboxane A2 play an 
important role in modifying the vascular response of the cirrhotic liver to 
vasoactive agents suggesting a role in the development of portal hypertension. 
(Graupera et al., 2003) Endothelins (ETs) are a family of homologous 21 amino 
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acid peptides which include the peptides ET-1, -2, -3, and -4. They exert various 
biological effects and cause vasoconstriction and stimulate cell proliferation. 
Plasma levels of ET-1 and ET-3 are increased in cirrhotic patients. (Moller et al., 
1995) The actual mechanism by which ETs modulate vascular tone in cirrhosis 
is unclear. (Maruyama and Yokosuka, 2012) In addition to these factors, 
angiotensin II, epinephrine, vasoactive endothelial growth factor (VEGF) and 
endothelial dysfunction have additional roles in the development and 
propagation of portal hypertension. Neo-angiogenesis occurs through a VEGF 
mediated pathway leading to the formation of portosystemic collaterals. These 
collaterals further perpetuate portal hypertension by maintaining increased 
portal pressures and increasing splanchnic vasodilatation. (Fernandez et al., 
2005) A schematic representation of the role of various factors involved in the 
pathogenesis of portal hypertension in cirrhosis is shown in Figure 3. 
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Figure 3: Schematic representation of factors involved in the pathogenesis of 
portal hypertension in cirrhosis
 
 
 
Vasoactive plasticity of the portal vein  
Vasoactive plasticity of the portal vein may be involved in the development of 
portal hypertension. When contractile responses were studied in isolated tubal 
segments of branches of the rat portal vein and hepatic artery, portal vein 
branches were approximately three times more sensitive to nor epinephrine 
than hepatic arteries. Vasopressin effectively contracted hepatic arteries, 
whereas it had no effect on portal veins. Both vessel types responded to 
prostaglandin F2 alpha with contractions although the effect was less potent 
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than the other vasoactive agents. (Hogestatt et al., 1986) This suggests that the 
portal vein in addition to the hepatic artery and the intrahepatic sinusoidal bed 
through the presence of vasoactive receptors is involved in the development of 
portal hypertension and in maintaining normal portal flow in health. 
Catecholamine modulation of the intrinsic rhythmical contractions of the portal 
vein are complemented by SP, released from intramural nerves, and vasoactive 
intestinal polypeptide (VIP), released from adventitial nerves, which extend into 
the circular and longitudinal muscle layers of the portal vein. (Barja and 
Mathison, 1982) 
1.1.3 GOV – a significant complication of portal hypertension 
Complications of portal hypertension include the development of portosystemic 
collaterals, ascites and hepatic encephalopathy. Clinically the most significant 
site of portosystemic collateral formation is at the distal oesophagus and 
proximal stomach resulting in the formation of GOV. Other important but 
clinically less relevant sites of portosystemic collateral formation include the 
rectum, where the systemic inferior mesenteric vein communicates with the 
internal pudendal vein resulting in the formation of rectal varices; the umbilicus, 
where the vestigial umbilical vein communicates with the left portal vein and 
gives rise to prominent collaterals externally visible around the umbilicus 
resulting in the caput medusae appearance and; the retroperitoneum, where 
collaterals, especially in women, communicate between ovarian vessels and 
iliac veins. Prevalence of GOV in cirrhosis is high and almost half of all patients 
with cirrhosis have GOV. (Garcia-Tsao et al., 2007) Prevalence increases with 
liver disease severity and ranges from 40% in patients with Child Pugh A 
cirrhosis to 80% in those with Child Pugh C disease. Cirrhotic patients develop 
varices at the rate of 8% per year (Groszmann et al., 2005) with a similar rate of 
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increase in size from small varices to large varices per year. The risk of 
bleeding from GOV ranges from 5-15%. This risk is directly proportional to the 
HVPG. Mortality form GOV bleeding is high and approaches 20% at 6 weeks. 
[reviewed by (Garcia-Tsao et al., 2007)]  
1.1.4 Diagnosis of Gastro-Oesophageal Varices 
The gold standard test for the diagnosis of GOV is Oesophageo Gastro 
Duodenoscopy (OGD). This involves the use of a flexible fibre-optic endoscope 
to visualize the upper gastrointestinal lumen and look for bluish tinged mucosal 
elevations in the upper GI tract. Oesophageal varices are seen in columns in 
the lower oesophagus whilst gastric varices are classically seen as a “bunch of 
grapes” in the fundus (Figure 4). The former are further classified as small (<5 
mm) or large (>5mm) depending on their size or small (just visible varices), 
medium (occupying < 1/3rd of the oesophageal lumen) or large (occupying 
>1/3rd of the oesophageal lumen) depending on how much of the oesophageal 
lumen is compromised by their presence. (The Northern Italian Endoscopic 
Club for the study and treatment of Esophageal Varices, 1988) The 
management of medium and large varices is identical and therefore current 
AASLD guidelines recommend that the 2 stage classification be used. (Garcia-
Tsao et al., 2007) Gastric varices are classified by location, which correlates 
with their risk of haemorrhage. Varices in direct continuity with the oesophagus 
along the lesser and greater curves of the stomach are called gastro 
oesophageal varices (GOV) types 1 and 2 respectively. Isolated gastric varices 
in the fundus (IGV1) occur less frequently than GOVs (10% versus 90%) but 
are most likely to bleed. (Toubia and Sanyal, 2008) On endoscopy, blood 
spurting from a varix confirms a bleed. However, in 40% of cases GOV bleeding 
settles spontaneously, and therefore stigmata of recent haemorrhage which 
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include red wale marks (longitudinal red streaks on varices that resemble red 
corduroy wales), cherry red spots, haematocystic spots (raised discrete red 
spots on the surface of varices that appear as blood blisters) and white nipple 
spots indicating a fibrin /platelet plug are sought at endoscopy where recent 
bleeding from GOV is suspected (Figure 4).  
Figure 4: Endoscopic views of Gastro Oesophageal Varices (GOV) 
 
A) Oesophageal varices which appear as columns of elevated oesophageal 
mucosa with a bluish hue with stigmata of recent haemorrhage which in this 
case is a red spot at the 3’O Clock and 4’O Clock position and B) Gastric 
varices seen in the fundus as a lobular / bunch of grape like mucosal elevations 
on retroflexion (Figure used under the commons open licence – author Samir) 
Given the high mortality associated with a bleed and the possibility of primary 
prophylaxis using betablockers in reducing this risk, both EASL and AASLD 
guidelines recommend endoscopic screening in all patients with cirrhosis. 
However, endoscopy is an invasive procedure accompanied by a risk of 
complications including bleeding and perforation. It is also not preferred by 
patients due to the perceived discomfort caused during intubation and gastric 
insufflation. A large proportion of patients with early stage cirrhosis undergoing 
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screening will not have varices. All of these factors have led to a number of 
studies that aim to develop or find non invasive markers or tests which would 
help predict the risk for having GOV and focus endoscopic screening in patients 
in whom the yield would be high or avoid it completely. 
1.1.5 Non Invasive Prediction of GOV 
Non invasive methods previously studied to predict GOV have included the use 
of  lab based parameters such as the platelet count either on its own or in 
combination with known complications of cirrhosis such as splenomegaly 
(Giannini et al., 2003), increased liver stiffness as demonstrated by transient 
elastography (Vizzutti et al., 2007), presence of imaging signs of portal 
hypertension such as multidetector CT scanning (Perri et al., 2008) and / or 
increased spleen stiffness measured by transient elastography (Colecchia et al., 
2012) or MR elastography. (Jayant A. Talwalkar et al., 2009) An example of a 
composite predictive score is the liver stiffness, spleen size and platelet count 
(LSPS) score. (Berzigotti et al., 2013) Though most show promise in derivation 
cohorts, none have been universally validated in large cohorts of cirrhotic 
patients and indeed some have found to be lacking in discriminating power 
when validated independently. (Riggio et al., 2002; Burton et al., 2007; Kemp 
and Roberts, 2009; Schwarzenberger et al., 2010) Due consideration should 
also been given to the fact that the aetiology of chronic liver disease in 
predictive modelling cohorts have typically under represented cholestatic liver 
disease, focusing more on alcohol and viral hepatitis (in particular hepatitis C). 
This limits the universal applicability of these predictive tools and highlights the 
need for further better validated and inexpensive tools to be developed 
especially in chronic cholestatic diseases such as PBC and PSC.
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1.1.6 Medical Management of Gastro-Oesophageal Varices 
Reducing portal pressure during the evolution of cirrhosis or maintaining it at 
thresholds below clinical significant levels would reduce the risk of developing 
GOV and this would be the ideal management of cirrhotic patients. Though 
theoretically attractive, there is currently no effective therapy for the prevention 
of varices in patients with cirrhosis and portal hypertension. Identifying patients 
with a high risk of bleeding from GOV and attempting to reduce the risk of 
bleeding by reducing portal pressure has been shown to be effective and is 
discussed below. Reducing the risk of bleeding relies on successfully reducing 
the HVPG either non-invasively by pharmacotherapy or by endotherapy when 
pharmacotherapy is not tolerated. Porto-systemic shunting is not recommended 
in the prophylactic setting. When bleeding does occur, vasopressin analogues 
such as Terlipressin, nitrates, somatostatin analogues and antibiotics are used 
to reduce portal pressure in the acute setting in combination with endotherapy 
to achieve haemostasis. Porto-systemic shunting, in this setting, is effective and 
can be a life saving measure as rescue therapy when endotherapy fails. 
Beta blockers 
Both selective and non selective beta blockers can reduce portal pressure. The 
latter are more potent because NSBBs cause vasoconstriction of the splanchnic 
circulation by β2-receptor inhibition whilst also decreasing cardiac output by β1-
receptor blockade. This results in unopposed alpha-1 activity, leads to a 
decrease in portal venous inflow, and thereby lowers portal pressure. (Westaby 
et al., 1984) Other effects of beta blocker therapy include the reduction of 
azygos blood flow and a decrease in bacterial translocation from the gut, both of 
which may play a role in the prevention of variceal haemorrhage. (Biecker, 
2013) Studies have shown that reducing the portal pressure to below 12mm Hg 
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or by at least 20% of baseline results in a significantly reduced risk of bleeding 
from varices and indeed this reduction has been associated with improved 
outcomes. (Groszmann et al., 1990; Feu et al., 1995; Casado et al., 1998) 
Meta-analyses suggest the reduction in risk of bleeding from GOV with NSBBs 
is about 40%. (Hayes et al., 1990; Bernard et al., 1997) Though Propranolol, 
Nadolol and Timolol have all been shown to successfully reduce portal 
pressure, more recently, Carvedilol with its mild intrinsic anti-α (1)-adrenergic 
activity has been shown to be more effective than conventionally used NSBBs. 
(Reiberger et al., 2012; Aguilar-Olivos et al., 2014)   
Timolol was unable to reduce the risk of developing varices in patients with 
cirrhosis and portal hypertension (Groszmann et al., 2005) and therefore NSBB 
use for prevention of GOV development is not recommended. (Ge and Runyon, 
2014) Though one trial suggested Nadolol prevented the growth of small 
oesophageal varices with a small increase in adverse events (Merkel et al., 
2004) there is insufficient evidence to recommend the use of NSBBs in patients 
with small varices, who have not bled and who do not have clinical risk factors 
associated with a high risk of bleeding.  In patients with small varices and Child 
Pugh B or C cirrhosis and / or stigmata of haemorrhage at endoscopy the 
benefits of NSBBs outweigh the risks and therefore they should be prescribed 
to reduce the risk of bleeding. All patients with medium to large varices however 
should receive prophylaxis with NSBBs. 
Not all patients receiving beta blockers respond with a reduction of the HVPG. 
(Turnes et al., 2006) A reduction in the resting heart rate by 25% of baseline, 
but not less than 55, is clinically predictive of efficacy of betablocker therapy in 
reducing portal pressures to desired levels. However, only a third of patients 
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manage to achieve this endpoint and about 20% of patients do not tolerate 
NSBBs. (Toubia and Sanyal, 2008)  In addition, beta-blocker therapy can result 
in both cardiac as well as non-cardiac adverse effects. The decrease in cardiac 
output from β-1 antagonism may cause major cardiac side effects such as 
worsening or induction of heart failure especially in patients with 
cardiomyopathy which can occur in cirrhosis and negative chronotopy. (Ge and 
Runyon, 2014) Non cardiac side effects include bronchospasm and reduced 
effort tolerance, exacerbation of peripheral arterial disease, poor recovery from 
insulin induced hypoglycaemia in diabetics, depression, fatigue, and sexual 
dysfunction. (Ge and Runyon, 2014)  
There is emerging evidence which suggests that NSBBs may only be effective 
within a “therapeutic window” in the natural progression of cirrhotic liver 
disease. (Krag et al., 2012) In advanced cirrhosis, in response to effective 
hypovolaemia, peripheral vasodilatation and arterial hypotension, a number of 
circulatory changes occur, including the up-regulation of the sympathetic 
nervous system and of the renin-angiotensin-aldosterone system which along 
with the development of sodium and water retention and the formation of 
ascites, are aimed at maintaining adequate cardiac output and organ perfusion. 
With progression of cirrhosis, this compensatory ability is lost and the 
maintenance of blood pressure and cardiac output is important in prolonging 
overall survival. Median survival was significantly lower in patients with cirrhosis 
and refractory ascites treated with propranolol (5 months, with 19% probability 
of survival at 1 year), as compared to the median survival in patients who were 
not treated with propranolol (20 months, with 64% probability of survival at 1 
year) (p<0.0001). (Sersté et al., 2010) Based on this data, NSBBs should not be 
prescribed to patients with advanced cirrhosis with refractory ascites and should 
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be used with caution in patients with cirrhosis at any stage with hypotension. 
(Ge and Runyon, 2014) 
Nitrates and other agents 
Nitrates cause splanchnic vasodilatation and can reduce portal pressure. 
However, they are non selective, and also cause systemic vasodilatation and 
hypotension. Their use in combination with betablockers has been shown to be 
associated with significant adverse effects without demonstrating a significant 
benefit when compared to using NSBBs alone. (Garcia-Pagan et al., 2003) 
Statins, beyond their cholesterol lowering actions, have been shown to increase 
NO bioavailability, modulate HSC contractile functions, inhibit both ET-1 
expression and release and have antioxidant/anti-inflammatory properties all of 
which play a role in reducing portal pressure. (Ramarez et al., 2012) In one 
study, Simvastatin significantly decreased HVPG (-8.3%) without affecting 
systemic haemodynamic effects and appear to be promising. (Juan G. Abraldes 
et al., 2009) Further randomised studies are needed to confirm these effects 
prior to their routine use in the management of portal hypertension. 
1.1.7 Endoscopic management of Gastro oesophageal varices 
Endoscopic therapy in the form of sclerotherapy or band ligation has been 
explored as an alternative to pharmacotherapy as primary prophylaxis against 
bleeding from GOV. In one study, endoscopic sclerotherapy, which involves the 
injection of a sclerosant such as ethanolamine into varices, was found to be 
associated with increased mortality. (The Veterans Affairs Cooperative Variceal 
Sclerotherapy Group, 1991) Endoscopic band ligation has been shown to 
significantly reduce the risk of variceal bleeding when compared to no treatment 
(Shiv K. Sarin et al., 1996; Lay et al., 1997) or propranolol. (S. K. Sarin et al., 
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1999; Imperiale and Chalasani, 2001) However, band ligation has not been 
shown to be associated with improved survival when compared with NSBBs 
and therefore its role in prophylaxis is limited to patients who express a 
preference for banding due to NSBB intolerance or those in whom NSBBs are 
contraindicated. Combined therapy with betablockers and band ligation has not 
been shown to be superior to treatment with betablockers alone. (Toubia and 
Sanyal, 2008) This might be reflective of poor trial design and further studies 
are needed to assess combination pharmacologic and endoscopic treatment on 
the development of GOV in cirrhosis. 
1.1.8 Management of acute variceal haemorrhage 
General Measures 
The initial treatment of acute variceal bleeding relies on resuscitative and 
supportive measures to maintain systemic perfusion whilst taking care to avoid 
over transfusion that might result in rebound increase in portal pressures. 
(McCormick et al., 1995; Castaneda et al., 2001) A recent randomised trial 
compared a restrictive transfusion strategy with a liberal transfusion strategy in 
277 cirrhotic patients who presented with an upper GI bleed, 190 of which were 
related to GOV bleeding. The probability of survival was significantly higher in 
the group who were randomised to the restrictive transfusion strategy as 
opposed to the liberal strategy in patients with Child Pugh A or B disease 
(hazard ratio, 0.30; 95% CI, 0.11 to 0.85), but not in those with cirrhosis and 
Child–Pugh class C disease (hazard ratio, 1.04; 95% CI, 0.45 to 2.37). Within 
the first 5 days, the portal-pressure gradient increased significantly in patients 
assigned to the liberal strategy (P=0.03) but not in those assigned to the 
restrictive strategy. (Villanueva et al., 2013)  It is therefore suggested that the 
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threshold Haemoglobin level for transfusion in acute variceal bleeding should be 
≤7g/dL with a target post transfusion range of 7-9 g/dL. Antibiotic prophylaxis 
has been shown to improve short term survival by reducing the incidence of 
infective complications resulting from gut bacterial translocation and by reducing 
the risk of rebleeding. (Hou et al., 2004; Garcia-Tsao et al., 2007) Though 
proton pump inhibitors are commonly used to maintain clot stability and prevent 
post endotherapy complications due to gastric acid, their role in this setting 
lacks evidence. Omeprazole, in a randomised controlled trial did not 
demonstrate a beneficial effect on post sclerotherapy ulcers. (Garg et al., 1995) 
Pantoprazole was shown to reduce the size but not the number of post band 
ligation ulcers in a randomised placebo controlled trial. (Shaheen et al., 2005) 
However no trial has studied the role of acid suppression on prophylaxis or 
rebleeding risk in the setting of GOV bleeding.  
Specific Measures 
Treatment with splanchnic vasoconstrictors such as vasopressin and its 
synthetic analogues such as Terlipressin (which has a longer half life) improve 
survival in patients with acute variceal bleeding by increasing the probability of 
achieving haemostasis when used along with endoscopic treatment. (Escorsell 
et al., 2000; Bañares et al., 2002) Definitive haemostasis can be achieved by 
endoscopic therapy. Band ligation has been found to be superior to 
sclerotherapy and is recommended first line. (Laine and Cook, 1995; de 
Franchis, 2010) Band Ligation has been shown to be associated with early 
reduction in portal pressures to baseline levels post therapy resulting in fewer 
re-bleeds when compared with endoscopic sclerotherapy, which is associated 
with persistently raised portal pressures post therapy. (Avgerinos et al., 2004) 
Band ligation is started at the oesophageo gastric junction and then continued 
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in a spiral manner every 2 cm upwards. If successful, band ligation is continued 
1-2 weekly until varices are too small to treat or are eradicated. A further 
endoscopy in 3 months with enhanced endoscopic surveillance 6-12 monthly 
thereafter is recommended for follow up. (Garcia-Tsao et al., 2007) Endoscopic 
band ligation is effective in achieving haemostasis in 80-90% of patients. 
(D'Amico et al., 1995) Intraluminal balloon tamponade with a Sengstaken 
Blakemore tube (Figure 5) or a Linton tube may be used in cases where 
endoscopic therapy is technically difficult, for example due to poor views, or 
where it is unsuccessful. Balloon tamponade is successful in achieving 
haemostasis in 80-90% of cases. Though deploying the gastric balloon usually 
suffices, a separate oesophageal balloon may be used when adequate 
haemostasis is not achieved. This oesophageal balloon must be intermittently 
deflated to prevent pressure necrosis of the oesophagus. The insertion and 
deployment of the Sengstaken tube can be associated with complications and 
cannot be used for longer than 48 hours. It is therefore used temporarily - either 
as a bridge whilst another attempt at therapeutic endoscopy is made or whilst 
arrangements to allow the definitive reduction in portal pressure by a 
radiologically inserted or surgically created porto-systemic shunt can be made. 
Self expanding metal stents can also be used to achieve tamponade when 
bleeding from oesophageal varices does not respond to endotherapy. 
(Hubmann et al., 2006) However, data on safety and efficacy from larger 
cohorts is needed prior to their use being recommended outside of a controlled 
trial setting. 
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Figure 5: Sengstaken Blakemore (SB) tube 
 
 
 
The Sengstaken Blakemore tube is used to control variceal bleeding as a 
rescue / bridging option when endotherapy fails or is unavailable. The SB tube 
is shown in yellow and has a gastric balloon which is inflated and wedged at the 
oesophageogastric junction to achieve haemostasis. An oesophageal balloon 
shown in red can also be inflated when gastric balloon insufflation is unable to 
control bleeding and blood is aspirated from the oesophageal suction port. A 
separate gastric aspiration port can be used to check if intragastric bleeding is 
persistent. (Figure used under the commons open licence – author Olek 
Ramesz) 
 
Key: 
1. Oesophageal balloon port 
2. Gastric balloon port 
3. Gastric aspiration port 
4. Oesophageal balloon 
5. Gastric balloon 
6. Gastric aspiration pores 
N. Nose 
P. Pharynx 
E. Oesophagus 
S. Stomach 
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1.1.9 Porto systemic shunts in the management of GOV 
Portosystemic shunting to decompress the portal system can be achieved 
surgically or percutaneously under radiological guidance. Portosystemic 
shunting is associated with increased risk of hepatic encephalopathy (HE) in 
patients with pre-existing cirrhosis and increases mortality and therefore it is not 
recommended for primary prophylaxis. (D'Amico et al., 1995; Garcia-Tsao et al., 
2007) When used early, surgical (porto-caval or distal splenorenal shunt 
surgery) or radiologically placed transjugular intrahepatic portosystemic shunts 
(TIPS) are effective at controlling bleeding and have been shown to improve 
survival. (Rossle et al., 1994; Sanyal et al., 1996; Banares et al., 1998; Garcia-
Pagan et al., 2010; Orloff et al., 2012) One group has reported better long term 
outcomes and cost effectiveness of surgical porto-caval shunting when 
compared to TIPS. The higher intervention needed for post TIPS complications 
of stent occlusion / stenosis when compared to surgery were cited as 
disadvantages. (Orloff et al., 2012) However, the outcomes reported by this 
centre have yet to be replicated elsewhere and might be due to the use of 
uncovered Wallstents®, which as described below, are associated with a higher 
incidence of post TIPS dysfunction. Furthermore, the incidence of post TIPS 
shunt occlusion is much lower with PTFE covered stents which are currently the 
preferred prosthesis used for this purpose. (Rossle et al., 2006; Yang et al., 
2010) A further advantage of TIPS is the opportunity to embolise the bleeding 
vessel visualised during venography offering superior control of bleeding and 
haemostasis. This along with the lack of availability of portosystemic shunt 
surgery as a treatment option, especially as salvage therapy due to limited 
surgical experience in most centres makes TIPS the preferred portosystemic 
shunt option to treat complications of severe portal hypertension. 
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1.1.10 Transjugular Intrahepatic Portosystemic Shunt (TIPS) 
TIPS is a non surgical method of reducing portal pressure by radiologically 
guiding the insertion of a stent between the hepatic and portal veins performed 
via the transjugular route. (Figure 6) The first TIPS was performed in animal 
experiments by Rösch in 1969 (Rosch et al., 1969) and its use was first 
described clinically in 1982 by Colapinto and colleagues. (Colapinto et al., 1982) 
Through improvements in stent design, especially the PTFE covered stents, 
refinements in techniques and better understanding and management and 
surveillance of post stent dysfunction / occlusion and complications, TIPS has 
presently become the preferred management option (to surgery) to treat life 
threatening complications of portal hypertension and chronic liver disease. 
(Rössle, 2013) 
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Figure 6: A Transjugular Intra-hepatic Shunt Stent (TIPS) in situ. 
 
 
TIPS placed through the right hepatic vein into the right branch of the portal vein 
using an expandable PTFE covered mesh stent. The procedure is usually 
carried out under general anaesthesia. The internal jugular vein is cannulated 
and a catheter is passed through the right atrium selectively into the right 
hepatic vein branch. A tract is created between the hepatic vein and a branch of 
the portal vein and this is dilated with a balloon. A stent, usually PTFE covered, 
is then placed in the tract and dilated to the required diameter. Pre and post 
stent HVPG measurements are taken to ensure clinically meaningful reduction 
in the gradient has occurred and the sheath removed after radiological patency 
using venography is confirmed. Figure used with permission from VIR, Chicago. 
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Indications for TIPS 
TIPS can be a life saving measure in carefully selected patients with severe 
complications of portal hypertension who do not or will not meet criteria for liver 
transplantation and in those awaiting liver transplantation - the so called “bridge 
to transplantation”. Apart from bleeding from GOV, as discussed above, 
indications for TIPS include refractory ascites, (F. Salerno et al., 2007) hepatic 
hydrothorax, (Strauss et al., 1994; Jeffries et al., 1998; Spencer et al., 2002) 
Budd Chiari Syndrome, (Olliff and Olliff, 2006; Corso et al., 2008) portal vein 
thrombosis, (Blum et al., 1995; Senzolo et al., 2006) hepatorenal syndrome 
(Guevara et al., 1998) (Rössle and Gerbes, 2010) and sinusoidal obstruction 
syndrome (Azoulay et al., 2000; Jacobi et al., 2006). A small study and a critical 
review of literature reported a significant improvement in body composition and 
body mass in sarcopaenic cirrhotic patients post TIPS with one study reporting 
an increase in muscle grip strength, (Camci et al., 2009; Dasarathy et al., 2011) 
suggesting a role in improving sarcopaenia, although this benefit needs further 
investigation in larger, better designed studies with standardised endpoints. 
Improvements in quality of life have been reported in a number of studies after 
TIPS. Nazarian and colleagues reported significant improvement in quality of 
life scores when assessed on a Karnofsky scoring scale when patients were 
followed up for 24 months (pre TIPS 48% post TIPS 86%). (Nazarian et al., 
1996) However, this scoring scale was developed in patients on chemotherapy 
for cancer where a score of 0 equated to death and 100% to normal health. 
Zhuang et al used a Rand 36 item health survey to study the impact of TIPS on 
quality of life. Though a significant improvement was seen in limitations due to 
emotional problems, emotional well being, energy and fatigue and health 
change domains, no difference was seen in general health, physical function, 
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limitations due to physical health, social functioning and pain domains. (Zhuang 
et al., 2002). 
Procedural considerations 
Pre-procedural broad spectrum antibiotics have been shown to reduce the 
incidence of infective complications after TIPS (Gulberg et al., 1999) and are 
offered to all patients. Patency of the portal vein, confirmation of anatomy and 
exclusion of multifocal tumours is excluded by pre procedural imaging usually in 
the form of a CT Scan. Though the procedure can be performed using 
conscious sedation, in our centre, general anaesthesia is used as majority of 
procedures are carried out as rescue therapy after unsuccessful endotherapy 
for bleeding GOV. Stents that can be used for TIPS include uncovered mesh 
stents such as the Wallstent ® (Boston Scientific) or PTFE covered Nytinol 
mesh stents such as the Viatorr® stent (W.L.Gore & Associates Inc.). The latter 
(Figure 7) has been shown to be associated with fewer complications long term 
and has become the preferred stent for this procedure. PTFE covering prevents 
bile permeation and intimal growth into the stent. The Viatorr® endoprosthesis 
additionally has an unlined bare portal venous section to allow unobstructed 
portal perfusion whilst at the same time allowing better anchorage of the stent. 
Using a transjugular approach the right hepatic vein is cannulated and a wedge 
pressure along with a portal venogram using CO2 is obtained. Thereafter portal 
venous cannulation is achieved, confirmed by portal venography and the 
portosystemic pressure gradient is determined. The tract hence formed is 
dilated to 8-10 mm using a balloon and a stent is then deployed across the 
dilated tract which is also dilated to 8-12 mm to achieve an appropriate 
reduction in portal pressure (<12 mm Hg). If the pre stent deployment pressures 
are not found to be elevated to clinically significant levels, a parallel 
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decompressing shunt might be responsible and this is isolated and embolised 
prior to stenting. A final venogram is obtained prior to the completion of the 
procedure. A post procedural baseline doppler ultrasound is requested prior to 
discharge to allow documentation of baseline shunt flow and hepatic vein flow. 
Figure 7: The Viatorr® PTFE covered endoprosthesis stent  
 
The Viatorr stent endoprosthesis has an uncovered bare portal section which 
allows unobstructed portal perfusion whilst at the same time allowing better 
anchorage of the stent whilst the covered portion prevents bile permeation and 
intimal hyperplasia which can result in stent occlusion. Adapted from 
www.goremedical.com/viatorr. 
TIPS related complications 
TIPS is an invasive procedure associated with risks and complications both 
short term and long term. Short term complications are related to the procedure 
itself and physiological changes that result from hepatic bypass of portal venous 
blood into the systemic circulation. In the longer term, problems encountered 
are those of stent occlusion and dysfunction. Technical complications occurring 
at the time of TIPS placement include capsular perforation and intraperitoneal 
haemorrhage (1-2%), which can be minimised if portal sonography is used at 
the time of portal venous puncture; pulmonary embolism, mainly if additional 
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variceal embolisation is performed; stent migration / misplacement and finally 
infection, which can be minimised with the use of pre-procedural antibiotics. 
(Gulberg et al., 1998; reviewed by Rössle, 2013) A clinically significant 
complication of TIPS is the occurrence of hepatic encephalopathy (HE) which 
occurs in 30-55% of patients. (Nolte et al., 1998; ter Borg et al., 2004a; Tripathi 
et al., 2004; Masson et al., 2008; Riggio et al., 2008) Pre-existing hepatic 
encephalopathy is the most important predictor of its recurrence post 
procedure. A significant proportion of these patients can be managed by 
pharmacotherapy using lactulose, Rifaximin and L-Ornithine L aspartic acid (L-
OLA). One study found the incidence of HE to be lower when using PTFE 
covered stents. (Tripathi et al., 2006) However, about 10% of patients will 
develop severe pharmacotherapy refractory HE after a TIPS which may only 
respond to stent revision with reduction in stent diameter or stent occlusion. 
(Riggio et al., 2008) Other complications of TIPS include hepatic dysfunction 
and stent occlusion which again occur less frequently with PTFE covered 
stents, which are now most commonly used for this procedure. (Haskal et al., 
1997b; Bureau et al., 2004; Barrio et al., 2005; Tripathi et al., 2006)  
Patient selection criteria for TIPS 
Given the clinical significance of complications, patient outcomes are 
determined by sound patient selection criteria which include accurate staging of 
liver disease and consideration of other concomitant co morbidity. Older age, 
(ter Borg et al., 2004b) high pre TIPS bilirubin >50 μmol/L, (Rajan et al., 2002) 
pre existing renal impairment (Naga Chalasani et al., 2000; M. Schepke et al., 
2003b; ter Borg et al., 2004b; Yoon et al., 2005) and pre existing HE (Jalan et 
al., 1995; Masson et al., 2008) have all been found to be independent predictors 
of poor outcome. The Child Pugh score has also been used to predict outcome 
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after TIPS (Encarnacion et al., 1995) but was found to be inferior to a composite 
score, using three variables – bilirubin, creatinine and INR, called the Model for 
End Stage Liver Disease (MELD) score. A MELD > 18 was found to be 
associated with a significantly high mortality at 90 days. (Malinchoc et al., 2000; 
Francesco Salerno et al., 2002; Angermayr et al., 2003; Michael Schepke et al., 
2003a) Non hepatological predictors of poor outcome include cardiac 
dysfunction and severe pulmonary hypertension. TIPS insertion causes an 
increase in the left atrial diameter, the pulmonary capillary wedge pressure, and 
total pulmonary resistance. This may unmask coexisting subclinical 
cardiomyopathy. (Van der Linden et al., 1996; Huonker et al., 1999; Naritaka et 
al., 2004) Diastolic dysfunction as predicted by an E/A ratio ≤1 (Rabie et al., 
2009) has been shown to accurately predict mortality in patients undergoing 
TIPS.  Therefore, the presence of cardiac systolic or diastolic dysfunction and 
clinically significant pulmonary hypertension are contraindications to TIPS. A 
small hard and shrunken liver, polycystic liver disease with large cysts, 
multifocal liver tumours and untreated active hepatic and systemic infection are 
other factors that relatively contraindicate TIPS placement both due to technical 
difficulties and higher rates of complications. As suggested by Rossle, 
predictors of outcome should only serve to guide choice and should not be used 
as absolute contraindications to carrying out the procedure. The risk of ex-
sanguination and definite death in the absence of this life saving alternative 
should always remain an important consideration when faced with this decision. 
(Rössle, 2013)  
Long term follow up of TIPS patency and outcome 
Given the long term complications of shunt occlusion, periodical check of shunt 
patency has been advocated. This can be carried out by means of TIPS 
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venography or doppler USS every 6-12 months. (Foshager et al., 1995; Latimer 
et al., 1998; Bureau et al., 2007) TIPS venography remains the gold standard 
modality of evaluating shunt patency. An advantage of venography is the 
potential to offer treatment with angioplasty or re stenting when shunt occlusion 
is detected. TIPS venography is carried out using a transjugular approach and 
is therefore invasive. Non invasive monitoring with the help of Doppler USS 
measurements of blood flow velocity in the shunt and / or portal vein have been 
used as surrogate markers of shunt patency. (Dodd et al., 1995; Ferguson et 
al., 1995; Foshager et al., 1995; Haskal et al., 1997a; Murphy et al., 1998; Zizka 
et al., 2000; J. G. Abraldes et al., 2005; Carr et al., 2006; Bureau et al., 2007; 
Pan et al., 2008) Though studies have reported on various doppler ultrasound 
criteria to predict patency with reasonable accuracy and high sensitivity, (Dodd 
et al., 1995; Foshager et al., 1995; Zizka et al., 2000; J. G. Abraldes et al., 
2005) these have not been validated independently. When used in non 
derivation cohorts, these criteria have not shown similar results, questioning the 
use of doppler ultrasound in the long term follow up for the early detection of 
shunt occlusion. (Haskal et al., 1997a; Murphy et al., 1998; Carr et al., 2006; 
Pan et al., 2008). One reason for this discordance may be that the 
measurement of shunt velocity using USS doppler might only be useful for 
simple mid shunt stenosis rather than complex neo intimal proliferation with 
variable occlusion along the shunt. (Rössle, 2013) With this in mind and given 
the low incidence of shunt occlusion seen with currently used PTFE covered 
stents, it might be reasonable to do away with USS doppler and venographic 
surveillance. (Pan et al., 2008) However, at the present time, this cannot be 
universally recommended as a proportion of patients under follow up continue 
to have uncovered wallstents and remain well compensated and need long term 
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follow up for the early detection of shunt dysfunction. In our own centre, patients 
are allowed to make an informed choice on the type of follow up, if any, they 
would prefer and follow up decisions jointly made by the patient and liver team. 
1.1.11 Endoscopic surveillance for GOV 
Current guidelines recommend endoscopy in all cirrhotic patients at diagnosis. 
However, these guidelines do acknowledge that in patients with Primary Biliary 
Cirrhosis (PBC) GOV can occur during early stage disease and that stage at 
which surveillance should be carried out is unclear. This is detailed in the 
section that follows. In patients without GOV and well compensated chronic liver 
disease (Child Pugh A disease), endoscopies should be repeated at 2-3 yearly 
intervals. In patients with small GOV that have never bled, surveillance 
endoscopies should be repeated at 1-2 yearly intervals. Patients with 
decompensated disease with no varices or small varices should have annual 
endoscopies. (Garcia-Tsao et al., 2007) 
1.1.12 Primary Biliary Cirrhosis (PBC) 
Primary biliary cirrhosis is characterized by progressive non-suppurative 
destruction of small intrahepatic bile ducts resulting in cholestasis, portal 
inflammation and fibrosis which may ultimately result in cirrhosis and portal 
hypertension. The name itself is a misnomer as not all patients with PBC 
develop or have cirrhosis at diagnosis. It was first described by Addison and 
Gull in 1851 though the first clear description of the disease was given by Ahren 
and colleagues from the Rockefeller Institute in New York in 1950. (J. Rodes et 
al., 2007b) 
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1.1.13 Pathophysiology of PBC 
PBC is considered to be a paradigm of autoimmune mediated liver disease with 
over 95% of patients (Oertelt et al., 2007) having highly specific M2 anti-
mitochondrial antibodies (AMA) directed against mitochondrial 2-oxo-acid 
dehydrogenase complexes. These include the pyruvate dehydrogenase 
complex (PDC-E2), the branched chain 2-oxo-acid dehydrogenase complex, 
and the 2-oxo-glutaric acid dehydrogenase complex. These enzymes catalyze 
oxidative decarboxylation of keto acid substrates and are located in the inner 
mitochondrial membrane. (K. D. Lindor et al., 2009) The cause for auto-
reactivity against these antigens is unclear and combination of genetic and 
environmental factors are thought to be involved. Studies have identified 
associations between smoking, urinary tract infections, hair dye and nail polish 
use, previous obstetric cholestasis, xenobiotic use (in animals), familial pre-
disposition and PBC. (Zhang et al., 1994; Parikh-Patel et al., 2001; Selmi et al., 
2004; Gershwin et al., 2005; R. Poupon, 2010; M.I. Prince, Ducker,S.J., James, 
O.F.W. , 2010) One study reported a reduced risk of PBC with the use of oral 
contraceptives. (Corpechot et al., 2010) Recent studies have highlighted the 
role of impaired nuclear receptor signalling in the pathogenesis of cholestasis. 
(Halilbasic et al., 2013) However, the greatest insight into the genetics of PBC 
comes from a number of recent Genome Wide Association Studies (GWAS) 
and iChip studies which have identified a number of Human Leucocyte Antigen 
(HLA) associations associated with the condition. Risk haplotypes associated 
with PBC include those carrying DRB1*08 and DRB1*04 alleles and protective 
haplotypes include those carrying DRB1*11 and DRB1*15 alleles. Several non 
HLA genetic loci associated with PBC listed in Table 4 have also been identified 
and may have implications for targeted treatment of the disease. (George F. 
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Mells and Hirschfield, 2001; Marco Carbone et al., 2014) These genetic studies 
have made it clear that PBC is a disease of immune dysregulation and have 
provided a conceptual framework to link augmented and impaired immunity of 
the Th-1 phenotype with conventional autoreactivity in the face of an impaired 
response to a possible pathogen. (David E. J. Jones and Mells, 2011; G.F. 
Mells et al., 2011)  
Table 4 Non HLA risk loci for PBC identified at genome-wide level of 
significance in at least one genome-wide association study or iCHIP study of 
primary biliary cirrhosis (Adapted from Marco Carbone et al., 2014) 
Locus SNP Odd 
ratio 
p-value Candidate 
gene 
Diseases sharing 
risk loci with PBC 
a,b 
1p36  rs3748816 1.33 3.15E-08 MMEL1 – 
1p31.3 rs72678531 1.61 2.47E-38 IL12RB2 – 
1q31.3 rs2488393 1.28 4.29E-12 DENND1B CD 
2q32.2 rs3024921 1.62 2.59E-18 STAT4 CeD, Ra, T1DM, 
SLE, SSc 
3p24.3 rs1372072 1.2 2.28E-08 PLCL2 MS 
3q13.3 rs2293370 1.39 6.84E-16 CD80 MS, CeD, Vit 
3q25.33 rs2366643 1.35 3.92E-22 IL12A MS, CeD 
4q24 rs7665090 1.26 8.48E-14 NFKB1 MS, UC 
5p13 rs6871748 1.3 2.26E-13 IL7R MS, UC 
7p14.1 rs6974491 1.57 4.44E-08 ELMO1 MS, CeD, PS 
7q32 rs35188261 1.52 6.52E-22 IRF5 UC, RA, SLE, SSc, 
9q32 rs4979462 1.57 1.85E-14 TNFSF15 UC, CD 
11q13 rs538147 1.23 2.06E-10 RPS6KA4 MS, CD, PS, 
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SARC 
11q23.3 rs80065107 1.39 7.20E-16 CXCR5 MS, CeD, SLE, VIT 
11q23 rs4938534 1.38 3.27E-08 POU2AF1 CeD 
12p13.2 rs1800693 1.27 1.18E-14 TNFRSF1A MS 
12q24 rs11065979 1.2 2.87E-09 SH2B3 CeD, RA, T1DM, 
VIT, AITD, PSC 
13q14 rs3862738 1.33 2.18E-08 TNFSF11 CD 
14q24 rs911263 1.26 9.95E-11 RAD51B – 
14q32 rs8017161 1.22 2.61E-13 TNFAIP2 – 
16p13.13 rs12708715 1.29 2.19E-13 CLEC16A MS, UC, T1DM 
16q24.1 rs11117433 1.26 1.41E-09 IRF8 MS, UC, RA, SSc 
17q12  rs17564829 1.26 6.05E-14 IKZF3 UC, CD, RA, T1DM 
17q21.1 rs17564829 1.25 2.15E-09 CRHR1 – 
19p13.2 rs34536443 1.91 1.23E-12 TYK2 MS, CD, RA, 
T1DM, SLE, PS 
19q13.3 rs3745516 1.46 7.97E-11 SPIB – 
22q13.1  rs2267407 1.29 1.29E-13 MAP3K7IP1 CD 
For each locus, results are from the study with strongest evidence of association. 
a. Phenotypically-associated disorders that share risk loci with PBC are listed. 
b. AITD, autoimmune thyroid disease; CD, Crohn's disease; CeD, celiac disease; 
T1DM, diabetes mellitus type 1; MS, multiple sclerosis; PS, psoriasis; RA, 
rheumatoid arthritis; SARC, sarcoidosis; SLE, systemic lupus erythematosis; SSc, 
systemic sclerosis; UC, ulcerative colitis; VIT, vitiligo. 
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1.1.14 Auto-antibodies in PBC 
95% of sera of patients with PBC are positive for AMAs. Depending on the test 
used, 5-10% of sera of PBC patients are negative for AMA. (Michieletti et al., 
1994) AMAs represent a heterogeneous group of auto-antibodies directed 
against antigens located on the inner mitochondrial membrane. According to 
their immunochemical structure, these antigens have been classified into 
different types from M1 to M9. Only anti-M2 antibodies (specific for E2 subunit 
of the pyruvate dehydrogenase complex, a multienzymatic complex localized 
within the inner mitochondrial membrane), anti-M4 antibodies (specific for 
solphito-ossidase), anti-M8 and anti M9 (specific for glycogeno-phosphorylase) 
are specific for PBC. Among these, anti-M2 antibodies have diagnostic 
importance and clinical significance as they are present in high titres in almost 
all the patients with PBC, while the other three are present in low titres and 
always accompany anti-M2 antibodies. Although the predominant autoreactive 
antibodies in PBC are AMA, a subgroup of PBC patient sera are positive for 
antibodies direct toward nuclear components (ANA) that at indirect 
immunofluorescence produce homogeneous, nuclear dot, speckled, 
centromere, or rim-like patterns. These antibodies occur in upto 43% of patients 
with PBC and their prevalence is shown in Table 5. During the last two 
decades, a number of nuclear structures have been recognized as specific 
targets of ANA in PBC. Two typical patterns of nuclear immunofluorescence 
staining (best described using Hep2 cells rather than the composite tissue 
blocks used in AMA immunofluorescence) have been described in PBC, one 
giving a membrane like pattern of staining (M-ANA) such as the anti gp210 and 
anti p65 antibodies and the other giving multiple nuclear dot (MND-ANA) 
staining such as anti sp100 and anti PML antibodies. Patients with AMA 
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negative PBC have significantly higher ANA detectable than patients with AMA 
positive PBC patients and although Anti gp210 and Anti SP100 antibodies lack 
sensitivity their high specificity allows the diagnosis of PBC to be made in the 
absence of AMA especially when a liver biopsy is not helpful or cannot be 
obtained. (Zeman and Hirschfield, 2009) Upto 50% of patients with PBC have 
extractable nuclear antigen antibodies (ENA) such as the anticentromere 
antibodies in the absence of co existing rheumatological disorders. Their 
presence in AMA negative patients should raise the suspicion of PBC in 
patients with cholestasis. (Granito et al., 2006) The clinical significance of the 
presence of non AMA antibodies in PBC is unclear. Recent studies have 
suggested a role in defining the nature of progression of liver disease in these 
patients. The presence of the anti gp210 in 276 patients with biopsy proven 
PBC was associated with an increased risk of liver associated death or the 
need for liver transplantation [odds ratio (OR) = 33.777, 95% CI: 5.930, 
636.745] suggesting their presence confers a poorer hepatological long term 
outcome and hence a need for enhanced follow up. In the same study, the 
presence of the anti-centromere antibody was associated with an increased risk 
of portal hypertension (OR = 4.202, 95% CI: 1.307, 14.763) therefore 
suggesting a need for screening of such patients for GOV early in the disease. 
(Nakamura et al., 2007) 
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Table 5: Autoantibodies in PBC- prevalence and sensitivity / specificity in PBC 
(Adapted from Zeman and Hirschfield, 2009) 
Autoantibody 
Prevalence, % PBC diagnosis, % 
AMA + AMA - Spec Sens 
ANA-positive 47–48 68–100 Very  low Very  low 
Multiple nuclear dot-like 
12–24 38–41 Unknown Unknown 
Perinuclear/rim-like 
membranous 6–14 31–50 Unknown Unknown 
Speckled 24 41–46 Unknown Unknown 
Anticentromere 14–20 14–23 Unknown Unknown 
Anti-Sp100 24–31 38–54 97 30 
Antiglycoprotein 210 16–18 15–45 99 10–25 
 
1.1.15 Natural History of PBC 
PBC is a slow and variably progressing disease mostly affecting women aged 
between 40-59 yrs over decades. (Danielsson et al., 1990; Witt-Sullivan et al., 
1990; James et al., 1999; M. Carbone et al., 2013) The estimated prevalence of 
PBC in the UK is about 35/100000, and the number of patients in UK with PBC 
is estimated at about 20000. (James et al., 1999) More recently, it has been 
suggested that there are 3 forms of PBC with a “typical form” with progression 
to cirrhosis if untreated over 10-20 years, a crossover syndrome type with 
fluctuating or persistent co existent features of autoimmune hepatitis 
characterised by rapid progression of disease and a premature ductopaenic 
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variant which presents with jaundice and progresses to cirrhosis rapidly over 5 
years. (R. Poupon, 2010) In addition, based on the presence or absence 
biochemical cholestasis and symptoms PBC may be further classified as 
asymptomatic and symptomatic PBC. Recent evidence suggests that the 
classification of PBC should include the clinical phenotype in relation to 
response to treatment, more specifically to UDCA (as detailed below), into 
“Responders” and “Non Responders” as there is an emerging body of evidence 
that this defines the long term outcome in these patients.  
AMA positive patients without other features of PBC 
AMA can be found in patients without any clinical or biochemical abnormalities 
consistent with PBC – sometimes referred to as “latent” PBC.  Many of these 
patients have histological changes consistent with PBC when biopsied and a 
significantly large proportion demonstrate liver test abnormalities and symptoms 
during follow up over decades. (Metcalf et al., 1996) None of these patients, 
however, develop portal hypertension or cirrhosis on follow up and therefore 
patients with “latent” PBC are considered to have very slowly progressing 
disease with survival similar to the general population. (Abe and Onji, 2008)  
Asymptomatic PBC 
With increasing awareness and the widespread use of generic autoimmune 
screening in the investigation of abnormal LFTs, a group of patients with 
positive serology and mild cholestatic liver tests without any symptoms of the 
disease have been identified. These are referred to as the asymptomatic PBC 
(a-PBC) patients. This cohort was first described by Long and colleagues in 
1977 who noted that a decade was required for symptoms to develop in these 
patients. (Long et al., 1977) Various groups have shown that these patients 
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have worse survival when compared to age and sex matched healthy controls. 
(Balasubramaniam et al., 1990; Mahl et al., 1994; Springer et al., 1999). In one 
of the largest studies of its kind, 469 asymptomatic PBC patients from the North 
East of England were followed for a median of about 7 years. The proportion of 
a-PBC patients developing symptoms was 50% at 5 years and 70% at 10 yrs 
post diagnosis. This study did not find any difference in overall survival between 
patients with a-PBC and symptomatic PBC (s-PBC) at diagnosis. The 
proportion of patients with a-PBC presenting with bleeding varices was 3% and 
9% at 5yr and 10 yrs respectively in this study. A fifth of all patients presenting 
with a-PBC died from liver disease or needed transplantation during the follow 
up period contradicting previous suggestions that this was a milder form of the 
disease (Mahl et al., 1994) and highlighting the importance of close monitoring 
and the need for long term surveillance in this cohort. (M. I. Prince et al., 2004) 
Symptomatic PBC 
The clinical course and natural history of patients with PBC who present with 
symptoms has been altered by a better understanding of the disease and 
improved management strategies including the use of Ursodeoxycholic Acid 
(UDCA) at doses now recognised to be therapeutic. Patients with s-PBC have 
accelerated progression of their liver disease compared with those who have a-
PBC. Mean survival time in these patients, in the pre-UDCA, era varies between 
6-10 years; (Abe and Onji, 2008) time to progression to histologically advanced 
stage of fibrosis is 2 years and the probability of remaining in early stage over a 
period of 4 years is 29%. (R. Poupon, 2010) The development of liver failure 
was noted to be 15% in a large community based cohort of PBC patients 
followed up for 5 years in the North-East of England. (M. Prince et al., 2002) 
One third of patients in a large cohort (a third of whom were cirrhotic) developed 
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varices when followed up over approximately 6 years. These patients had 
poorer 3 year survival (60%) and this was further worsened (45%) after an 
episode of GOV bleeding. (G.J. Gores et al., 1989a) UDCA delays histological 
progression in PBC with a 5 fold lower progression per year when compared to 
placebo. (Corpechot et al., 2000) UDCA treatment also improves transplant free 
survival in patients with PBC, the magnitude of this effect being 24% - 32% 
reduction in the risk of transplantation or death. (R.E. Poupon et al., 1994; K. D. 
Lindor et al., 1996) In one study, UDCA improved transplant free survival rates 
to 84% and 66% at 10 and 20 years, respectively, which were better than the 
spontaneous survival rate as predicted by the updated Mayo model, a 
prognostic scoring tool used in PBC discussed below (RR, .5; P < .01). The 
survival rate of patients in early stage disease was similar to that in the control 
population whereas the probability of death or OLT remained significantly 
increased in treated patients in late histologic stages (RR, 2.2; P < .05). 
(Corpechot et al., 2005) 
AMA negative PBC 
A separate group of patients who are negative for AMA but who present with 
symptoms, signs, lab biochemistry and histology similar to patients with PBC 
who are AMA positive have been described. (Michieletti et al., 1994; Goodman 
et al., 1995; Lacerda et al., 1995) 8% of 297 patients with clinical and 
histological features of PBC in an Italian cohort were found to be AMA negative. 
This group had a higher prevalence of Anti Nuclear and Anti Smooth Muscle 
antibodies than those with AMA positive disease. No significant differences 
were noted between the two groups with regards to complications of cirrhosis 
and development of liver failure resulting in death or referral for liver 
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transplantation. (P. Invernizzi et al., 1997) A discussion of various antibody 
profiles and their clinical significance is presented below. 
1.1.16 Prognostic Predictors and Prognostic Scoring Systems in PBC 
A number of clinical, laboratory biochemical variables and histological staging 
have been used to predict prognosis in PBC. Bilirubin is the most powerful 
predictor of outcome in PBC (Shapiro et al., 1979; R. Poupon, 2010) and a 
component of various prognostic scoring systems used in PBC. These scoring 
systems most commonly use regression to create mathematical formulae to 
help predict prognosis. Common variables included in these scores include age, 
bilirubin, albumin, prothrombin time, cholesterol, degree of cholestasis, severity 
of fibrosis, features of the overlap syndrome with autoimmune hepatitis and the 
presence of peripheral oedema. (Roll et al., 1983; E.R. Dickson et al., 1990; 
Inoue et al., 1995) The Mayo Risk scoring system, (E. Rolland Dickson et al., 
1989) the updated Mayo model (Murtaugh et al., 1994) and the and the revised 
Autoimmune Hepatitis Group Score (J. A. Talwalkar et al., 2002) are the most 
commonly used scoring systems in PBC. The Mayo scores do not seem to be 
affected by the use of UDCA (P. Angulo et al., 1999c) and include age, serum 
levels of bilirubin and albumin, prothrombin time and presence or absence of 
peripheral oedema, including response to diuretic therapy. The advantage of 
the Mayo score is that it does not need a liver biopsy. Its predominant use 
currently is to predict the survival in untreated patients and to help compare this 
with patients receiving an intervention for PBC in trial settings. (Y. M. Lee and 
Kaplan, 2005) A number of scoring systems based on regression have been 
also developed to help predict prognosis in patients based on their response to 
UDCA. These are discussed in detail below. 
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1.1.17 Clinical Manifestations of PBC 
Fatigue and pruritus are the main symptoms of PBC and described in detail 
below. Xanthomas and hyperlipidaemia are commonly seen in patients with 
PBC. (Longo et al., 2002) Symptoms and signs of coexistent autoimmune 
conditions such as the Sicca syndrome, Sjogren’s syndrome, Raynaud’s 
syndrome, hypothyroidism and arthritis may be seen. PBC patients may be at a 
higher risk of developing osteoporosis, with severity of bone disease correlating 
with advanced PBC stage and disease severity. (Menon et al., 2001; Mounach 
et al., 2008) Signs and symptoms of portal hypertension can occur both in early 
and late disease as described below. Finally, signs of established chronic liver 
disease may be seen in advanced stages. 
Fatigue 
Fatigue was first reported as a symptom in PBC in the early 80s’ (Christensen 
et al., 1980) and has been shown to be associated with decreased overall 
survival. (D.E Jones et al., 2006; D.E.J. Jones et al., 2010) It is present in over 
2/3rd of PBC patients, with prevalence being reported to be as high as 85% in 
some studies, and has been shown to have a significant impact on perception 
of quality of life whilst not being associated with clinical, biochemical, or 
histological criteria suggestive of advanced liver disease. (Cauch-Dudek et al., 
1998; P.M. Huet et al., 2000; Younossi et al., 2000; Goldblatt et al., 2002; R.E. 
Poupon et al., 2004; Stanca et al., 2005; G. F. Mells et al., 2013) Recent 
evidence suggests that autonomic dysfunction is highly prevalent in patients 
with PBC and correlates with severity of fatigue. (Newton et al., 2004; Newton 
et al., 2007) Increased daytime somnolence, (Newton et al., 2011) accelerated 
myocardial senescence (Hollingsworth et al.
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hypothyroidism (Elta et al., 1983) may be contributory and worsen fatigue 
experienced by PBC patients.  
Pruritus 
Pruritus is another common and significant symptom of PBC occurring in upto 
55% of all patients. (J. A. Talwalkar et al., 2003) Its mechanism is poorly 
understood and it is thought to be a combination of increased opioidergic tone 
(E.A. Jones and Bergasa, 1999) and the result of increased levels of bile acids 
in skin tissue. (Ghent et al., 1977) A recent study has suggested increased 
levels of serum lysophospholipase, autotaxin (ATX), and its product, 
lysophosphatidic acid (LPA), as potential mediators of cholestatic pruritus. 
(Kremer et al., 2012) Once pruritus develops, it does not go away completely 
unless treated. (K. D. Lindor et al., 2009) Patients with AMA negative disease 
have been shown to have lesser pruritus than those with AMA positive disease. 
(Sakauchi et al., 2006)  
1.1.18 Diagnosis and histological staging of PBC 
The diagnosis of PBC requires the presence of cholestasis (with preferentially 
raised alkaline phosphatase levels) in the presence of either compatible 
serology with anti mitochondrial auto antibodies with M2 specificity detected by 
ELISA or immunoblot assays and / or histological demonstration of 
characteristic signs suggesting non suppurative destructive cholangiopathy. (K. 
D. Lindor et al., 2009; R. Poupon, 2010) Patients with compatible serology 
without biochemical or symptomatic features consistent with PBC may have 
latent PBC as described above. A markedly raised ALT or AST and raised 
immunoglobulin G levels may occur in patients with the autoimmune hepatitis / 
PBC overlap syndrome and in these patients a liver biopsy is needed to 
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ascertain the diagnosis. Biopsies may also be needed if a coexistent pathology 
such as non alcoholic steatohepatitis is suspected. Histologically, the severity of 
PBC can be graded using scoring systems proposed by Scheuer or Ludwig.  
(P.J. Scheuer, 1967; Ludwig et al., 1978) Histological staging of PBC is shown 
in Table 6. Given the patchy nature of lesions (P. J. Scheuer, 1998) and the fact 
that severity of underlying fibrosis might be underestimated at needle biopsy, 
(Garrido and Hubscher, 1996) a biopsy with at least 10 – 15 portal tracts (K. D. 
Lindor et al., 2009; R. Poupon, 2010) and a tissue width of at least >1 mm 
(Colloredo et al., 2003) have been suggested to reduce the incidence of 
sampling error. 
Table 6: Histological staging system for PBC 
 Description 
Stage I 
Florid lesion. Bile duct damage with inflammatory reaction. (Portal 
hepatitis) 
Stage II 
Vanished bile ducts, portal and periportal inflammation and 
ductular proliferation (Ductular reaction and periportal hepatitis). 
Periportal fibrosis. 
Stage III 
Portal fibrosis with periportal expansion and bridging fibrosis, 
typically without bile ducts. Septal fibrosis. 
Stage IV Cirrhosis 
 
1.1.19 Treatment of PBC 
Ursodeoxycholic acid 
Ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/Kg/day is currently 
recommended as the first line therapy for Primary Biliary Cirrhosis and should 
be considered for all patients with abnormal biochemistry. (European 
Association for the Study of the, 2009; K. D. Lindor et al., 2009; R. Poupon, 
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2010) It is the only drug approved by the US FDA for treatment in PBC. UDCA 
is found in large quantities in bear bile (hence the name) and has been used in 
Chinese medicine for over 5000 years. Commercially available UDCA is a 
synthetic 24 carbon steroid bile acid which is hydrophilic and replaces the 
endogenic lipophilic bile acid pool by 40-50%. In PBC, UDCA acts by increasing 
the hydrophilic nature of endogenous bile acid pool thereby increasing 
choleresis. It also acts by immunomodulation and has cyto protective effects 
against cytokine and bile acid mediated damage. (Raoul Poupon, 2012) A 
number of studies have shown the beneficial effect of UDCA in PBC on 
improving liver biochemistry, (R. E. Poupon et al., 1991; Battezzati et al., 1993; 
Heathcote et al., 1994; Combes et al., 1995) delaying histological progression, 
(Paul Angulo et al., 1999a; Corpechot et al., 2000; R.E. Poupon et al., 2003) 
and improving survival. (Corpechot et al., 2005) In a combined study using data 
from 3 clinical studies, PBC patients with moderate to high risk (as defined by 
serum bilirubin levels and those with stage IV disease) treated with UDCA at a 
dose of 13-15 mg/Kg/day had a transplant free survival which was significantly 
better than those treated with placebo. (R.E. Poupon et al., 1997) UDCA may 
also have a role in lowering portal pressures in PBC. In one prospective trial, 
UDCA use was shown to reduce the risk of varices in patients with PBC. Over 4 
years 16% of patients on UDCA versus 58% of those on placebo developed 
varices (p<0.001). (K.D. Lindor et al., 1997b) The effect of the use of UDCA on 
the natural history of disease has been to reduce the number of patients with 
PBC undergoing liver transplantation. (D.E.J. Jones et al., 1995; J. Lee et al., 
2007; Milkiewicz, 2008) Some meta-analyses, however, have questioned this 
beneficial effect. In one meta-analysis, no significant difference was found in the 
incidence of death (odds ratio 1.21, 95% CI 0.71-2.04), liver related death (0.72, 
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0.22-2.32), liver transplantation (1.27, 0.78-2.07), death or liver transplantation 
(1.26, 0.87-1.82), and in the development of complications of liver disease 
(1.11, 0.64-1.92) when compared with placebo. (Goulis et al., 1999) 2 recent 
Cochrane reviews seemed to support these findings. (Gong et al., 2007b; Gong 
et al., 2008; Rudic et al., 2012) However, it is generally accepted that the results 
of these meta-analyses might have been affected by the inclusion of trials with 
too short a duration of follow up and suboptimal UDCA doses to observe a 
beneficial effect on long term outcomes. (K. D. Lindor et al., 2009; R. Poupon, 
2010) Furthermore, these results do not take into consideration the fact that not 
all patients with PBC respond to UDCA and that non responsive PBC may be a 
separate clinical phenotype when compared to responsive PBC. This is 
discussed in more detail in the next chapter. A number of alternative treatment 
modalities have been considered for the treatment of PBC in those who do not 
respond adequately to UDCA. 
Budesonide 
Budesonide along with UDCA has been shown to improve biochemistry and 
histology in patients with PBC. (Leuschner et al., 1999) In a 3 yr prospective 
open labelled randomised trial 77 patients were randomised to receiving UDCA 
at a dose of 15mg/Kg/day alone or in combination with Budesonide at a dose of 
6 mg/day. Fibrosis decreased by 25% in the combined group but increased by 
70% in the monotherapy group (p=0.0009). Bilirubin values however increased 
in the combination group and were lowered in the monotherapy group.  
However, endogenous steroid response blunting was noted at 2 years 
suggesting systemic exposure after long term use. (Rautiainen et al., 2005) In 
another study when 22 patients with suboptimal response to UDCA were given 
budesonide at a dose of 9mg/day for 1 year a significant, but transitory 
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improvement in bilirubin was seen and a significant, but marginal improvement 
in serum alkaline phosphatase was seen with combination therapy. The Mayo 
risk score however increased significantly (p =0.02) and there was a significant 
loss of bone mass (p <0.001) in the lumbar spine. Budesonide-induced 
hyperglycaemia and cosmetic adverse effects were noted in 10% of the study 
cohort. (P. Angulo et al., 2000) Budesonide use was associated with the 
development of portal vein thrombosis in patients with stage 4 disease. 
(Hempfling et al., 2003) Given the lack of long term data on improving outcomes 
in PBC and concerns about its safety in patients with advanced disease, current 
guidelines recommend the use of budesonide only in patients with early stage 
disease where autoimmune overlap is clinically suspected. 
Fibric acid derivatives 
Fibric acid derivatives such as fenofibrate and bezafibrate in combination with 
UDCA (Hazzan and Tur-Kaspa, 2010) have been shown to improve liver 
biochemistry, IgM levels and histology in those with incomplete response. 
(Kanda et al., 2003; Dohmen et al., 2004; Itakura et al., 2004; Walker et al., 
2009; C. Levy et al., 2011) Most of these studies are of short duration with 
variable end points and therefore further longer term studies are warranted 
before fibric acid derivatives can be routinely recommended.  
Other treatments for PBC 
No difference in survival as predicted by the Mayo Score was observed when 
methotrexate or colchicine were added to UDCA when compared to UDCA 
alone in a 10 year study of these medications in patients with PBC. (Kaplan et 
al., 2004) Other trials have also not demonstrated any benefit of methotrexate in 
the treatment of PBC. (Bach et al., 2003; Combes et al., 2005) Cyclosporine 
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has been trialled in PBC with a few early reports suggesting a benefit. (Wiesner 
et al., 1990; Lombard et al., 1993) However significant side effects greatly limit 
its use and a recent Cochrane review found no evidence supporting or refuting 
the hypothesis that Cyclosporine delays progression, death or liver 
transplantation in PBC. (Gong et al., 2007a) Obeticholic acid, a farnesoid X 
receptor ligand has recently been shown to improve liver biochemistry in PBC. 
Significant pruritus was however noted in these patients. (A. Mason et al., 2010) 
Various other therapies, in phase I or II trials have been shown to be effective in 
PBC. These including the anti CD20  agent Rituximab, (Tsuda et al., 2012) 
antiretroviral agents (A. L. Mason et al., 2004) and tamoxifen (Pietro Invernizzi 
et al., 2004; Reddy et al., 2004). Long term studies have yet to be performed to 
routinely recommend these agents in the management of PBC. Mycophenolate 
Mofetil, (J. A. Talwalkar et al., 2005) chlorambucil, (Li et al., 2012) thalidomide 
(McCormick et al., 1994) and D- penicillamine (Gong et al., 2004) have not 
been found to be useful for the treatment of PBC. In patients with end stage 
liver disease or severe pruritus liver transplantation should be considered and is 
associated with excellent graft and long term patient survival. (Jacob et al., 
2005) Fatigue responds poorly to transplantation and therefore it should not be 
considered as the sole indication for listing. Post transplant surveillance for 
recurrence is not needed given that it is rarely clinically significant. (Neuberger, 
2003) 
1.1.20 Portal hypertension and GOV in the context of PBC 
Incidence and Prevalence of GOV in PBC 
Early reports suggested that the incidence of portal hypertension in PBC was 
low and that GOV were a characteristic of advanced disease. (Sherlock, 1959) 
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Both of these presumptions have been challenged in recent years. Incidental 
finding of GOV on OGD or a de novo bleed from GOV prior to the onset of 
jaundice or cirrhosis have been reported as a presenting feature in PBC in a 
number of studies. (Zeegen et al., 1969; Kew et al., 1971; Navasa et al., 1987; 
Colina et al., 1992; Vlachogiannakos et al., 2009) In a report on the 
development of portal hypertension in PBC, 47% of patients with PBC were 
found to have GOV and the development of GOV was associated with 
significantly reduced survival. One of the most comprehensive reports on GOV 
development included 265 patients without GOV who were enrolled in a trial of 
Penicillamine D for the treatment of PBC and followed up for a median of 6 
years. 31% of patients in this cohort developed GOV. Almost half (48%) of 
those that developed GOV in this study experienced a variceal bleed and 
survival in those that bled was 63% and 43% at 1 and 3 years respectively. 
Histological stage and bilirubin levels were the only predictors of time to 
development of GOV. (G. J. Gores et al., 1989b) Similar point prevalence has 
been reported in other cohorts. Point prevalence of endoscopically proven GOV 
and bleeding from GOV were 25% (42/166), 8% (13/166) and 1% (2/166) 
respectively in the Newcastle PBC cohort. (D.E.J. Jones et al., 2002a) GOV 
were found to be present in 23% of PBC patients entering a trial of UDCA at the 
Mayo Clinic in USA (K. D. Lindor et al., 1997a) and in 30% of PBC patients in a 
Canadian study. (Bressler et al., 2005) In a recent trial designed to evaluate the 
effect of UDCA treatment on PBC that included HVPG measurements, portal 
hypertension as defined by a pressure of >6mm Hg was found in 37% of 
unselected patients with PBC and clinically relevant portal hypertension as 
defined by a pressure of >12mm Hg was found in 20% of the cohort. (Pierre-
Michel Huet et al., 2008) 
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Pathogenesis of portal hypertension in PBC 
The pathogenesis of portal hypertension in PBC patients with advanced stage 
IV disease (cirrhosis) is similar to that seen in non PBC cirrhotic patients and 
has been described in detail above. In patients with early stage PBC, portal 
inflammation and portal venulitis are thought to result in portal venous 
microthrombi formation. This vascular injury is then thought to result in nodular 
regenerative hyperplasia causing architectural distortion and leading to 
presinusoidal portal hypertension. (J. Rodes et al., 2007b) Nodular regenerative 
hyperplasia was reported in upto half of all patients with early stage disease in 
one study. (Colina et al., 1992) Nodular regenerative hyperplasia was also seen 
in all PBC patients presenting with portal hypertension and in 60% of those with 
PBC who developed GOV within the first 2 years after diagnosis in another 
study. (Kew et al., 1971) In addition to nodular regenerative hyperplasia, portal 
phlebosclerosis has been demonstrated in patients with early PBC and might be 
an additional factor in the development of portal hypertension in these patients. 
(Nakanuma, 2003) Navasa et al showed that though the prevalence of portal 
hypertension was similar in stage II and stage III disease (57% vs. 55% 
respectively), pre sinusoidal hypertension was only seen in patients with stage II 
disease. This further adds credence to the hypothesis that portal hypertension 
in PBC starts with a presinusoidal component which is added onto by a 
sinusoidal component as the disease progresses. (Navasa et al., 1987) The 
presence of anti centromere antibodies is associated with a higher risk of 
progression to portal hypertension in patients with PBC. (Nakamura et al., 2007; 
Gao et al., 2008) In this subset of patients, a ductular reaction is more 
pronounced and would seem to suggest an additional autoimmune mediated 
pathogenic mechanism for GOV development that has yet not been defined.  
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GOV in early stage and asymptomatic PBC 
GOV development can occur in early stage and asymptomatic PBC patients. In 
the study by Gores et al, 7% and 12% of patients with histological stage I and II 
PBC had developed varices at 3 years and 5 years respectively. (G. J. Gores et 
al., 1989b) Similar finding have been reported in other studies. 7% of a-PBC 
patients and 8% of patients with histological stage I and II (early stage PBC) 
were found to have varices in a Japanese study. (Takeshita et al., 2003) In a 
more recent study, from the Mayo clinic, 6% of patients with Stage I and II 
disease and 16% of patients with Stage III disease were found to have GOV. 
(Ali et al., 2011) The Japanese study noted that the survival in a-PBC patients 
with GOV was significantly poorer than in a-PBC patients without GOV, 
however the numbers of patients included in the analysis was small. (Takeshita 
et al., 2003)  
Impact of GOV on outcomes in PBC 
As discussed above, the development of GOV and portal hypertension in 
patients with PBC heralds a poor prognosis. Though the development of GOV 
carries a poor prognosis in general, patients with normal bilirubin levels and 
bleeding from GOV as the presenting feature leading to the diagnosis have a 
survival similar to those who have never bled. (M R Biagini et al., 1990b; 
Vlachogiannakos et al., 2009)  There remains some controversy about whether 
bleeding from GOV affects survival when GOV develop in patients with 
established PBC. Though Gores et al reported a poorer survival after a bleeding 
episode, (G. J. Gores et al., 1989b) Biagini et al reported no difference in the 
mean survival between bleeders (79 months) and non bleeders (90 months) in 
patients with an established diagnosis of PBC. (M. R. Biagini et al., 1990a)  
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The role of UDCA therapy on development of GOV 
The role of UDCA therapy on the development of GOV is unclear. In bile duct 
ligated rats, hepatocyte and sinusoidal volume fractions were significantly 
higher whilst portal pressure, portal tributary blood flow and cardiac index were 
significantly lower in rats receiving UDCA for 4 weeks when compared with rats 
receiving placebo. Serum aminotransferase and alkaline phosphatase activities, 
and total serum bile acids and individual bile acid concentrations were not 
significantly different between the two groups. (Poo et al., 1992) The effect of 
UDCA treatment on the development of GOV in 180 patients with PBC was 
prospectively studied over a 4 year period in one study. The risk of developing 
varices in patients treated with UDCA was 16% versus 58% in those treated 
with placebo. (K. D. Lindor et al., 1997a) In contrast, the results of another study 
by Combes et al suggested a slight increase (however non significant 
statistically) in the risk of development of GOV and bleeding in patients treated 
with UDCA over 2 years. (Combes et al., 2004) A more recent study by Huet et 
al using HVPG demonstrated that UDCA use over 6 years prevented the 
progression of portal hypertension when compared with placebo. The use of 
placebo was associated with an increase in HVPG over 2 years and this 
returned to baseline values after a crossover phase in which patients were 
treated with UDCA over 4 years. (Pierre-Michel Huet et al., 2008) An important 
observation in the Huet study which might explain the contradictory findings 
seen in the study by Combes et al is that not all patients respond to UDCA in 
terms of normalisation of AST and improvement in HVPG and that patients who 
responded had better liver function at the time of initiation of UDCA therapy thus 
reiterating the importance of the responder and non responder concept and of 
starting UDCA as early in the course of the disease as possible. The 
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management of well established GOV in PBC is similar to that in chronic liver 
disease of other aetiology. 
1.1.21 Screening strategies for GOV in patients with PBC 
Given the high prevalence of GOV in PBC, the fact that almost 1 in 10 patients 
with asymptomatic / early PBC have GOV, and that this impacts poorly on 
survival be it in early or late stage disease, screening for GOV has an important 
place in the risk stratification and prognostication of these patients and has to 
be considered at diagnosis. However, current EASL and AASLD guidelines 
recommend screening for GOV with OGD in advanced (Stage IV) disease. 
(European Association for the Study of the, 2009; K. D. Lindor et al., 2009) 
These recommendations acknowledge previous evidence that histology may 
underestimate disease severity. (Garrido and Hubscher, 1996) They also 
acknowledge that the evidence regarding the selection of patients and timing of 
screening is contradictory (European Association for the Study of the, 2009; K. 
D. Lindor et al., 2009) especially in patients with early stage disease. 
Furthermore, a liver biopsy is rarely requested to make the diagnosis of PBC. 
(Zein et al., 2003) The default of indiscriminate screening all PBC patients with 
an OGD is associated with increased risk and cost and is likely to be 
unacceptable to all patients and healthcare providers. Alternative triggers are 
therefore needed to decide when to screen for varices, independent of 
histology. Several non-invasive tools based on laboratory parameters alone, or 
in combination with imaging, have been suggested to help identify PBC patients 
with GOV and who would benefit from OGD screening. Angulo et. al. 
prospectively followed 180 patients with PBC enrolled into a randomised 
placebo controlled trial of UDCA and found that 93% of patients with varices 
had a Mayo Score >4. (P. Angulo et al., 1999b) Bressler et al included a diverse 
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Canadian cohort of patients with varying aetiologies for chronic liver disease 
and demonstrated that in 86 patients with PBC or Primary Sclerosing 
Cholangitis, on multiple logistic regression, a platelet count < 200000 / mm3 
(Odds Ratio 6), an albumin <40 g/L (Odds Ratio 6) and serum bilirubin > 20 
μmol/L (Odds Ratio 4) were independently associated with the risk of finding 
varices. This study also suggested that non invasive GOV screening thresholds 
previously suggested for patients with cirrhosis, where the aetiology of cirrhosis 
was predominantly non cholestatic disease, were not applicable in PBC. 
(Bressler et al., 2005) In another study from Florida, Levy et al found a platelet 
count of <140 000 mm3 and / or a Mayo risk score of ≥ 4.5 to be independently 
associated with the risk of GOV in PBC. (Cynthia Levy et al., 2007) More 
recently male gender, albumin <3.5 g/dL, bilirubin ≥1.2mg/dL or 20 mmol/L, 
and/or PT ≥12.9 seconds has been suggested as a model (MABPT model) by 
the Mayo group to predict the presence of GOV in patients with early PBC. (Ali 
et al., 2011) Splenomegaly, on clinical examination has previously been shown 
to be an independent risk factor associate with the presence of large varices. 
(Naga Chalasani et al., 1999) However in a study including 9% of patients with 
cholestatic chronic liver disease, the presence of splenomegaly as defined on 
ultrasound criteria was not shown to be associated with the presence of GOV. 
(Zaman et al., 1999) Splenomegaly was found to significantly associated with 
the presence of GOV on univariate but not on multivariate analysis in another 
study including 143 patients. (Schepis et al., 2001) However the ideal criteria for 
non invasive prediction of GOV in PBC remain elusive. Furthermore, none of 
these criteria have been validated in the UK, it remains unclear if these non 
invasive predictive strategies are cost effective and finally, none help with 
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defining a percentage probability of detecting GOV in PBC patients to allow risk 
stratification.  
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1.2 Aims 
Primary Aim 
To develop and externally validate a cost effective and non-invasive clinical tool 
to predict the probability of finding GOV in patients with PBC – the Newcastle 
Varices in PBC (NVP) Score. 
Secondary Aims 
1. To identify risk factors associated with the development of GOV and bleeding 
from GOV in patients with PBC. 
2. To establish the clinical impact of GOV on the natural history of PBC with 
particular reference to variceal bleeding episodes. 
3. To establish the effect of the development of GOV and variceal bleeding on 
survival in patients with PBC. 
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1.3 Methods 
1.3.1 Study setting, design and population 
 Newcastle Cohort 
A cross sectional retrospective study was designed to identify all patients with a 
diagnosis of PBC (EASL and AASLD guidelines) who are under follow up at the 
Freeman Hospital, Newcastle upon Tyne, and who have undergone OGD for 
various clinical indications including screening for varices. The specialist liver 
service at the Freeman maintains a comprehensive database of all PBC 
patients under follow up. All patients on this database have been 
comprehensively characterised making the cohort fully representative. (Metcalf 
et al., 1997; James et al., 1999; M.I. Prince et al., 2001) Data from this cohort 
was used to develop the predictive tool and for internal validation as described 
below.  
Cambridge Cohort 
Similar to the Newcastle cohort, a cohort of PBC patients who have undergone 
an OGD for any clinical indication and under follow up at the Addenbrooke’s 
Hospital in Cambridge were identified. Clinical details for this cohort were 
collected. This cohort was used to externally validate the model.  
Toronto Cohort 
A further external validation cohort was set up using clinical details of PBC 
patients who attend the Toronto Western Hospital in Canada who have 
undergone an OGD for various reasons.  
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1.3.2 Inclusion and exclusion criteria 
Inclusion criteria 
1. All patients meeting diagnostic criteria for PBC according to EASL and 
AASLD guidelines (combination of cholestatic liver function tests and 
raised AMA (>1:40) and / or compatible histology) followed up at 
participating centres. 
2. PBC patients who had OGD for any clinical reason including screening 
for varices 
Exclusion criteria 
1. PBC patients with HCC or portal vein thrombosis 
1.3.3 Clinical data collection  
Newcastle Cohort 
Clinical records were reviewed for each patient on the PBC database and 
detailed clinical data collected. A previous study on the prevalence of portal 
hypertension in this cohort of PBC patients (D.E.J. Jones et al., 2002a) 
recorded biochemical, haematological, endoscopic and radiological / imaging 
data for each patient at various time points into this database. For the purposes 
of this study, data was extracted from this database at two time points – at first 
diagnosis of PBC and at the time of first OGD. In patients who were unstable at 
the time of the OGD, most recent steady state values were used. The Freeman 
Hospital Liver Transplant unit maintains a database of all patients who have had 
a liver transplant in the unit. This database was used to identify transplanted 
PBC patients. The national summary care records service, an online database 
that is constantly updated from primary care records, was used to gather 
mortality data. Collected data included the following: 
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x Demographic details including 
o Date of birth 
o Gender 
o Date first diagnosed with PBC as defined by the date at which the 
diagnostic criteria for PBC were first met 
x Liver biochemistry and blood haematological parameters including 
o Full blood count 
o Coagulation profile 
o Liver function tests including bilirubin, albumin, alanine amino-
transferase (ALT) and alkaline phosphatase (ALP) 
x Findings on OGD including 
o Number of OGDs 
o Date of each OGD 
o Presence or absence of GOV 
o Presence or absence of variceal bleeding as defined by the 
presence of bleeding seen from GOV or stigmata of recent 
haemorrhage present on GOV and associated blood in the upper 
GI tract or presence of GOV occupying more than 1/3rd of the 
oesophageal lumen and associated blood in the upper GI tract 
without other mucosal lesions 
x Mayo Score at diagnosis 
x Liver biopsy staging using the Scheuer score  
x Abdominal ultrasound scan findings with particular attention to the 
presence of splenomegaly as defined by a bipolar measurement of >12 
cm 
x Ursodeoxycholic Acid (UDCA) and beta blocker use, and finally, 
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x Outcome data in terms of date of death or liver transplantation in patients 
not transplanted and alive at the time of the study 
Validation Cohorts (Cambridge and Toronto) 
Clinical records were reviewed retrospectively for PBC patients from Cambridge 
and Toronto that met the inclusion and exclusion criteria requirements. 
Collected data included: 
x Demographic details 
x Liver biochemistry and blood haematological parameters similar to the 
Newcastle cohort  
x Abdominal ultrasound findings with particular attention to the presence or 
absence of splenomegaly as defined above (available in the Cambridge 
cohort only), and 
x Findings on OGD with reference to the presence or absence of GOV 
1.3.4 Data Analyses and Statistical Methods 
Data were collected using Microsoft Excel® and Microsoft Access® and 
analysed using Minitab® 15 and SPSS® 17 statistical packages. Health 
economics modelling was carried out using the Markov model which was 
constructed using java-script. 
Univariate and Multivariate analyses 
Each cohort of PBC patients from Newcastle, Cambridge and Toronto who 
underwent an OGD were divided into 2 groups based on the presence or 
absence of GOV. The group with GOV from the Newcastle cohort was further 
subdivided based on whether they had bled at index endoscopy or during the 
follow up period. Each group was characterised using basic descriptive 
statistics. Univariate analysis was used to identify statistically significant clinical 
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parameters from results of blood tests, imaging and liver biopsy to distinguish 
the 2 groups. Non-parametric continuous data were analysed using the Mann 
Whitney U test and categorical data using 2-tailed Fishers Exact test. In keeping 
with the aim of creating a tool that is inexpensive, non invasive and universally 
applicable, results from blood analyses that are measured routinely or available 
in clinic during follow up of PBC patients and were significantly (p<0.05) 
associated with the presence of GOV and bleeding on univariate analysis were 
entered into binary logistic regression analyses. The presence or absence of 
splenomegaly on ultrasound and PBC staging on liver biopsy were excluded 
from this analysis. The former is an additional cost investigation in the UK which 
would limit the use and cost effectiveness of the tool and the latter is an 
invasive procedure which is not routinely performed in patients with PBC. 
However, to cater to clinical environments where ultrasound is available 
routinely in clinic without additional cost, a variant of the score was created to 
include the presence or absence of splenomegaly on ultrasound. The Mayo 
Score, a composite score created using the same variables as those entered 
into the analyses individually, was also excluded from this analysis to avoid 
multi-co-linearity. This is a statistical phenomenon that occurs when parameters 
used for regression analysis are highly correlated, as would occur when a 
composite score and the individual variables used to create this score were 
entered into the same logistic regression analysis. 
 In the Newcastle cohort, where outcome data were collected, Kaplan-Meier 
survival curves, censored for transplantation, were generated and the log-rank 
test was used to compare survival amongst PBC patients with and without GOV 
and amongst those who bled versus those that did not. 
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Predictive tool creation 
Results of binary logistic regression of data from the entire Newcastle cohort 
were used to define the Odds Ratio (CI set at 95%) of finding GOV in these 
patients. Using a random number generator in SPSS, data from 70% of the 
cohort was grouped into a tool creation cohort and the remainder 30% was 
grouped into an internal validation cohort. Using binary logistic regression 
analysis on data from the tool creation cohort β coefficients for each statistically 
significant parameter were identified. β coefficients are statistically standardized 
estimates that establish the magnitude of effect of different independent 
variables on a dependant variable, when variables are measured in different 
units. (Schroeder et al., 1986) These β coefficients can be used to create a 
prediction tool using a logit equation. This equation is derived as follows : 
Probability = 1 / (1 + e –z ), where e represents the exponential function and z is 
a number obtained by adding the products of the β coefficients associated with 
each parameter and its numerical value. In other words z = β0 + β1*C1 + β2*C2 + 
β3*C3+… and so on. Using these coefficients a probability tool was created to 
predict the probability of finding GOV in patients with PBC.  The modelled tool 
created was checked for goodness of fit using the Hosmer-Lemeshow test 
which tests how closely the observed and predicted probabilities match and has  
the null hypothesis that the “model fits”; therefore a p value of >0.05 being 
desired. This tool was then both internally and externally validated using data 
from the internal validation cohort, the Cambridge cohort and the Toronto 
cohort. Sensitivity, specificity, positive predictive value and negative predictive 
value were calculated for the modelling, internal and external validation cohorts 
and finally for the entire cohort. A flexible approach was used and the 
performance characteristics calculated using 2 different cut offs (0.5 and 0.3) 
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which represent predicted probabilities of GOV being present of 50% and 30% 
respectively; the latter cut-off benefits from increased sensitivity at the expense 
of specificity and the former from increased accuracy at the expense of 
sensitivity.  Receiver Operating Characteristic (ROC) curves were generated for 
the predictive tool in the modelling set, internal, external validation cohorts and 
a combination cohort. Performance characteristics and area under the ROC 
curve (AUROC) curve of the tool was compared to previously proposed 
predictive tools aiming to identify patients with suspected GOV. 
Modelling of treatment implications of using the NVP score 
Health economics modelling to define the cost implications of using the NVP 
Score was carried out with the assistance of Peter Mcmeekin, Institute of 
Society and Health, Newcastle University. An analysis was undertaken to 
explore the two metrics we believe are those by which the utility of the NVP 
Score will be judged, namely the number of bleeds prevented and the number 
of endoscopies carried out to prevent those bleeds.  A multi-state Markov model 
was used to create a unique Cost Consequences analysis where 7 screening 
strategies were compared in terms of the number of endoscopies required and 
the number of bleeds. These included a “do nothing” arm where no screening 
would be initiated, an “OGD all” arm where every patient would undergo OGD at 
the onset of the cycle and then every 2 or 3 years according to AASLD 
guidelines and finally a “NVP Score” arm where every patient would be risk 
stratified using the NVP score at the onset and then every 2 or 3 years and 
endoscopy performed in those at high risk of GOV. The Markov model was 
terminated after 4 yearly cycles. The results represent the trade off between 
additional endoscopies saved (the consequences) versus incremental bleeds 
incurred (the costs). The Risk Prediction tool and the Cost-Consequences 
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analyses with options to choose various input models of prevalence and risk 
was uploaded onto the UK-PBC website as a supplemental tool that can be 
accessed online free of cost at http://www.uk-pbc.com/resources/uk-pbc-
varices-prediction-tool.html.  A number of assumptions (see Appendix – 
decision tree) were made about state transition probabilities in the Markov 
model. Aspects of these can be individually factored into this online model. This 
allows the model to be tailored to different healthcare systems and populations 
and allows flexibility amongst users to choose cut offs that best suit their 
practice. 
1.3.5 Ethical Approval 
As this was a clinical evaluation exercise, formal ethical approval was not 
sought and written informed consent was not needed. 
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1.4 Results 
1.4.1 Demographics and prevalence of GOV in the study cohorts 
Newcastle Cohort 
The Newcastle Cohort comprised 330 PBC patients who underwent OGD at 
any time-point for any indication. Median age at first endoscopy was 64 years; 
91.5 % were female. OGD took place a mean 5 years following the diagnosis of 
PBC for any clinical reason including screening for varices. 159 patients who 
underwent OGD had GOV at that point. Baseline demographics and descriptive 
statistics of the 2 groups are shown in Table 7. Both groups were similar in age, 
gender, median dose of UDCA prescribed and time from diagnosis to OGD. 
Toronto Cohort 
The Toronto cohort comprised 157 patients who underwent OGD; 90% were 
female, median age at endoscopy was 55.6 and 22% had GOV at OGD. Patient 
characteristics are shown in Table 8.  
Cambridge Cohort 
The Cambridge cohort comprised 52; 89% were female, median age at OGD 
was 62.5 years and 31% had GOV at OGD. Patient characteristics are shown in 
Table 9. 
Clinical characteristics of all cohorts are shown in Table 10. 
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Table 7: Patient characteristics and univariate analyses of factors associated 
with presence of GOV in the Newcastle cohort 
 
Varices 
(N=159) 
No Varices 
(N=171) 
p  
value 
Median Age at OGD (IQR)  64 yr. (13) 64 yr. (15) 0.394 
Females (%) 90 93 0.173 
Median time lag of OGD from PBC diagnosis (IQR)  4 yr. (5) 5 yr. (7) 0.952 
Mayo Score at PBC diagnosis (IQR)  5.7 (2.4) 4.4 (1.2) <0.001 
Ursodeoxycholic Acid Use (%) 41.5 62.6 <0.001 
Ursodeoxycholic acid dose, median (IQR) 600 (250) 600 (150) 0.055 
 
Histological Stage at Diagnosis (%)    
Missing  14 17 0.723 
Stage I, I-II, II  21  (13) 74 (43) <0.001 
Stage II-III, III 25  (16) 45 (26) 0.017 
Stage III-IV, IV  99 (62) 35 (20) <0.001 
 
 
Blood analyses at OGD (Median and IQR)     
Bilirubin (µmol/L)  31 (32) 10 (9) <0.001 
Alkaline Phosphatase (IU)  486 (451) 300 (461) <0.001 
Albumin (g/L)  35 (8) 42 (5) <0.001 
Platelets (x 109)  135 (80) 252 (116) <0.001 
Prothrombin Time (sec)  14 (2) 12 (2) <0.001 
 
Splenomegaly on Ultrasound at OGD (> 12cm)  91% 30% <0.001 
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Table 8: Patient characteristics and univariate analyses of factors associated 
with presence of GOV in the Toronto Cohort 
 
Varices 
(N=32) 
No 
Varices 
(N=115) 
p value 
Median Age at OGD (IQR)  55 yr. 
(15.0) 
56 yr. 
(15.5) 
0.8 
Females (%)  90 91 0.9 
Blood analyses at OGD (Median and IQR)  
Bilirubin (µmol/L)  19 (20) 11 (12) <0.0001 
Alkaline Phosphatase (IU)  212 (265) 172 (150) 0.06 
Albumin (g/L)  37 (7) 41 (4) <0.0001 
Platelets (x 109)  130 (78) 218 (128) <0.0001 
INR  1.06 (0.2) 0.99 (0.1) 0.0003 
 
Table 9: Patient characteristics and univariate analyses of factors associated 
with presence of GOV in the Cambridge Cohort 
 
Varices 
(N=16) 
No Varices 
(N=36) 
p value 
Median Age at OGD (IQR)  61 yr. 
(21.5) 
64 yr. (17.3) 0.6 
Females (%)  100 83 0.160 
Blood analyses at OGD (Median and IQR)  
Bilirubin (µmol/L)  26.5(33) 9 (5.5) <0.001 
Alkaline Phosphatase (IU)  209 (81) 179 (155) 0.33 
Albumin (g/L)  36 (8) 43 (7) <0.001 
Platelets (x 109)  71.5 
(45.5) 
217.5 (113) <0.001 
Prothrombin Time (sec)  12.8(1.95) 11.7 (1.1) 0.0054 
Splenomegaly on Ultrasound at OGD (> 12cm)  81.25% 36% 0.006 
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Table 10: Comparison between Newcastle, Toronto and Cambridge cohorts 
 
Newcastle 
Cohort (N=330) 
Toronto Cohort 
(N=147) 
Cambridge 
Cohort (N=52) 
Median Age at OGD  64 yr.  55 yr. 62.5 yr.  
Females (%)  91.5 90 89 
Blood analyses at OGD (Median)  
Bilirubin (µmol/L)  18 15 11 
Alkaline Phosphatase (IU)  384 186 200 
Albumin (g/L)  39 41 37 
Platelets (x 109)  189 193 150 
INR  1.11 1.02 1.02 
1.4.2 Clinical impact of GOV 
83 of 159 patients in the Newcastle cohort with GOV (52% 95 CI 44%-60%) 
suffered 245 episodes of variceal bleeding during a median 11 years follow up 
(IQR 8). Patients with GOV that bled and those that did not, were similar in sex, 
age at endoscopy, UDCA use and dose of UDCA (Table 11). 39 of 159 patients 
(25% 95CI 18%-32%) presented with a variceal bleed at index endoscopy. Of 
the 120 patients who did not present with haemorrhage, 44 (37% 95CI 28%-
46%) bled a median of 1.5years (IQR 3.75) after GOV were identified. The 
proportion of patients with GOV that bled was similar in those on non-selective 
beta blockers and those that did not receive or tolerate these agents (48% vs. 
52% respectively, p=0.75 Fisher’s exact test). However, the study was neither 
designed nor powered to detect any impact of beta blockade on variceal 
bleeding; data on adequacy of dose or the pharmacological response were 
unavailable.  Of note, 21 (13% 95CI 8%-19%) of the 159 PBC patients with 
GOV had early stage (Stage I, I-II, II) disease at most recent biopsy. Variceal 
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haemorrhage was the first presentation of GOV in 3 early stage PBC patients 
(14% 95CI 3%-36%) and a further 5 (24% 95CI 8%-47%) bled during follow up. 
 
Table 11: Patient characteristics and univariate analyses of factors associated 
with bleeding in those with GOV in the Newcastle cohort.  IQR – Inter Quartile 
Range 
 Bleeder 
(N=83) 
Non 
Bleeders 
(N=76) 
p  
value 
Median Age at OGD (IQR)  62 yr. (13) 62 yr. (15.8) 0.850 
Females (%) 93 86 0.199 
Mayo Score at PBC diagnosis (IQR)  5.9(2.7) 5.5(1.6) 0.909 
Ursodeoxycholic Acid Use (%) 37 35 0.334 
Ursodeoxycholic acid dose, median (IQR) 600(100) 600(250) 0.777 
 
Histological Stage at Diagnosis (%)    
Missing  8 (10) 6 (8) 0.706 
Stage I, I-II, II  8  (10) 13 (17) 0.217 
Stage II-III, III 12  (14) 13 (17) 1.000 
Stage III-IV, IV  55 (66) 44 (58) 0.155 
 
Blood analyses at OGD (Median and IQR)     
Bilirubin (µmol/L)  35.5 (41) 29 (23.75) 0.027 
Alkaline Phosphatase (IU)  469 
(419.25) 
514 (506) 0.522 
Albumin (g/L)  35 (9.5) 36 (5.5) 0.133 
Platelets (x 109)  120 (60) 147 (88.5) 0.029 
Prothrombin Time (sec)  14 (2) 13 (2) 0.135 
Splenomegaly on Ultrasound at OGD (> 12cm)  98% 83% 0.002 
 
79 
 
1.4.3 Factors associated with the presence of GOV 
Univariate Analyses 
On univariate analysis, in the Newcastle cohort, high bilirubin, high alkaline 
phosphatase, low albumin, low platelet count, higher prothrombin time, 
advanced histological stage at diagnosis (Scheuer stage >II), Mayo Score at 
diagnosis, not being on UDCA and splenomegaly on ultrasound were 
associated with the presence of GOV (all p<0.01) (Table 7).  
Multivariate Analyses 
In multivariate analyses using non invasively obtained variables only albumin, 
platelet count, alkaline phosphatase and the presence of splenomegaly were 
associated significantly with the presence or absence of GOV. The odds-ratios 
defining these associations are shown in Table 12 and can be used to quantify 
the incremental risk of having varices depending on every unit change in each 
clinical parameter. Therefore, a platelet count reduced by a value of 1x109, 
albumin that is lower by 1 g/L and the presence of splenomegaly are associated 
with a 1.15% (95% CI 1.1% to 1.2%), 18% (95% CI 10% to 25%) and a 67% 
(95% CI 31% to 145%) increase in the odds of finding GOV, respectively. 
1.4.4 Factors associated with bleeding in those with GOV 
Univariate analyses 
On univariate analysis, high bilirubin, low platelet count and splenomegaly were 
associated significantly with bleeding from GOV (Table 11).  
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Table 12: Multivariate analyses of parameters significantly associated with the 
presence of varices on univariate analyses  
 
P value 
Odds ratio 
(Exp B) 
95% CI for odds ratios 
Lower Upper 
Platelets (x109) <0.001* 0.985 0.980 0.990 
Albumin (g/L) < 0.001* 0.822 0.747 0.905 
Alkaline Phosphatase (IU) 0.032* 1.001 1.000 1.002 
Presence of Splenomegaly <0.001* 6.742 3.139 14.480 
Age 0.272 0.981 0.949 1.015 
Sex 0.496 0.608 0.145 2.551 
Bilirubin (µmol/L) 0.418 0.996 0.986 1.006 
Prothrombin Time (s) 0.628 0.973 0.768 1.233 
UDCA use 0.480 0.739 0.319 1.710 
The Odds ratios signify the percentage odds of finding GOV for every 1 point change in 
that variable. * - statistically significant variables used to create the predictive equation. 
 
Multivariate analyses 
 After adjusting for other variables significantly associated with bleeding in 
univariate analysis only the presence of splenomegaly was associated with 
bleeding (p=0.046) on multivariate analyses (Table 13). As lag time post 
diagnosis to presentation with bleeding may be a confounder and clinically 
significant, this was also entered into the multivariate analysis. 
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Table 13: Multivariate analyses of parameters significantly associated with 
bleeding from GOV on univariate analyses.  
 
P value 
Odds ratio 
(Exp B) 
95% CI for odds ratios 
Lower Upper 
Presence of Splenomegaly <0.046* 0.111 0.013 0.964 
Platelets (x109) 0.435 0.998 0.991 1.004 
Bilirubin (µmol/L) 0.167 1.010 0.996 1.024 
Time lag post diagnosis (yrs) 0.621 0.974 0.877 1.082 
The Odds ratios signify the percentage odds of bleeding for every 1 point change in 
that variable. * - statistically significant variables 
 
1.4.5 Impact of GOV on survival 
Transplant free survival after diagnosis of PBC was better without GOV than 
with GOV (p<0.001) (Figure 8).  
 
Figure 8: Kaplan Meier curves comparing survival following endoscopy in PBC 
patients with GOV versus those without GOV 
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1.4.6 Impact of GOV bleeding on survival 
There was no significant difference in survival in patients with GOV that bled on 
follow up and those that did not (p=0.1) (Figure 9). 
 
Figure 9: Kaplan Meier curves comparing survival in patients with PBC with 
GOV that bled vs. those that did not. 
 
1.4.7 The Newcastle Varices in PBC Score 
Using statistical methods described above, the probability of finding GOV in 
PBC was given either by the equation 
The Newcastle Varices in PBC Score (NVP) =                                                        
1 / [1 + e^-(9.186 + 0.001*ALP – 0.178 *Alb – 0.015*PLT)] 
Or The Newcastle Varices in PBC Score – Splenomegaly variant (NVP-S) =  
1 / [1 + e^-(6.385 - 0.138*Alb - 0.012*PLT + 2.013*X)] 
where: Alb = Albumin in g/L, ALP = Alkaline Phosphatase in IU, PLT = Platelet x 
109 and X=1 if splenomegaly was present on USS and X=0 otherwise.   
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An online calculator for the NVP is available at http://www.uk-
pbc.com/resources/uk-pbc-varices-prediction-tool.html. The online tool includes 
a correction factor to standardise ALP results measured in laboratories with 
different reference upper and lower limit of normal to those of the reference 
range used for this study (30-130 IU). This correction factor (Chuang-Stein, 
1992) is given as follows: standardised ALP to use in score = 30 + [(ALP - LLN) 
* (100/ (ULN-LLN))] where ALP = ALP result as obtained in external lab, LLN = 
lower limit of normal in external lab and ULN = Upper limit of normal in external 
lab. The p values of Hosmer-Lemeshow goodness of fit test for these models 
were 0.256 and 0.073 respectively indicating the models were adequate for the 
data set. Both models remained valid in both the internal (30% of the Newcastle 
cohort) and external Cambridge validation cohort. In addition the NVP score 
remained valid in the international Toronto external validation cohort. 
1.4.8 Performance characteristics of the Score in all PBC patients 
Both scores demonstrated discrimination exceeding 0.85 (AUROC) in the 
internal and external validation cohorts (Table 14 and Table 15) out-performing 
current criteria in both discrimination and accuracy. AUROC curves comparing 
the NVP with previously suggested criteria are shown in Figure 10 and Figure 
11. 
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Table 14: Performance characteristics of the NVP score in modelling and 
internal validation cohorts and in the combined cohort at different probability cut 
offs and comparison with other criteria. 
Test (probability cut off) Sen. 
% 
Spe. 
% 
PPV 
% 
NPV 
% 
Acc.  
% 
AUROC 
(95% CI) 
NVP Score – Modelling Set 
(0.5) 
81.4 82.9 82.1 82.2 82 0.897 
(0.856-0.938) 
NVP Score – Internal Validation Set  
(0.5) 
83.8 80 79.5 82.4 82 0.861 
(0.777-0.944) 
NVP Score - Combined cohort 
(0.5)  
81.2 80.8 73 87 80.9 0.863 
(0.831-0.896) 
NVP Score - Combined cohort 
(0.3)  
92.8 60.6 60.2 92.9 73.2 0.863 
(0.831-0.896) 
Cirrhotic (Stage IV) PBC  64.2 73.1 68.9 68.7 68.7 0.686 
(0.628-0.744) 
MRS > 4.1 90.3 33 46.4 84.1 61.7 0.617 
(0.536-0.697) 
Platelets <200 82.2 74.3 74.6 81.9 78.3 0.782 
(0.731-0.834 
Platelets <140 51.6 90.1 82.7 67 70.9 0.708 
(0.651-0.766) 
Platelets<100 22.3 95.9 83.3 57.3 59.1 0.591 
(0.529-0.653) 
Total Bil  ≥ 1.1 mg/dl &/or alb < 3.5 
g/dL 
80.9 73.1 73.4 80.6 77 0.768 
(0.715-0.821) 
MABPT 96.8 25.3 54.2 89.6 61 0.610 
(0.549-0.671) 
MRS - Mayo Risk Score, (P. Angulo et al., 1999b) MABPT – Males, Low Alb (<3.5 g/dL), 
High bil (≥ 1.2 mg/dL) and / or High PT (> 12.9), (Ali et al., 2011) Platelet cut off values as 
suggested by Bressler (Bressler et al., 2005) and Levy (Cynthia Levy et al., 2007) 
 
 
85 
 
Table 15: Performance characteristics of the variant NVP-S (Newcastle Varices 
in PBC-splenomegaly) score in various cohorts 
Test (probability cut off) Sen. 
% 
Spe. 
% 
PPV 
% 
NPV 
% 
Acc.  
% 
AUROC 
(95% CI) 
NVP-S Score – Modelling Set 
(0.5) 
88 82.6 83 87.7 85 0.912 
(0.873-0.851) 
NVP-S Score- Internal Validation Set 
(0.5) 
86.8 68.3 71.7 84.8 77 0.874 
(0.797-0.951) 
NVP-S Score – Cambridge Validation 
Set (0.5) 
94 67 56 96 81 0.934 
0.868-1.000 
NVP-S Score – Modelling Set 
(0.3) 
94 74.4 78 92.8 84 0.912 
(0.873-0.851) 
NVP-S Score – Internal Validation Set 
(0.3) 
94.7 58.5 67.9 92.3 75.9 0.874 
(0.797-0.951) 
AASLD  / EASL - Cirrhotic (Stage IV) 
PBC  
64.2 73.1 68.9 68.7 68.7 0.686 
(0.628-0.744) 
MRS > 4.1 90 .3 33 46.4 84.1 61.7 0.617 
(0.536-0.697) 
Platelets <200 82.2 74.3 74.6 81.9 78.3 0.782 
(0.731-0.834 
Platelets <140 51.6 90.1 82.7 67 70.9 0.708 
(0.651-0.766) 
Total Bil  ≥ 1.1 mg/dl &/or alb < 3.5 
g/dL  
80.9 73.1 73.4 80.6 77 0.768 
(0.715-0.821) 
MABPT 96.8 25.3 54.2 89.6 61 0.610 
(0.549-0.671) 
Sen. –Sensitivity, Spe. Specificity, PPV – Positive Predictive Value, NPV – Negative 
Predictive Value, Acc. – Accuracy, AUROC – Area under receiver operating characteristic 
curve, MRS - Mayo Risk Score, Bil – Bilirubin, alb – albumin, MABPT – Males, Low Alb 
(<3.5 g/dL), High bil (≥ 1.2 mg/dL) and / or High PT (> 12.9). Platelet cut off values as 
suggested by Bressler et al  and Levy et al . 
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Figure 10 ROC curves of the Newcastle Varices in PBC score derived in A) 
Tool derivation cohort, B) Internal validation cohort and C) Combined external 
validation cohorts 
 
Figure 11 Performance and Comparison of ROC curves of NVP score with 
currently suggested criteria as used in A) the Newcastle cohort and in B) the 
subgroup of patients with early PBC from the Newcastle cohort.
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1.4.9 Performance characteristics of the NVP Score in early PBC patients 
When applied to the subgroup of patients with early PBC the AUROC of the 
NVP score exceeded 0.9 again out-performing current criteria in discrimination 
and accuracy (Table 16). 
Table 16: Performance characteristics of NVP Score in Early Stage Patients 
(Stages I-III) from the Newcastle cohort in comparison with previously 
suggested tools 
Test (probability cut off) Sen. 
% 
Spe. 
% 
PPV 
% 
NPV 
% 
Acc.  
% 
AUROC 
(95% CI) 
NVP Score  
(0.3) 
80 86 62 94 83 0.904 
(0.827-0.980) 
NVP Score  
(0.5) 
65 96 81 91 81 0.904 
(0.827-0.980) 
Total Bil  ≥ 1.1 mg/dl &/or alb < 3.5 
g/dL 
71.4 95.8 83.3 91.9 83.6 0.829 
(0.703-0.954) 
Platelets <200 76.2 81.1 53.3 92.3 78.6 0.782 
(0.660-0.905) 
Platelets <140  47.6 94.6 71.4 86.4 71.1 0.696  
(0.548-0.845) 
Platelets<100 14.3 95.9 50 79.8 55.1 0.551 
(0.405-0.697) 
MABPT  95.2 31 29 95.7 63.1 0.632 
(0.508-0.757) 
Sen. –Sensitivity, Spe. Specificity, PPV – Positive Predictive Value, NPV – Negative 
Predictive Value, Acc. – Accuracy, AUROC – Area under receiver operating characteristic 
curve, Bil – Bilirubin, alb – albumin, MABPT – Males, Low Alb (<3.5 g/dL), High bil (≥ 1.2 
mg/dL) and / or High PT (> 12.9). Platelet cut off values as suggested by Bressler et al  and 
Levy et al  
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1.4.10 Modelling the cost implications of using the NVP Score 
Results of the cost consequence analyses in a hypothetical cohort of 1000 PBC 
patients, assuming prevalence of varices in PBC at 30%, (Bressler et al., 2005) 
bleeding from varices at 33% at 1 year and 41% at 3 year, (G.J. Gores et al., 
1989a) rate of development of varices 11% per year (Mayo data) and standard 
prevalence data of outcomes in those with varices treated with beta-blockers or 
endoscopic band ligation and the performance characteristics of the tool in the 
combined cohort at a cut off of 0.3 as input was carried out with the help of 
Peter Mcmeekin, Institute of Society and Health, Newcastle University and 
results are shown in Table 17.  Use of “OGD in all” every 2 years was 
associated with a significant reduction in the number of variceal bleeds 
compared to “doing nothing” (191 per 1000 patients over 4 years compared with 
629, p<0.0001). This was, however, at the cost of 1938 endoscopies per 
thousand patients over the 4 year period.  Application of the NVP score to pre-
screen for need for OGD would be associated with only 13 additional bleeds, 
but would save over 1000 endoscopies over the 4 year period. The other 
screening modalities were equally effective at reducing the numbers of bleeds 
but did so at the cost of a significantly greater number of endoscopies than 
would have been the case with use of the NVP using the modelling approach.  
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Table 17: Cost Consequences analysis representing potential screening 
strategies for varices in PBC in a notional group of 1000 patients over a 4 year 
periods. 
 
  
Screening Approach 
Variceal Bleeds 
 Over 4 Years 
OGDs  
Over 4 Years 
n p (vs. 
NVP) 
n p (vs. 
NVP) 
Extra OGD/1000 
patients/yr 
Do Nothing 629 <0.000
1 
629 <0.0001 - 
OGD 191 ns 1938 <0.0001 256 
Newcastle Varices in PBC 
Score (NVP) 
204 - 915 - - 
MRS>4.5 and/or plat<140  200 ns 1385 <0.0001 120 
MRS >4.1 199 ns 1785 <0.0001 220 
Total Bil> 1.1mg/dl and/or 
alb<3.5g/dl  
203 ns 1466 <0.0001 138 
MABPT  198 ns 1550 <0.0001 159 
Extra endoscopy values represent the additional endoscopies which would take place per 
1000 patients per year using the relevant screening modality compared to the NVP to 
achieve the same level of varices prevention.  Bil – Bilirubin, alb – Albumin, Plat – 
Platelets, MRS - Mayo Risk Score, MABPT – Males, Low Alb (<3.5 g/dL), High bil (≥ 1.2 
mg/dL) and / or High PT (> 12.9) 
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1.5 Discussion 
1.5.1 The Newcastle Varices in PBC Score 
The Newcastle Varices in PBC (NVP) Score, and its variant model for use 
where ultrasound assessment of splenomegaly is readily available the 
Newcastle Varices in PBC Score – Splenomegaly (NVP-S), are  non-invasive 
tools that predict the presence of GOV in patients with PBC, developed in a 
large well characterised cohort and validated internally and externally.  Using a 
cut-off at 0.3 the NVP score has high sensitivity (93%), negative predictive 
value (93%) and discriminating value (AUROC of 0.86).  The tool uses objective 
laboratory parameters that are measured routinely, readily and at low cost at 
follow up; it outperforms recent guidelines for screening in terms of accuracy 
and discrimination including previously suggested threshold cut offs values of 
platelet counts. In particular, it retains high sensitivity, negative predictive value 
and discriminating power (AUROC of 0.9) in patients with early PBC, a group in 
whom the use of such a tool would be of greatest value.  A cost consequences 
evaluation of the NVP score to screen patients with PBC demonstrated 
significant savings in the number of endoscopies performed at the cost of a 
small increment in the number of variceal bleeds when compared to endoscopy 
as the screening strategy. The variant NVP-S score also demonstrated similar 
performance characteristics and discriminating power. 
1.5.2 Prevalence and impact of GOV in patients with PBC 
This study provides further evidence that GOV is common in PBC, found in 
early disease and associated with significant morbidity and mortality.  More than 
10% of patients with GOV had early stage PBC.  The 5- and 10-year survival in 
PBC patients with GOV was 63% and 26% respectively, in contrast to 91% and 
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83% in patients without GOV.  This reiterates the importance of using effective 
strategies, such as the NVP score, to identify PBC patients with GOV at an 
early stage to allow appropriate intervention.  
1.5.3 Impact of bleeding from GOV in PBC patients 
In this cohort, survival was similar in those with varices whether they bled or 
not.  Patients with PBC tolerate variceal haemorrhage well. (M. R. Biagini et al., 
1990a) It is also known that PBC patients have decreased blood loss when 
transplanted, (Popov et al., 1972) possibly due to an underlying 
hypercoagulable state. (Ritter et al., 1989; Ben-Ari et al., 1997; Segal et al., 
1997; Pihusch et al., 2002) It is likely that severity of underlying liver disease 
predicts survival in PBC rather than decompensated portal hypertension. 
1.5.4 Lack of Bilirubin and PT in the predictive score 
Both bilirubin and alkaline phosphatase are independent predictors of outcome 
in PBC and are components of UDCA response criteria (Parés et al., 2006; 
Corpechot et al., 2008; Edith M. M. Kuiper et al., 2009) that predict survival in 
PBC patients who are treated with UDCA. Prothrombin time is an important 
measure of hepatic synthetic dysfunction in advanced cirrhosis and end stage 
liver disease. The absence of bilirubin and prothrombin time in the NVP Score 
and their statistical insignificance in multivariate analyses is noteworthy. A 
similar lack of significance of these parameters in predicting GOV in patients 
with PBC has been noted in previous studies. (Bressler et al., 2005; Cynthia 
Levy et al., 2007; Ali et al., 2011) In particular Ali et. al. showed that in early and 
mid histological stage PBC, PT and bilirubin were not significantly different 
between patients with and without GOV suggesting the role of presinusoidal 
portal hypertension in PBC. (Ali et al., 2011)  
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1.5.5 The role of pre sinusoidal portal hypertension in patients with PBC 
Results from this and previous studies reiterate evidence that pre-sinusoidal 
portal hypertension secondary to nodular regenerative hyperplasia or the 
presence of portal phlebosclerosis (Colina et al., 1992; Nakanuma, 2003) might 
play a role in the development of GOV in PBC.  These changes antecede 
abnormal lab parameters that accompany synthetic dysfunction accompanying 
cirrhotic late stage PBC or significant cholestasis which are features of 
advanced PBC, again emphasizing the value of the NVP tool in screening early 
stage patients with normal laboratory indices. 
1.5.6 The role of splenomegaly in predicting GOV in patients with PBC 
The presence or absence of splenomegaly on USS was shown in our study to 
be the single most important predictor of the presence of GOV. The presence of 
splenomegaly increases the odds of finding GOV six fold. However it is 
important to note that splenomegaly, or indeed, other biochemical and 
haematological parameters of portal hypertension may not be evident in early 
PBC and the greatest utility of the NVP score is to allow prediction of GOV in 
this group of patients where the results of this score may be the only 
discriminator available suggesting the need for OGD. Furthermore, the NVP 
Score outperformed the presence of splenomegaly, used on its own,  in 
discriminating PBC patients with GOV (AUROC 0.88 vs. 0.79 respectively in the 
entire Newcastle Cohort). In fact, the NVP score itself can be used to accurately 
predict patients with splenomegaly with a high discriminating power (AUROC 
0.85). 
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1.5.7 Exploring the role of UDCA in the development of GOV in PBC 
The role of UDCA in preventing the development of GOV was highlighted 
recently. (Pierre-Michel Huet et al., 2008) The proportion of patients with GOV 
treated with UDCA was significantly lower than those without GOV, but not 
being treated with UDCA was not associated with GOV on multivariate analysis.  
Including UDCA in the predictive tool, for reasons of clinical significance, did not 
improve the model performance characteristics (accuracy 83% and 79% in 
modelling and validation cohorts respectively). The use of UDCA in PBC (and 
response) is associated with improvement in liver biochemistry including 
bilirubin, ALP and ALT. (Paul Angulo et al., 1999a; Parés et al., 2006; Pierre-
Michel Huet et al., 2008; Edith M. M. Kuiper et al., 2009) ALP is included in the 
predictive score and improvement in this parameter after treatment with UDCA 
may outweigh the effect of UDCA on the NVP score. Appropriate weight-based 
dosing and adherence to UDCA treatment is difficult to ascertain during such 
clinical follow-up studies and this could influence results, limiting the 
interpretation of lack of significance of UDCA in multivariate analysis and 
exclusion from the score. The predictive value of alkaline phosphatase levels for 
GOV risk across all populations (UDCA treated and non-treated), together with 
the non-independence of UDCA therapy and alkaline phosphatase levels in 
predicting GOV on multivariate analysis and the well established reduction in 
alkaline phosphatase levels with UDCA would all be supportive, within the 
constraints of the data available, of the beneficial effect of UDCA therapy on 
GOV risk being linked to its anti-cholestatic effects further supporting its 
universal use in PBC.  
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1.5.8 Limitations of this study 
This study was retrospective and therefore it was not possible to draw 
conclusions relating to size of GOV. However, the NVP tool is an initial 
screening strategy to help decide on the need for endoscopic screening of high 
risk patients and to seek those that would benefit from additional investigations.  
The absence of a qualifier describing the size of GOV did not reduce 
performance of the score.  The study does suffer from selection bias as patients 
were included because an endoscopy had been requested, for various reasons 
including screening.  However, the cohort was large and diverse and the score 
performed well in external validation. The retrospective nature of the study also 
precluded us from comparing NVP with transient elastography (“FibroScan®”) 
as a further potential modality for non-invasive assessment of portal 
hypertension risk in PBC. 
1.5.9 Usability of this score in different health economic climates 
An important attribute of the NVP tool is that it offers an objective percentage 
probability assessment of the risk of finding GOV in PBC patients and allows 
tailoring the cut off at which the need for further endoscopic evaluation is 
needed. An extension of this is reflected in choosing cost-consequences 
analysis to evaluate the health economics of the tool. A cost consequences 
analyses best reflects the outcomes that a decision maker would consider most 
important when deciding between alternative screening strategies (is minimising 
the risk of bleed form undiagnosed GOV or minimising the number of un-
necessary OGD the local priority).  Furthermore, extending the analysis by 
including financial costs or by associating quality of life measures with health 
outcomes would focus any results to distinct locales. 
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1.6 Conclusion  
In conclusion, GOV in PBC are common, even in early PBC and have 
substantial effects on survival irrespective of whether they bleed or not. The 
Newcastle Varices in PBC Score is a simple, universally available, externally 
validated, highly discriminating and accurate predictive tool for clinical practice. 
Over a 1000 endoscopies would be saved if the score was used to screen 1000 
PBC patients for varices over 4 years without any statistically significant 
increase in the number of variceal bleeds when compared to screening all PBC 
patients with an OGD over the same period.   
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CHAPTER 2: ROLE OF UDCA RESPONSE CRITERIA IN 
PREDICTING OUTCOMES IN PBC 
  
97 
 
2.1 Introduction 
About 20% of patients with PBC do not respond to UDCA. It has been shown in 
a number of studies that the prognosis of patients who respond to UDCA is 
significantly better than that predicted by their Mayo Scores and that patients 
who normalise liver biochemistry on UDCA have no risk of progression to 
cirrhosis. (R. Poupon, 2010) Improvement in liver biochemistry during an initial 
period after commencement of UDCA treatment has therefore been evaluated 
in a number of cohort studies as a surrogate marker to predict outcome and 
impact on survival. These studies aim to identify “responders” to treatment who 
will benefit from UDCA versus non responders who will not and in doing so 
allow risk stratification to rationalise follow up and to enable early consideration 
of alternative treatment options including liver transplantation. 
2.1.1 UDCA Response criteria 
Various UDCA response criteria have been proposed previously and these are 
summarised in Table 18. The most commonly used criteria to gauge response 
to UDCA is the Paris I criteria which defines response as a bilirubin ≤ 1 mg/dL 
and ALP ≤ 3 ULN and AST ≤ 2 ULN 12 months after treatment with UDCA at a 
dose of 13-15 mg/Kg/d. (Corpechot et al., 2008) Patients who achieve response 
as per this criteria have a 10 year transplant free survival rate of 90% compared 
to 51% in those who do not (p <0.001). The Paris I criteria were recently 
validated as the most discriminatory predictor of response and outcome in a 
large well characterised PBC cohort in the UK. This study also suggested that 
female sex, age at diagnosis, low ALP, low bilirubin, high creatinine and lack of 
splenomegaly predicted response. (M. Carbone et al., 2013) The merits of this 
study are the inclusion of a large unselected cohort from the UK with detailed 
phenotypic data available at the time of analysis. This study cohort for the first 
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time included a significant proportion of younger age group and male patients 
making the analysis and interpretation of data meaningful.  A recent study by 
the Dutch PBC group has shown that UDCA response was associated with 
lower risk of developing hepatocellular carcinoma. In this study, non response 
was associated with 10% and 20% risk of developing cancer at 9 and 15 years 
respectively (Figure 12) highlighting the need for screening in these patients. 
(E. M. Kuiper et al., 2010)  In a recent international study, non-treatment with 
UDCA itself was not associated with cancer development; however, 
stratification by biochemical non-response at 12 months was associated 
significantly with future risk of HCC (HR 4.52, p<0.0001; IR 6.6 vs. 1.4, 
p<0.0001). Non-response predicted future risk in patients with early stage 
disease (IR 4.7 vs. 1.2, p=0.005), advanced disease (HR 2.79, p=0.02; IR 11.2 
vs. 4.4, p=0.033), and when restricting the analysis to only male patients (HR 
4.44, p<0.001; IR 18.2 vs. 5.4, p<0.001). On multivariate analysis biochemical 
non-response remained the most significant factor predictive of future HCC risk 
(adjusted HR 3.44, p<0.0001). (Trivedi et al., 2015)  
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Figure 12: Long term HCC risk in PBC patients in a Dutch cohort based on 
response and Non response to UDCA. 
 
The log rank test suggests a significantly increased risk of developing HCC in 
patients who do not respond, equating to 10% and 20% risk of developing 
cancer at 9 and 15 years, when compared to patients with biochemical 
response to UDCA. Figure adapted from Kuiper et al Eur J Gastroenterol 
Hepatol, 2010: 22(12), 1495-502. 
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Table 18: UDCA Response Criteria as suggested by various groups 
Name of 
criteria 
Yr. 
No. 
of 
pts. 
Dose of 
UDCA 
mg/Kg/d 
Criteria 
Time 
point 
(m) 
Outcome  
(Responders) 
Mayo (Paul 
Angulo et al., 
1999a)  
1999 180 13-15 ALP < 2 fold ULN 
OR Mayo Risk 
Score <4.5 
6 Favourable 
prognosis 
Barcelona 
(Parés et al., 
2006) 
2006 192 15 ALP reduction 40% 
of pretreatment or 
ALP normalisation 
12 Improved 
survival 
Paris I 
(Corpechot 
et al., 2008) 
2008 292 13-15 Bilirubin ≤ 1 mg/dL 
and ALP ≤ 3 ULN 
and AST ≤ 2 ULN 
12 Survival 
similar to 
controls 
Rotterdam 
(Edith M. M. 
Kuiper et al., 
2009) 
2009 375 13-15 Normalisation of 
bilirubin and 
albumin 
12 Survival 
comparable to 
normal 
population 
Paris II 
(Corpechot 
et al., 2011) 
2011 165 13-15 Normal bilirubin 
ALP and AST ≤ 1.5 
ULN 
12 Survival 
without AE* 
Sex and Age 
Criteria  
(M. Carbone 
et al., 2013) 
2013 1090 13-15 Female gender and 
Age <50 at 
presentation 
- Likelihood of 
response 
based on 
Paris I criteria 
 
* AE = Adverse events over 7 yrs of liver-related death, OLT or referral to transplant 
unit, complication of cirrhosis, or histological evidence of cirrhosis.  
ULN = Upper Limit of Normal 
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2.1.2 Do “Response Criteria” identify patients who have a good prognosis 
per se irrespective of treatment with UDCA? 
An interesting question when considering response criteria is whether the 
attainment of these response criteria during follow up indicate a specific 
response to UDCA treatment or whether they reflect an inherent difference in 
the behaviour between two groups of PBC patients with a different course of 
disease progression whether it is treated or not? Components of response 
criteria are independent markers of prognosis in PBC. Bilirubin is an 
independent marker of severity in PBC and is the most powerful component of 
the Mayo risk score. ALP is an independent marker of outcome and is also a 
marker of cholestasis. Raised ALT and AST are markers of Autoimmune 
Hepatitis and the overlap syndrome which is associated with a poorer outcome. 
It may therefore be suggested that in those patients who have biochemistry 
consistent with “response” one year after diagnosis whether this is a result of 
treatment or not, have a good prognosis.  
A review of our database of patients with PBC to develop the Newcastle Varices 
in PBC score allowed a further opportunity to study the hypothesis that UDCA 
response criteria identify a subgroup of patients with PBC who have an 
inherently good prognosis irrespective of whether they have been treated with 
UDCA or not.  
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2.2 Aim 
To assess in patients with PBC if “UDCA response” as per the Paris I criteria 
identify a cohort of patients with an inherently good prognosis whether they 
receive UDCA or not. 
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2.3 Methods 
2.3.1 Study setting, design and population 
A 10 yr prospective longitudinal follow up study was designed. 136 patients with 
PBC, who were initially identified in 1999 from our centre to study the impact 
and severity of fatigue, (Goldblatt et al., 2002) were included. 136 age and sex 
matched controls were identified from primary physician registers. Ten years 
ago, UDCA was not universally given to all PBC patients at our center – this 
was an era effect and reflected clinical practice at that time. 
2.3.2 Clinical data collection 
Apart from baseline demographic data, for the purposes of this study, 
biochemical data was collected for the entire cohort including bilirubin, ALT, 
ALP levels and Prothrombin time. Histological data on staging of disease was 
collected for all patients. Based on biochemical parameters that would define 
“response” as per the Paris I criteria (Corpechot et al., 2008) - reduction in ALP 
≤ 3 times ULN, reduction in AST ≤ twice the ULN and a Bilirubin of ≤ 1mg/dl at 
least one year after beginning UDCA therapy, UDCA- receivers and Non-UDCA 
receivers were assigned to “responders” and “non- responder” groups (defined 
as per Paris I criteria after a minimum of 1 year of UDCA theray in 1999 for the 
UDCA-group and at baseline in the non-UDCA group). Outcome data in terms 
of transplant free survival was collected by accessing the summary care record 
database to identify those patients and controls who were alive and cross 
referenced against the Freeman Hospital liver unit transplant database to 
identify patients who had been transplanted at the time of this study. 
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2.3.3 Data Analyses 
Each group was characterised using basic descriptive statistics. Univariate 
analyses were used to identify statistically significant clinical parameters from 
results of blood tests and liver biopsy to assess if there were any differences 
between the groups. The log Rank test was used to compare survival between 
the PBC patient groups and controls. 
2.3.4 Ethical Approval 
As this was a clinical evaluation exercise, formal ethical approval was not 
sought and written informed consent was not needed. 
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2.4 Results 
2.4.1 Demographic data 
Of the 136 PBC patients in this study, 94(69%) did not receive UDCA whilst 
42(31%) patients received UDCA. 124 (91%) of the 136 patients were female. 
Median age was 65.5yr (range 21-88yrs). There were no differences between 
the 2 groups at baseline with reference to biochemical parameters or 
histological stage. Demographic data is presented in Table 19. 
Table 19: Baseline demographic data and comparison of UDCA receiving and 
Non UDCA Receiving PBC patients  
 
All patients 
N=136 
Median 
(range) 
 
UDCA 
Receiving 
patients 
N=42 
Median 
(range) 
Non UDCA 
receiving 
patients 
N=94 
Median 
(range) 
p 
value 
Females 124(91%)    
Age (yrs) 65.5(21-88) 64 (45-86) 68 (21-87) 0.723 
Bilirubin (mg/dL) 0.5 (0.2-7.7) 0.5 (0.2-7.7) 0.5 (0.2-6.1) 0.680 
Alkaline Phosphatase (U/L) 131 (35-844) 
159 (60-
673) 
120 (35-844) 0.697 
Albumin (g/dL) 4.2 (2.8-5.1) 4.1 (3.0-4.9) 4.2 (2.8-5.1) 0.227 
Prothrombin time (s) 13 (11-24) 13 (11-24) 13 (11-16) 0.441 
Histological Stage 2 2 2 N.S 
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2.4.2 Responders and Non Responders 
Of the 42 patients treated with UDCA 34 (81% 95% CI 66%-90%) of PBC 
patients treated with UDCA responded. Of the 94 that did not receive UDCA, 80 
(85% 95% CI 76%-91%)) had biochemical features that would be compatible 
with “response”. There was no significant difference in the proportion that met 
response criteria after UDCA treatment when this was compared with those that 
did not receive UDCA (p=0.559). However this study was not powered nor 
designed to detect this difference. 
2.4.3 Comparison of survival between PBC patients and controls 
The survival of patients with PBC as a whole was worse than that of age and 
sex matched controls. (Figure 13) 
Figure 13: Kaplan Meier curves comparing survival between patients with PBC 
and age and sex matched controls. 
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2.4.4 Comparison of survival between UDCA receiving and non receiving 
PBC patients versus controls 
Transplant free survival in UDCA receiving responders in our study mirrored 
that of controls, as expected. This was also significantly better than the 
transplant-free survival of PBC patients that do not receive UDCA at all 
(p<0.05). Importantly, transplant-free survival in non-UDCA receiving 
“responders” in our cohort was similar to that of UDCA receiving responders 
and indeed, to age and sex matched population controls (p=ns, Figure 14). 
Non-UDCA receiving Non-Responders had a significantly worse outcome 
compared to responders and controls. 
Figure 14: Transplant free survival in controls compared with PBC patients that 
“responded” to UDCA, those that did not receive UDCA but met the biochemical 
response criteria and with those that did not receive UDCA and did not meet the 
“response” criteria on follow up 
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2.5 Discussion 
The question we initially posed is one of prognostic risk stratification based on 
lab parameters that have been used in the context of measuring response to 
UDCA. Whether the same laboratory criteria predict prognosis in PBC patients 
who have not been treated with UDCA remains unclear and in an era where 
UDCA is universally prescribed to all patients with PBC, this question is difficult 
to answer. This study allows an insight into this area of ambiguity and provides 
some idea of the usefulness of these parameters in prognostic stratification in 
PBC irrespective of UDCA use. The findings in this study confirm that a lack of 
improvement in biochemical parameters after follow up for one year identifies a 
group of PBC patients that have a poor prognosis and for whom additional 
therapeutic options should be sought. Over a 10 year follow up period, patients 
who did not receive UDCA as a result of clinical practice at that time and who 
did not reveal any improvement in biochemistry had a prognosis that was 
significantly worse than those who had criteria consistent with a responder 
state. Most importantly, these patients had a survival that mirrored the Mayo 
predicted survival. The results seen in this study are consistent with those of 
other studies which aim to assess response in PBC patients treated with UDCA 
and to study the effect of response on survival.  
There are some limitations of this study. The actual dose of UDCA in those that 
received UDCA was suboptimal (Mean dose 655mg). However, this does not 
affect the interpretation of the results as the key aim was to define if response 
criteria are effective as prognostic indicators if UDCA was not to be used. 
Furthermore, it would have been useful to compare various response criteria in 
terms of selection of criteria best predicting response in our cohort. However 
only the Paris I criteria were used. Recent evidence from the UK-PBC cohort 
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suggests that the Paris I criteria is the most discriminatory predictor of outcome 
in patients with PBC in the UK. (M. Carbone et al., 2013)  Furthermore, the 
consistency of findings in larger cohorts of the general applicability of the 
different individual criteria implies that using the Paris I criteria should not 
disadvantage the interpretation of the results of this study. 
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2.6 Conclusion 
It does not matter whether the attainment of parameters of biochemical 
response is a natural feature of untreated disease or a result of treatment. The 
usability of UDCA response criteria extend beyond their usefulness in predicting 
treatment outcomes in PBC patients treated with UDCA.  
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CHAPTER 3: EXACT SITE OF BIOTRANSFORMATION OF 
FOLATES IN HUMANS USING PORTAL VENOUS SAMPLING AT 
TIPS VENOGRAPHY 
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3.1 Introduction 
The gastrointestinal tract and the liver are responsible for the absorption and 
biotransformation of a number of nutrients and drugs - the former by providing a 
metabolically active absorptive surface which allows active and passive 
movement of nutrients and solutes across it, possessing enzymes that allow 
biotransformation of various nutrients and the latter during first pass 
metabolism. Experimental assessment of bioavailability and the exact site of 
biotransformation of orally ingested essential nutrients and drugs can 
definitively be estimated in humans by means of portal venous blood sampling. 
However, accessing the human portal venous system to sample portal venous 
blood is challenging. (Sherlock, 1978) A number of methods have evolved to 
access portal venous blood. Direct cannulation of the portal vein and its 
tributaries via percutaneous transhepatic approach from a right mid-axillary line 
or subxiphoid approach can be performed. This is invasive and in one study 
was associated with an overall 20% complication rate, predominantly abdominal 
pain and a 6% rate of serious life threatening complications. (Miller et al., 1992) 
Trans-umbilical catheterisation of the portal vein may be undertaken for portal 
venous sampling. This however is again associated with significant adverse 
events including portal vein thrombosis and bleeding. (GÖthlin et al., 1975) 
None of these techniques can be used to sample portal venous blood in healthy 
human volunteers to study the biotransformation and metabolism of nutrients or 
drugs and allow pharmacokinetic profiling. To circumvent the need for human 
portal venous access, a number of studies requiring portal venous sampling 
have been performed in animals. However, a recent systematic review 
concluded that animal studies do not translate well into the clinical human 
domain with discordance seen between animal experiments and human trials. 
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(Perel et al., 2007) Animals used in experimental studies, are young and not 
exposed to the same environmental influences or competing interactions and 
interventions as humans. (Hackam, 2007) These influences and interactions 
may modify phenotypic expression of genes and metabolic processes and 
therefore metabolic studies in animals may not be representative of human 
metabolic pathways. The biotransformation of folates is a typical example where 
currently accepted wisdom on the exact site and bioavailability of folic acid 
based on rat studies is contradictory to emerging evidence from preliminary in 
vitro human cell culture studies.  
3.1.1 Portal venous sampling in humans using TIPS 
Some patients with early chronic liver disease and portal hypertension with 
previous decompensation and TIPS have stable disease and almost normal 
liver function especially when the inciting aetiology is modifiable or removed - as 
seen most commonly after abstinence from alcohol. (Powell and Klatskin, 1968; 
Brunt et al., 1974; Borowsky et al., 1981) Portal venography at the time of 
insertion of TIPS or at surveillance venography offers a unique opportunity to 
sample portal venous blood and in doing so, an opportunity to determine the 
metabolic pathways of orally ingested nutrients and vitamins and the 
pharmacokinetics of synthetic substitutes in vivo in humans. Portal venous 
sampling at TIPS, as described above, has already been used to study the 
occurrence of portal venous bacterial translocation in patients with cirrhosis 
(Cohnen et al., 2003) and to measure the levels of endotoxaemia and Tumour 
Necrosis Factor alpha in patients with alcoholic cirrhosis. (Trebicka et al., 2011) 
More recently, portal venous sampling through TIPS has been used to 
accurately measure pulsatile insulin release directly into the portal circulation of 
human subjects (Song et al., 2000; Pørksen et al., 2002) and to directly study 
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hormonal changes in the portal circulation during an oral metabolic tolerance 
test. (Raddatz et al., 2008) These studies show that portal venous sampling 
through TIPS is feasible and safe. 
3.1.2 The exact site of biotransformation of folates in humans 
There exists significant controversy about the exact site of biotransformation of 
folates and in particular folic acid in humans. This has been comprehensively 
reviewed by Wright et. al. (Wright et al., 2007) On the basis of studies 
predominantly in rat models, it was previously suggested that the predominant 
site of reduction of folic acid to dihydrofolate and then tetrahydrofolate forms 
was at the apical brush border cells of the small intestinal epithelium . Thus, 
currently accepted belief is that all folates including folic acid are converted to 
5MTHF by the human small intestinal mucosa. These studies also suggested 
that when larger doses of folic acid (which may be considered non 
physiological) are administered, excess folic acid is passively transported into 
the systemic circulation. This currently accepted model is summarised in Figure 
15.  These assumptions have resulted in the validation of all short term 
experimental models that assess the relative absorption of various dietary and 
other folates with folic acid being considered as the standard reference folate. 
These views are challenged on 3 grounds - the complete absence of a 5MTHF 
response in the portal veins of human subjects given oral dose of folic acid 
when directly sampled, the low mucosal dihydrofolate reductase activity seen in 
man (exposing the pitfalls of extrapolating data from rat models to humans) and 
implications of the results of mathematical modelling of plasma response of 
5MTHF to oral physiological doses of isotope 13C6 labelled folic acid. (Wright et 
al., 2007) Measuring folates in the human portal vein is particularly challenging 
as accessing portal venous blood in healthy human volunteers is invasive, 
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associated with significant risk and neither feasible nor justifiable for the 
purposes of studying metabolic pathways. To date only 2 studies have been 
undertaken in human volunteers to assess the exact role of the small intestinal 
mucosa in the biotransformation of folic acid using portal venous sampling after 
an oral dose of folic acid was administered.  Whitehead and Cooper undertook 
portal, hepatic vein and systemic venous sampling for 2 hours after oral dosing 
with 1000ug of folic acid in 3 adult volunteer patients undergoing umbilical vein 
catheterisation. It was shown that the intestinal mucosa changes 5-FTHF to 5 
MTHF and transports FA unchanged.(Whitehead and Cooper, 1967)  In another 
study carried out in Birmingham by Melikian and colleagues, portal and hepatic 
vein sampling was carried out in 11 patients who either had colorectal cancer 
with liver metastasis undergoing liver resection with umbilical vein and portal 
vein cannulation to deliver targeted chemotherapy or were undergoing hepatic 
vein catherisation during investigation for portal hypertension. 0.5 mg of pure 
folic acid was administered and portal and hepatic vein sampling was carried 
out for a total of 2 hours post dose. Interestingly, no 5 MTHF was seen in the 
portal vein during this period whilst the folic acid levels were found to be 
transported unchanged into the portal vein. (Melikian et al., 1971) These studies 
suggest that the small intestinal mucosa was not involved in the 
biotransformation of folic acid but were criticised for the use of volunteers with 
cancer or those who had decompensated cirrhosis. They also used a differential 
microbiological assay to differentiate non methyl folate from total folate rather 
than mass spectrometric analysis now available in laboratories which can 
accurately measure individual folates.  A novel method of accessing portal 
venous blood in humans at the time of a routine TIPS patency check by means 
of venography as mentioned above might allow an opportunity to study the role 
116 
 
of the small intestinal mucosa in the biotransformation of folic acid in humans. 
Whereas there is good evidence to suggest that a low folate status is 
associated with significant health problems for some individuals, dietary 
supplementation with folic acid may also be associated with significant patient 
and population-wide risk. This is a paradox given that both dietary reduced 
tetrahydrofolates and folic acid are taken up with similar affinity by the ‘proton-
coupled folate transporter’ and the accepted wisdom mainly derived from rodent 
studies that physiological doses of folic acid are fully reduced and methylated in 
the intestinal absorptive mucosa and transferred to the hepatic portal vein as 5-
MTHF.  The latter being the main circulating plasma folate form as occurs after 
ingestion of all dietary folates.  Mathematical modelling of systemic plasma 
response to single oral physiological doses of stable-isotope-labelled vitamin 
folates and folic acid has, however, challenged this consensus.  
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Figure 15: Schematic representation of folate absorption and biotransformation 
across the small intestinal mucosa.  
 
Folate absorption from the gut lumen, metabolism in the mucosal cells and 
transport out into the hepatic portal vein as per currently accepted based on rat 
studies. All folates, according to current concepts, including folic acid are 
converted to 5MTHF by the human small intestinal mucosa prior to being 
transported into the portal vein. When larger doses of folic acid (which may be 
considered non physiological) are administered, excess folic acid is passively 
transported into the systemic circulation.   PCFT – proton coupled folate 
transporter; DHFR – dihydrofolate reductase; MRP3 - multidrug resistance 
protein, THF – tetrahydrofolate. 
3.1.3 Folates 
In 1931, Lucy Wills, a chemical pathologist at the Royal Free Hospital in 
London, first described a nutritional factor in yeast extract (marmite) that when 
added to the diet could prevent and cure megaloblastic anaemia in pregnant 
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textile workers in Mumbai. (Wills, 1931) A number of different names were given 
to this factor by different pathologists including Vitamin M, Vitamin B9, Vitamin 
Bc (folacin). The factor was finally named folic acid by Mitchell, Snell and 
Williams in 1941 in reference to its isolation from spinach leaves (folium = Latin 
for leaf). (Mitchell et al., 1941) The term “Folate” is a generic term that includes 
all pteroylglutamates that possess vitamin activity. They are one of eight 
different compounds which constitute the B vitamin family. Yeast extract 
(marmite), liver (turkey liver has the highest content), dried herbs especially 
dried spearmint, dark leafy greens like spinach, turnip greens and collards, 
beans such as mung and pinto, legumes, bean sprouts, asparagus, citrus fruits 
and peanuts are foods with a high folate content. Since their discovery, folates 
have been extensively investigated both with regards to their metabolic 
pathways and their role in health and disease. 
3.1.4 Chemistry of Folates 
Folates are a family of pteroylglutamates with different levels of reduction of the 
pteridine ring, different one carbon unit [methyl (CH3-), formyl (CHO-), 
methylene (CH2=), methenyl (CH4-)] substitution and a varying number of 
glutamate residues. (Chango, 2012) Folic acid, pteroylmonoglutamic acid 
(PteGlu), is a synthetic form of the vitamin that does not occur naturally in 
significant amounts. (Wright et al., 2003) The chemical structure of folic acid is 
shown in Figure 16 and is made up of a pteridine ring, p-aminobenzoic acid 
and glutamic acid. Naturally occurring folates on the other hand are 
tetrahydrofolates with a hydrogen moiety at the 5, 6, 7 and 8 positions or 
dihydrofolates with a hydrogen moiety at the 7 and 8 positions and have one 
carbon units at the N5 and / or N10 positions. The chemical structures of 
tetrahydrofolate, 5 Methyl Tetrahydrofolate (5MTHF) and 5 Formyl 
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Tetrahydrofolate (5FTHF) have been shown in Figure 16. Folate 
polyglutamates (H4PteGlun, where n= number of glutamate residues) are 
preferred by folate dependant enzymes as they are more metabolically active 
and better retained in cells when compared with folate monoglutamates 
(H4PteGlu) and therefore natural folates are conjugated to a polyglutamyl chain 
containing different numbers of glutamic acids depending on the type of food. 
Natural folates lose their activity quite quickly over days to weeks when stored 
and a significant proportion of folate activity is lost during food harvesting, 
processing and preparation. (World Health Organisation, 2002) Folic acid on the 
other hand is a stable folate and therefore is most widely used in food 
supplementation. The molecular weight of PteGlu is 441.4 g/mol and the 
molecule is slightly soluble in water, quite soluble in salt form and insoluble in 
alcohol. It is sensitive to ultraviolet and visible light. (Chango, 2012) A number 
of stable isotope labelled folates have recently become available allowing the 
scientific community to make greater inroads into the study of folate metabolism 
than was ever possible before. (Powers, 2007) 
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Figure 16: Chemical structures of A) Folic Acid (Pteroyl monoglutamic acid)  B) 
5-Methyl Tetra Hydrofolate and C) 5-Formyl Tetra Hydrofolate.  
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Folates are a family of pteroylglutamates with different levels of reduction of the 
pteridine ring, different one carbon unit [methyl (CH3-), formyl (CHO-), 
methylene (CH2=), methenyl (CH4-)] substitution and a varying number of 
glutamate residues. All folates have a pteridine ring, Paraminobezoic acid and 
glutamic acid. 
3.1.5 Absorption of Folates 
Naturally occurring folates are available to humans from 2 sources – that which 
is available in the diet and that which is synthetised by colonic bacteria. Dietary 
folates are polyglutamates which are associated with dietary proteins and from 
which they are released by digestive proteases. (Chango et al., 2012) Folate 
polyglutamates are then deconjugated by hydrolysis at the mucosal epithelium 
brush border cells by folyl-poly-J- glutamate carboxypeptidase to the 
corresponding monoglutamates. Prior to 2007, a large number of studies had 
focused on 2 predominant mechanisms of folate transport – a neutral pH 
optimized reduced folate carrier, RFC, which is an anion exchanger expressed 
ubiquitously in all human cells and the folate receptors (FR), FRα and FRβ, 
which are glycosylphosphoinositol (GPI)-linked high-affinity folate binding 
proteins that deliver their substrates into cells via an endocytic process. 
However, these transport mechanisms did not adequately explain the large 
quantities of folate transport across the intestinal epithelium. Furthermore, 
intestinal folate transport characteristically occurs at low pH. In 2007, Zhao et al 
characterised a saturable carrier mediated pH and energy dependant transport 
mechanism in the duodenum and proximal jejunum  which unlike other epithelial 
tissues, is unique in its non selectivity - having similar affinity for both oxidised 
(folic acid) and reduced folate forms and for antifolates such as methotrexate. 
(Rongbao Zhao and Goldman, 2007) This is in accordance with a number of 
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studies that have shown that untransformed folic acid can appear in the 
systemic circulation when large presumably un-physiological doses of folic acid 
were administered. (Whitehead and Cooper, 1967; Melikian et al., 1971) In one 
study, when oral doses of folic acid in excess of 589nmol were administered 
orally, untransformed folic acid was shown to appear in the systemic circulation 
of man. (Kelly et al., 1997) This suggests that the there is a saturation point and 
evidence that intestinal conversion to 5-MTHF is not a prerequisite for transport 
therefore indicating that non physiological overdosing with folic acid is possible. 
This is particularly relevant in light of emerging evidence that suggests that in 
comparison to animals, human livers have low dihydrofolate reductase activity 
which can convert folic acid to dihydrofolate and which can then be converted to 
tetrahydrofolate. (Kamen et al., 1985; Whitehead et al., 1987) This would lead 
to significantly increased amounts of untransformed folic acid in the systemic 
circulation should un-physiological high doses be administered.  This is 
important because it is believed that Folic acid has significantly higher 
bioavailability when compared with natural folates and given the fact that it is 
one of the most stable folates, it is used extensively in food supplementation 
and fortification. However, a recent study showed that the bioavailability of 
dietary folates is about 80% that of the amount present in natural dietary folates 
obtained from vegetables, fruit and liver (Winkels et al., 2007) and therefore a 
diet rich in natural folates may be all that is necessary to improve folate status in 
deficiency states. (Powers, 2007) Folates transported across the intestinal 
epithelium enter the mesenteric veins and then via the portal vein reach the liver 
where they undergo extensive first pass metabolism. The liver rapidly removes 
about 10-20% of the dietary folates (Chango et al., 2012) preferentially 
removing folic acid and allowing a significant proportion of 5-MTHF to pass 
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through into the systemic circulation making it the major plasma folate available 
for tissues. (Rogers et al., 1997) Folates in the body are mainly stored in the 
liver and undergo entero – hepatic recirculation which allows the plasma folate 
levels to be maintained. (Wright et al., 2007) With regards to excretion, folates 
are filtered by the glomerulus and re absorbed in the proximal tubule with daily 
excretion of folates being in the range of 1 to 12 μg. The proximal tubular 
capacity for re absorption of folates can be saturated when plasma folate levels 
are high, resulting in net renal folate excretion. (Chango et al., 2012)  
3.1.6 Metabolism and Biochemical Function of folates 
Folates are the major one carbon donors within cells. Normal cellular folate 
status is essential for cell division and homeostasis. Folates are involved in the 
synthesis of purine bases adenosine and guanosine, the pyrimidine nucleoside 
base thymidine and in many methylation reactions. Folates are of utmost 
importance in the methionine cycle wherein 5-MTHF re-methylates 
homocysteine to methionine which in turn is metabolized to S-
adenosylmethionine. The latter is the major methyl donor in cellular reactions 
and may control gene transcription by cytosine methylation in the DNA which in 
turn affects gene expression and protein synthesis. A number of ill effects of 
folate deficiency are due to increased levels of circulating homocysteine and 
these have been extensively investigated in literature. Likewise, a high folate 
intake may be associated with low homocysteine levels which have been 
associated with cardiovascular risk, cerebrovascular disease and cognitive 
decline. (Reviewed by Dierkes and Nygard, 2012) The metabolism of folic acid 
and a summary of its interactions are shown in Figure 17 (as adapted from 
Fowler, 2001). After transferring the methyl group to homocysteine, 5MTHF is 
converted to tetrahydrofolate (THF) which enters the folate cycle to enable the 
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synthesis of purine nucleosides and thymidine and allow for further single 
carbon needing pathways to function. Folate metabolism occurs both in the 
cytoplasm and the mitochondria both containing a parallel array of enzymes 
with the former preferring incorporation of one carbon units from formate with 
purine and thymidine synthesis and homocysteine remethylation whilst the latter 
preferring one carbon incorporation from serine and resulting in the release of 
formate. (Chango, 2012) Lack of thymidine in folate deficiency may result in the 
mis-incorporation of uracil into DNA leading to DNA breakage and chromosomal 
breakage (Blount et al., 1997) and DNA instability which is associated with 
carcinogenesis especially in cases where the repair interferes with normal 
apoptotic mechanisms. (Blount et al., 1997; Duthie et al., 2010) 
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Figure 17: Schematic representation of the metabolism of folic acid and its 
interactions (adapted from Fowler et al., 2001) 
 
Intracellularly, 5-methylTHF functions as a methyl donor for homocysteine re-
methylation. The resulting THF can directly be converted into 5,10-
methyleneTHF by the action of serine hydroxymethyltransferase (SHMT). 
Conversion of THF into 5,10-methyleneTHF, via 10-formylTHF and 5,10-
methenylTHF, is catalyzed by the trifunctional enzyme 
methylenetetrahydrofolate dehydrogenase (MTHFD1) that has 
126 
 
formyltetrahydrofolate synthetase, methenyltetrahydrofolate cyclohydrolase and 
methylenetetrahydrofolate dehydrogenase activities. The 10-formylTHF can 
donate one-carbon groups for purines biosynthesis, whereas 5,10-
methylenetetrahydrofolate can be used as a cofactor for the conversion of 
Uridine 5’ Phosphate (dUMP) into Thymidine 5’ Phosphate (dTMP). The latter 
reaction is catalyzed by the thymidine synthase (TYMS) enzyme and produces 
dihydrofolate (DHF), which requires subsequent reduction back to THF by the 
action of dihydrofolate reductase (DHFR). In addition to being a cosubstrate for 
dTMP synthesis, 5,10-methyleneTHF can also be reduced to 5-methylTHF by 
the riboflavin (vitamin B2)-dependent enzyme methylenetetrahydrofolate 
reductase (MTHFR), which competes for 5,10-methyleneTHF with TYMS. 
3.1.7 Folates in health and disease 
The primary manifestation of a low folate status in humans is macrocytic or 
megaloblastic anaemia. Peri-conceptual supplementation of folic acid in women 
has been shown to lead to a significant reduction in the incidence and 
recurrence of neural tube defects such as spina bifida in new borns. (MRC 
Vitamin Study Research Group, 1991; Czeizel and Dudás, 1992) A low folate 
status as explained above results in high levels of homocysteine which in turn 
has been shown to be a risk factor for cardiovascular disease, (David et al., 
2002) stroke (Casas et al., 2005) and has been associated with dementia and 
Alzheimer’s disease. (Seshadri et al., 2002)  
3.1.8 Folic acid supplementation – too much of a good thing? 
Studies in the early nineties showing a reduction in neural tube defects in 
newborns with peri-conceptual folic acid supplementation led to the mandatory 
fortification of flour in the USA (1.4mg/Kg, 1998), Canada (1.5mg/Kg, 1998) and 
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Chile (2.2mg/Kg, 2000). (Wright et al., 2007) This has been shown to double the 
plasma folate levels in these countries after fortification was introduced. 
(Jacques et al., 1999) Given the identification of a low folate status or high 
homocysteine levels as risk factors, a number of observational cohort studies, 
randomised controlled trials of FA supplementation and meta-analysis have 
been carried out to establish if FA supplementation prevents or reduces the 
burden of cardiovascular, cerebrovascular, cognitive decline and malignant 
disease (especially colorectal cancer) in communities. The results of these 
randomised controlled trials and meta-analysis have been contradictory, in that 
though observational cohort studies have shown a reduced risk for participants 
ingesting high amounts of folate or taking supplemental folic acid, or those with 
high blood folate levels, randomised controlled trials of folic acid 
supplementation and other meta-analysis have failed to demonstrate these 
benefits. (Dierkes and Nygard, 2012) The authors of this article comment that 
though this discrepancy might reflect bias in observational studies and the 
insufficient length of time supplementation is needed to demonstrate clinically 
relevant endpoints, differences in the chemical structures and metabolic 
pathways of natural folates and synthetically derived folic acid might be one of 
the most important reasons. A recent large and well cited meta analysis 
involving data from 8 large randomised trials and including almost 37500 
patients confirmed that dietary supplementation with folic acid to lower 
homocysteine levels had no significant effects within 5 years on cardiovascular 
events or on overall cancer or mortality in the populations studied. (Clarke et al., 
2010) Worryingly however, a number of concerns have been raised about the 
possibility of causing harm by folate fortification programs and folic acid 
supplementation. (Kim, 2006) In 2006, an NIH study of just over 25000 women 
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participants with a baseline age of 55 to 74 years with complete information on 
dietary and multivitamin intake information, the risk of post menopausal breast 
cancer was increased in women taking supplemental folic acid. Similarly, a trial 
designed to assess the effect of folic acid supplementation on lowering 
colorectal adenoma incidence, reported quite unexpectedly, an increased risk of 
multiple and advanced colorectal adenomas and prostate cancer in the 
supplemented cohort. (Cole et al., 2007) The temporal relationship between 
colorectal cancer incidence and folic acid fortification programs was subjected 
to mathematical modelling. Fortification, in this model, was wholly or partially 
responsible for the increase in colorectal cancer incidence in the mid 1990s. (J. 
B. Mason et al., 2007) One explanation for this unexpected increase risk of 
developing advanced neoplasia is the possibility, as is seen in animals, that 
high folate levels might suppress tumourigenesis in normal tissue but might 
enhance the growth of established early tumours. (Kim, 2004b; Kim, 2004a) 
Other concerns about mandatory fortification of folic acid include accelerating 
the risk of cognitive decline in older patients with low vitamin B12 status (which 
might be masked), inducing a suboptimal response to methotrexate based 
therapy in with autoimmune conditions such as rheumatoid arthritis and 
increasing the risk of multiple births and therefore maternal and neonatal 
mortality. (Wright et al., 2007) Thus an understanding of the exact site of 
biotransformation of folates and in particular folic acid in humans is essential 
before any further folic acid programs, such as the one being considered by the 
Department of Health in the UK, are undertaken. 
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3.2 Aims 
Primary Aim 
To define, in-vivo, the exact site of biotransformation of folic acid in humans by 
portal venous sampling from well compensated chronic liver disease patients 
with in-situ TIPS exposed to orally ingested labelled folic acid or a labelled 
dietary folate (formyltetrahydrofolic acid). 
Secondary Aims 
1. Create a descriptive database of all patients who have had TIPS at the 
Freeman Hospital, Newcastle upon Tyne 
2. To compare transplant free survival between patients with covered and 
uncovered TIPS 
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3.3 Methods 
3.3.1 Study setting, design and population 
A randomised, prospective, open-labelled, cross-over study was designed to 
ascertain the exact site of biotransformation of folic acid in humans. The study 
was carried out in collaboration with the Institute of Food Research (IFR), 
Norwich and Nottingham University. The Freeman Hospital, Newcastle upon 
Tyne, is a tertiary referral centre that has been offering a regional TIPS service 
to patients with complications of portal hypertension since 1992. All patients 
who had TIPS from the year 1992 to the end of the year 2000 were identified 
through an extensive search of all paper based interventional radiology 
requests and all interventional radiology activity registers. The latter record all 
interventional radiology attendances, for any indication, at the point of entry into 
the intervention room and are updated with summary results after the 
procedure. Patients who had TIPS after the year 2000 and until 2009 were 
identified from paper requests and activity registers and in addition cross 
referenced with an online radiology database that logs all radiology activity 
which has been active since 2000. All patient attendances at the Freeman 
Hospital are clinically coded and logged into a central database. For 
completeness, clinical coding was used to find all patients with in-situ TIPS 
under active or previous follow up at the Freeman Hospital. These were then 
cross checked with the existing database to ensure that the TIPS database is 
accurate, comprehensive and up-to-date. Around 44000 requests were 
reviewed to identify patients that have had TIPS for any clinical indication. A 
detailed search using the national summary care records database was carried 
out to identify patients alive at the time of this study. The Freeman Hospital 
Liver Transplant database was used to identify patients that had been 
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transplanted. This master database was used to identify participants for this 
study and to obtain preliminary data about outcomes in these patients. Clinical 
records were reviewed to collect the following data: 
x Demographic details including 
o Date of birth 
o Gender 
o Aetiology of liver disease 
o Date of Liver Transplantation, if transplanted 
o Survival data and date of death 
x Data at the time of TIPS including 
o Date of TIPS placement 
o Type of Stent used (covered / uncovered) 
o HVPG measurements before and after TIPS 
Patients with a patent TIPS offer a unique opportunity to sample portal venous 
blood at the time of their TIPS patency check when carried out using 
venography. Such patients followed up at the Freeman Hospital, Newcastle 
upon Tyne, were invited to take part in the folate study subject to the inclusion 
and exclusion criteria listed below. Pharmacokinetic analysis of portal plasma 
samples obtained from study participants for folate metabolites was carried out 
at the IFR Norwich using processes derived at the University of Nottingham. 
3.3.2 Inclusion and exclusion criteria 
Inclusion criteria 
1. Compensated Child Pugh A cirrhosis with TIPS in situ with patency 
demonstrated on US doppler or TIPS venogram at the last annual check 
2. No evidence of decompensation of liver disease in the last 6 months  
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3. Abstinent from alcohol use 
4. Intact normally functioning gut 
Exclusion criteria 
1. Ongoing oral folate supplementation 
2. Co existing malignancy or recent treatment for malignant disease 
3. Unable to provide informed consent 
3.3.3 Patient consent and allocation 
Eligible patients identified from amongst those in the TIPS database were sent 
information about the study and those who expressed an interest in taking part 
were invited to discuss the study in further detail in a preconsent clinic and to 
undergo further screening using a screening questionnaire. (Appendix – 
FOLTIPS screening questionnaire v1) Interested patients were given detailed 
written information (Appendix -Patient information leaflet 5) about the study 
and a consent form to take home, read, sign and return if they were willing to 
participate. Participants were then allocated randomly and sequentially to 
receiving either a physiological 500nmole dose of  13C5-folic acid or  13C5-6S-5-
FTHF (Merck Eprova, Schauffhausen, Switzerland) at the time of their annual 
TIPS venography check and 13C5-6S-FTHF or 13C5-folic acid, respectively, in 
the cross-over phase at their next annual patency check. 
3.3.4 Preparation of labelled folate doses 
Oral doses of labelled folic acid (L-Folic Acid-13C5; Pte[13C5]Glu) and labelled 
formyl folate (5-formyltetrahydrofolate; [6S]-5-CHO-H4Pte[13C5]Glu, Ca salt) 
were prepared for use in the study in the designated diet kitchen in the Human 
Nutrition Unit (HNU) at the Institute of Food Research by our collaborators. The 
diet kitchen is registered for food preparation with the local Environmental 
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Health Organisation and complies with their guidelines. Each dose was 
prepared using the following standard operating protocol. 
Labelled Folic Acid 
Folic Acid (L-Folic Acid-13C5; Pte[13C5]Glu) was purchased from Merck Eprova 
AG, Schaffhuausen supplied as a sealed vial containing 20mg powder stored at 
-20ºC in the HNU freezer until further use. In the HNU kitchen, wearing 
appropriate coat, hat and gloves, a 7.5% solution of sodium bicarbonate 
(Sodium Bicarbonate BP; pharmaceutical grade, purchased from a pharmacy, 
e.g. Boots the Chemist) was prepared using sterile water. 1 ml of this solution 
was added to a vial containing 20 mg of Pte[13C5]Glu to bring the pH to slightly 
alkaline, in order for the Folic Acid, which was provided as a free acid, to 
dissolve fully in water. This mixture was gently swirled till the yellow powder was 
completely dissolved and transferred to a sterile bottle with at least 100 ml 
capacity using a sterile plastic pastette. The vial containing the Folic Acid was 
then rinsed out with sterile water and the rinsing solution was transferred to the 
sterile bottle to collect any residue remaining in the vial. The solution in the 
sterile bottle was made up to a total volume of approximately 100ml using 
sterile water and mixed gently. 1ml of this solution was then transferred to a 
sterile 50ml falcon tube and to it was added19ml of sodium phosphate buffer 
(0.1M sodium phosphate (PO4-Na) buffer, pH 7.0) to achieve a 20x dilution. 
Using the spectrophotometer (UV/Vis) and a matched pair of cuvettes, 
absorbance of the 20x dilution was read against buffer i.e. the sodium 
phosphate buffer used to dilute the folic acid solution as the blank at 282nm 
wavelength. The amount of stock solution required for 500nmole folic acid was 
calculated using the following equation:  0.690/A282 of the stock solution = x 
volume required (mls) for 500nmole. This volume was dispensed to 2 ml amber 
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tubes (amber 2ml sterile screw cap tubes from Fisher, cat.no. TUL-918-076H). 
The spectrophotometer was wavelength-checked using calibration standards 
prior to use.  A “test sheet” was created at each instance of dose preparation 
and a copy kept with the paperwork for the dose preparation. The phosphate 
buffer-diluted solution of folic acid was discarded and the amber tubes stored 
upright (racked) at -20ºC in a designated HNU food-grade freezer (temperature 
monitored twice a day, and linked to  a  monitored  warning system should 
temperature fluctuate above or below the set temp). The tubes containing 
500nmol doses were transported in person to the Freeman Hospital (Newcastle 
upon Tyne) over dry ice (temperature recorded at the beginning and end of 
transportation) and transferred to -20ºC storage at the central pharmacy at the 
Freeman Hospital (24 hour temperature monitoring). All pipetting was carried 
out using a Gilson P1000 pipette purchased solely for use in the HNU kitchen 
and sterile tips (1000ml) purchased from stores and taken directly to the HNU 
kitchen. 
Labelled Formyl Folate 
5-formyltetrahydrofolate -  [6S]-5-CHO-H4Pte[13C5]Glu, Ca salt was purchased 
from Merck Eprova AG, Schaffhuausen supplied as a sealed vial containing 
20mg powder stored at -20ºC in the HNU freezer until further use. 1 ml of sterile 
water was added to a vial containing 20 mg of [6S]-5-CHO-H4Pte[13C5]Glu and 
swirled gently to dissolve fully and transferred to a sterile bottle with at least 100 
ml capacity using a sterile plastic pastette. The vial containing the formyl folate 
was then rinsed out with sterile water and the rinsing solution was transferred to 
the sterile bottle to collect any residue remaining in the vial. The solution in the 
sterile bottle was made up to a total volume of approximately 100ml using 
sterile water and mixed gently. 1ml of this solution was then transferred to a 
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sterile 50ml falcon tube and to it was added19ml of sodium phosphate buffer 
(0.1M sodium phosphate (PO4-Na) buffer, pH 7.0) to achieve a 20x dilution. 
Using the spectrophotometer (UV/Vis) and a matched pair of cuvettes, 
absorbance of the 20x dilution was read against buffer i.e. the sodium 
phosphate buffer used to dilute the formyl folate solution as the blank at 282nm 
wavelength. The amount of stock solution required for 500nmole formyl folate 
was calculated using the following equation:  0.930/A282 of the stock solution = 
x volume required (mls) for 500nmole. This volume was dispensed to 2 ml 
amber tubes (amber 2ml sterile screw cap tubes from Fisher, cat.no. TUL-918-
076H). The spectrophotometer was wavelength-checked using calibration 
standards prior to use.  A “test sheet” was created at each instance of dose 
preparation and a copy kept with the paperwork for the dose preparation. The 
phosphate buffer-diluted solution of formyl folate was discarded and the amber 
tubes stored upright (racked) at -20ºC in a designated HNU food-grade freezer 
(temperature monitored twice a day, and linked to  a  monitored  warning 
system should temperature fluctuate above or below the set temp). The tubes 
containing 500nmol doses were transported in person to the Freeman Hospital 
(Newcastle upon Tyne) over dry ice (temperature recorded at the beginning and 
end of transportation) and transferred to -20ºC storage at the central pharmacy 
at the Freeman Hospital (24 hour temperature monitoring). All pipetting was 
carried out using a Gilson P1000 pipette purchased solely for use in the HNU 
kitchen and sterile tips (1000ml) purchased from stores and taken directly to the 
HNU kitchen. 
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3.3.5 Study protocol 
Pre sampling preparation 
Eligible consented patients scheduled to come in for their routine annual TIPS 
surveillance were requested to have blood tests, which included liver function 
tests, renal functions, full blood count, coagulation profile, CRP and B12 and 
folate levels, prior to the procedure. A Pre TIPS venography information leaflet 
was sent to the patient no later than 1 month prior to the test day and receipt / 
understanding of preparation required confirmed by a telephone call. To avoid 
increased gut permeability, participants were asked to avoid alcohol and non 
steroidal anti inflammatory drugs for 2 weeks prior to the procedure. Similarly, to 
avoid spurious results due to supplementation, they were asked to avoid vitamin 
B containing supplements for at least 2 weeks prior to the procedure. Patients 
were fasted for at least 8 hours or overnight prior to the test but were 
encouraged to keep themselves well hydrated with water. On the day of the 
procedure, patient consent was re-confirmed and preliminary brief interview was 
carried out to confirm abstinence from alcohol, the absence of non steroidal 
anti-inflammatory drug use within the last few weeks and the absence of recent 
illness or new medications being started prior to the test day. Participants were 
then escorted to interventional radiology where a routine TIPS venogram was 
carried out by an experienced radiologist (JR) to assess and confirm TIPS 
patency. A portal venous catheter (Beacon ® Tip Royal Flush® Plus High Flow 
Catheter 65 cm 5Fr Cook Medical Europe Limited) was left in situ in the portal 
vein and the position of the tip confirmed radiologically using fluoroscopy. The 
non inserted catheter length was marked and the catheter was then flushed with 
heparin sodium 10 I.U./ml (Hepsal® Wockhardt UK Ltd.) solution. The catheter 
was secured using TegadermTM (3M United Kingdom PLC) transparent 
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adhesive plaster and the participant transferred in supine position to the 
programmed investigation unit ward for the study. 
Portal and Systemic Venous Sampling 
The study was carried out in a side room on the programmed investigation unit 
in the Freeman Hospital, Newcastle upon Tyne. After an uncomplicated TIPS 
venography, the participant was nursed in a supine position and allowed to 
recover for 30 minutes with routine post venography vital observations including 
temperature, heart rate, blood pressure and oxygen saturations being 
measured at transfer and every 15 minutes thereafter for 1 hour and hourly until 
the completion of the study. Depending on sequential randomization a vial 
containing either labelled folic acid or labelled formyl folate was retrieved from - 
20ºC storage and allowed to reach room temperature whilst being shielded from 
light in an opaque bag during participant recovery. Participant consent to 
continue with the study was re confirmed and a large bore 18g cannula (BD 
VenflonTM  Becton, Dickinson U.K. Limited) was sited in the left median cubital 
fossa and flushed with 0.9% sodium chloride solution. The site of the portal 
venous catheter was checked to confirm that it was not displaced. The vial 
contents were transferred to a new clean plastic beaker. The vial was then 
rinsed with 10 ml of sterile water and the rinsate transferred to the beaker and 
gently swirled to ensure mixing. Using a plastic straw the patient was asked to 
ingest the 500nmol dose of either labelled folic acid or formyl folate dissolved in 
sterile water from the plastic beaker. The beaker was rinsed twice with 10 ml of 
sterile water and the participant asked to ingest this rinsate using the straw. The 
time at point 0 was noted on the study sampling sheet and a clock timer was 
started. The study sampling sheet including the participant study code number, 
the date of the test, the details of the sampling points and a provision for 
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entering the exact time of portal and systemic venous sampling and comments 
(Appendix – Time Sheet). Timed portal (15, 25, 35, 45, 55, 65 and 85 minutes) 
and systemic (30, 60, 90, 120, 150, 180, 210 and 240 min) venous blood 
samples were collected in green topped 13 mm x 75 mm 4ml Lithium Heparin 
BD vacutainers®  and held at 4ºC. At each portal sampling time point, using 
strict aseptic precautions and after confirming the marked non inserted position 
of the catheter, a 2.5 ml disposable syringe was used to aspirate 2 ml of 
serosanguinous fluid (0.9 ml heparin saline flush with 1.1 ml of portal venous 
blood). The syringe containing this mix of flush and portal venous blood was 
discarded. A new 2.5 ml syringe was then used to aspirate 2 ml of portal venous 
blood and transferred into a previously labelled vacutainer which was gently 
inverted 5 times. This vacutainer was held at 4ºC prior to processing. The portal 
catheter was flushed with 0.9 ml of Heparin Sodium 10 IU/ml solution and 
position confirmed again. At each systemic venous sampling, using strict 
aseptic precautions, a 2.5 ml syringe was used to aspirate 2 ml of systemic 
blood from the peripheral 18g cannula previously sited and the entire syringe 
with contents was discarded. 2 ml of systemic blood was then aspirated from 
the peripheral cannula and transferred to a pre labelled lithium heparin 
vacutainer®, inverted 5 times and held at 4ºC prior to processing. The 
peripheral cannula was flushed with 0.9% sodium chloride. The portal cannula 
was removed at 100 minutes and the site of insertion was dressed 
appropriately. The patient was then allowed to sit up. Throughout the procedure 
regular vital observations were measured. Care was taken to maintain strict 
asepsis throughout sampling and to avoid displacing the portal venous catheter 
from its original insertion site. After study sampling was completed, the 
peripheral cannula was removed and the site dressed. The site of insertion of 
139 
 
the portal venous catheter was checked and the patient observed for 30 
minutes and given a light meal. A post discharge information leaflet was given 
to each participant including my contact details and out of hours contact details 
should they feel unwell in any way. Each participant was contacted by 
telephone the same day in the evening to check well being and to report any 
adverse events experienced and then in 1 week and 1 months time.  
Plasma preparation and analysis 
Portal and systemic venous samples were held at 4ºC prior to plasma 
preparation which was carried out by chilled centrifugation (3300G for 10 
minutes at 4ºC) using a Heraeus Primo R Thermo Centrifuge (Thermo 
Scientific, UK). Post preparation, 250μl aliquots of plasma were transferred to 
two 2 ml amber light protected micro tubes (Eppendorf Safe-Lock tubesTM) 
using a 1000μl pipette and snap frozen in dry ice prior to being transported to 
catalogued storage at -80ºC at Newcastle University. These were finally 
transferred in dry ice to long term storage at -80ºC at the IFR in Norwich for 
analyses using a high sensitivity LC-MS/MS assay developed to enable this 
study and described in detail previously. (King et al., 2012) In brief, each 
sample (5 µL)  was analysed using an Agilent 1200 binary HPLC  coupled to an 
AB Sciex 4000 Qtrap triple quadrupole mass spectrometer. HPLC was achieved 
using a binary gradient of solvent A (MilliQ Water + 0.1% formic acid) and 
solvent B (HPLC grade acetonitrile + 0.1% formic acid) at a constant flow rate of 
250 µl/min. Separation was made using a Phenomenex Kinetex 2.6u C18 100 x 
2.1 mm column maintained at 50°C. Injection was made at 2% B and held for 
2.5 min, ramped to 10% B to 6 min and then to 43% B by 15 min.  A 98% B 
column wash was then applied until 23 min and then the column equilibrated to 
initial conditions for 10 minutes. The mass spectrometer was operated in 
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electrospray positive mode to monitor specific parent / fragment transitions for 
the folate target compounds as folic acid (FA): 442/295, 13C-FA : 447/295, 
5MeTHF : 460/313,  13C-5MeTHF : 465/313, 5F0THF: 474/327, 13C-5F0THF : 
479/327, MTX: 455/308. Optimised ionisation and collision energies were tuned 
and applied to each transition (not reported). Quantification was applied using 
AB Sciex Analyst 1.5 software to integrate detected peak areas relative to the 
MTX internal standard. 
3.3.6 Pharmacokinetic Modelling and Statistical Analysis 
Pharmacokinetic modelling and statistical analysis for this part of the study was 
carried out with the help of Dr. Jack Dainty at the Institute of Food Research, 
Norwich. It has been shown previously that it is possible to estimate the 
apparent absorption of labelled folate doses by modelling their appearance in 
plasma. (Kok et al., 2004; de Meer et al., 2005; Wright et al., 2005) The analysis 
for this is based on a technique called Compartmental Modelling. (Dainty, 2001) 
A compartment is a theoretical construct that may combine material from 
several different physical spaces and defined as an amount of material that acts 
as though it is well mixed and kinetically homogeneous and a compartmental 
model consists of a finite number of compartments with specified 
interconnections between them. The interconnections are a representation of 
the flux of material that is transported from one location to another. By defining 
a compartmental model in this way, researchers can reduce a complex 
metabolic system into a small number of pathways and compartments. The 
outputs from such a model include the quantity of mineral or vitamin stored in 
certain body pools, the rate and extent to which the nutrient moves from one 
pool to another and how long it will remain in the body before being excreted. 
This can inform the approach of the nutritionist about status, daily requirements 
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and retention and, only through modelling, can this type of information be 
obtained from humans in a non-invasive way. 
Figure 18: A 2 compartment model (used with permission from Dr. Jack Dainty)  
 
 As an example, consider the 2-compartment model shown in Figure 18. The 
circles represent compartments and the arrows are pathways showing the 
direction of transfer of material. Associated with each pathway is a rate 
constant, which is conventionally written as k (i,j) that denotes transfer of 
material, from compartment “j”, to compartment “i”, per unit time. The types of 
compartment models which are usually found in nutrition are described by 
constant coefficient, ordinary, first-order differential equations. The basis of 
these equations is that the rate constants do not alter over the course of the 
experiment and, by applying The Conservation Of Mass to the system under 
study, it is possible to solve the resultant series of equations. If the mass of 
material in compartment 1 is denoted as P (for plasma) and that in compartment 
2 as E (the “rest” of the body), the system can be described by: 
P)k(k-Ek
dt
dP
0,12,11,2   
Ek - Pk
dt
dE
1,22,1   
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To solve these equations, one of the two compartments needs to be sampled 
(measured) so that the parameters (k0,1, k1,2 and k2,1) can be fitted to the 
resultant, measurement data. It is often the case that the only compartment that 
can be sampled is the plasma. This limits the number of “other” compartments 
that can be used in the model, if the parameters are to be identified, uniquely.  
This is called a priori identifiability and is used to identify, given noise-free data, 
the number of compartments a model may have in order that all its parameters 
will have a single solution. Often investigators have an in-depth knowledge of 
the metabolism of a particular nutrient, and want to include many 
compartments, but this can lead to uncertainty in the value of the subsequent 
parameters. Any model that is not a priori identifiable must be carefully 
evaluated and the results from it used cautiously. The fitted parameters from a 
model should always be quoted with their calculated precision so that an 
assessment of the quality of the model can be made. This is called a posteriori 
identifiability and plays an important part in drawing nutritional conclusions from 
the modelling of real data. The a posteriori identifiability is dependent on good 
quality data and the correct choice of model structure for the system under 
investigation. The 2-compartment model is a priori identifiable. If the data from 
the plasma samples are of sufficient quality and they support a 2-compartment 
rather than, say, a one or three compartment structure then the model should 
be a posteriori identifiable. A compartment model is, therefore, constrained by 
the type of data collected, the location it is collected from and the statistical 
considerations involved in fitting experimental data to models. It is known from 
pharmacokinetic studies, that the bioavailability of certain drugs can be 
estimated from their appearance in the plasma, over the first few hours post-
ingestion. The underlying mathematics (differential equations) of compartmental 
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modelling depend on the principle of mass balance – the rate of change in the 
plasma folate concentration is equal to the rate of folate absorption minus the 
rate of removal of folate from the plasma for utilisation and storage. So, the 
estimation of rate of folate removal is very important if the absorption is to be 
estimated correctly. Intensive blood sampling was carried out to ensure that the 
peak in plasma concentration was not missed and the changes in folate 
concentration were fully characterised. Simulation of ten sampling times, 
equally spaced over 360 minutes, indicated that there would be enough 
degrees of freedom to estimate all the model parameters “a priori” from a one or 
two compartment model, given noise free data. This is an important part of the 
modelling process and must be performed to ensure that a model is 
theoretically possible, given the experimental design. The number of 
parameters that need to be estimated in the one compartment model are the 
quantity of folate absorbed, the rate of folate loss from the plasma and the time 
period during which absorption is taking place. The same parameters would be 
estimated from a two compartment model, as well as the rate of re-appearance 
of folate from the second compartment (rest of body). In developing a model 
whose only function is the estimation of folate absorption, sampling for days is 
unnecessary because the absorptive process takes place over a few hours. It 
became possible to decide which of the two competing models (one or two 
compartment) was the most appropriate after the human study was performed 
and the data were collected. This was carried out in SAAMII (SAAM Institute 
Inc, Seattle, WA) by looking at the residual plots, examining the uncertainty on 
the parameters and using the model comparison parameters called Akaike's 
information criterion (AIC) and Bayesian information criterion (BIC). When 
comparing two or more model structures, the one with the lowest AIC (or BIC) is 
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preferred, because these parameters measure the goodness of fit of the model 
and also take into account the number of parameters that are used in fitting it. If 
two models have a comparable goodness of fit to the data, the simplest model 
(one with the least parameters) is preferred.  
Figure 19: Schematic overview of compartmental model for folate absorption 
(used with permission from Dr. Jack Dainty) 
 
Figure 19 illustrates the final model which is a single compartment. It is 
assumed that mass, M, of the folate dose, is absorbed from the small intestine, 
into the plasma, at a constant rate, R, for a time, T. This is known as “zero-
order” absorption and equates to a constant infusion of folate from the gut into 
the plasma, which is, of course, a simplification, as the true process is more 
likely to be first-order (time-varying) in nature. A first-order absorptive process 
had been examined as part of the model development but it did not improve the 
absorption predictions and also required the estimation of an additional 
parameter. Therefore, by applying the Principle of Parsimony, the simpler 
process of zero-order absorption was preferred. By fitting equations to the 
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plasma concentration data (C) for either labelled or unlabelled folate, it is 
possible to estimate the mass of folate absorbed (M), the period of time when 
absorption has taken place (T) and the rate constant of elimination from the 
plasma (k). All fitting can be performed in Excel (Microsoft Corporation, 2002) or 
SAAMII but the latter is preferable as it gives statistics that indicate how good 
the fit is. The fractional folate absorption can then be calculated by knowledge 
of the mass of folate (M) appearing in plasma, divided by the mass of the dose 
of folate. In the present work, the estimate for folic acid absorption is based on 
the appearance of labelled folic acid in the portal and systemic blood after the 
administration of the labelled folic acid dose. The estimate for formyl absorption 
is based on the appearance of labelled 5MTHF in the portal and systemic blood 
after the administration of the labelled formyl dose.  
The proportion of folate in un-modified and modified form in the portal vein and 
systemic circulation for the different oral dosing formulations at the initial 15m 
post-dosing time-point was compared using a paired t-test. 
3.3.7 Ethical Approval 
The study was formally approved by the Newcastle and North Tyneside 1 
Research Ethics Committee (08/H0906/82) and via a substantial amendment to 
accommodate crossover sampling (08/H0906/82/ ver 2.0 dated 09/02/11) 
(Appendix – Ethics) 
3.3.8 Study Funding 
This work was funded by responsive mode grants BBF0144571, BBF0141041 & 
BBF0125941 from the UK Biotechnology and Biological Sciences Research 
Council (BBSRC). 
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3.4 Results 
3.4.1 Study participants 
Using the comprehensive search strategy as outlined in the methods section, 
336 patients were identified who have had a TIPS at the Freeman Hospital, 
Newcastle upon Tyne since this service has been available from 1992 upto 
2009. 13 (4% 95% CI 2% - 6%) of the 336 patients were either non UK 
residents who had been treated whilst on their visit to the UK and returned to 
their country or had relocated in the UK without any further contact details 
available either through their last known primary care provider or the hospital 
records. Their demographic records were unavailable. 323 (96%; 95% CI 94%-
98%) of the 336 patients had demographic records available. Median age at 
TIPS was 53yrs (Range 20-82). 60% (95%CI 54%-65%) of the entire cohort 
was male. Alcoholic liver cirrhosis was the commonest cause of portal 
hypertension requiring TIPS (Figure 20). Data about the type of stent used was 
available in all but 17 patients (almost all were in the pre 2000 era). Almost all 
patients had an uncovered Wallstent prior to the year 2000 (N=176). After this 
period, the covered Viatorr® stent was the main stent used (N=130). 191 
patients had documentation of HVPG measurements before and after TIPS in 
either the radiology report or clinical records. Mean HVPG pre TIPS was 18.2 
(±5.7) Hg mm and mean HVPG post TIPS was 7.3 (± 2.5) Hg mm.  
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Figure 20: Aetiology of decompensated portal hypertension leading to TIPS 
 
For the folate study, using the strategy described in the methods, 32 patients 
with an in-situ TIPS were identified as potential participants and their records 
reviewed to identify those patients who would meet inclusion criteria for this 
study. A CONSORT flow chart is shown in Figure 21. Six subjects meeting all 
study criteria participated in the study. 2 of 6 participants could not take part in a 
cross over study. As a consequence, data from 4 cross over studies (4 labelled 
folic acid and 4 labelled formyl folate) and 2 labelled folic acid studies were 
included in the final analyses. 
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Figure 21: CONSORT flow diagram for Folate study 
 
3.4.2 Baseline characteristics and Demographics  
Demographic details for patients in the folate study are shown in Table 20. All 
participants had well compensated Child Pugh A liver disease, normal synthetic 
liver function and normal renal functions. All participants underwent routine 
TIPS venography that confirmed a patent TIPS prior to each study. 
 
 
149 
 
3.4.3 Portal and systemic folate concentrations 
When the portal venous concentrations of provitamin folic acid and its reduced 
and methylated vitamin form 5-methyltetrahydrofolic acid (5-MTHF), the product 
of physiological reduction and methylation by the gut wall) were compared after 
dosing with labelled folic acid, un-metabolised labelled folic acid levels were 
seen to rise significantly and more rapidly than labelled 5-MTHF concentrations 
(Figure 22). This suggests a greater proportion of absorbed folic acid crossed 
the gut wall unmodified than is reduced and methylated within the cells of the 
gut wall. The finding of portal labelled folic acid early after dosing was mirrored 
by its appearance in the peripheral circulation (Figure 23). In contrast, the 
unmodified form was extremely low in the portal circulation when patients were 
dosed with labelled formyltetrahydrofolic acid (13C5-6S-5-FTHF), a reduced form 
of “natural folate”, in the cross-over arm of the study (Figure 24).  
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Table 20: Demographics and clinical characteristics of participants 
Sex & 
Age (y) 
Aetiology of 
chronic liver 
disease 
BMI 
(Kg/
m2)  
CP CPG MELD eGFR 
(ml/min/
1.73m2) 
B12 
(pmol
/L) 
RCF 
(nmol
/L) 
M 
57 
NASH 33 6 A 10 115 806 741 
M 
56 
Alcohol 42 5 A 6 119 576 392 
M 
61 
Alcohol 27 5 A 6 107 336 144 
F 
59 
Alcohol 26 5 A 7 119 569 151 
M 
44 
Alcohol 47 6 A 10 82 349 185 
F 
53 
Budd Chiari  
(on warfarin) 
23 * * * 96 692 236 
* This patient was on warfarin therefore coagulation parameters were not 
interpretable. M- male, F-Female, BMI – Body Mass Index, CP – Child Pugh Score, 
CPG – Child Pugh Grade, MELD – Model for End Stage Liver disease, eGFR – E 
Glomerular Filtration rate, B12 – Vitamin B12 reference range 170-700 ng/L, RCF – 
Red cell folate reference range 160-600 Ug/L 
 
 
 
 
 
 
 
151 
 
Figure 22: Measured concentrations of labelled folic acid and labelled 5-MTHF 
in portal venous blood after dosing with labelled folic acid. 
 
Figure 23: Measured concentrations of labelled folic acid and labelled 5-MTHF 
in systemic venous blood after dosing with labelled folic acid. 
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Figure 24: Measured concentrations of labelled 5-formyltetrahydrofolic acid (5-
FTHF or “natural folate”) and labelled 5-MTHF in portal venous blood after 
dosing with labelled 5-FTHF 
 
Figure 25: Measured concentrations of labelled 5-FTHF and labelled 5-MTHF 
in systemic venous blood after dosing with labelled 5-FTHF 
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At the initial 15 minute sampling time point, a consistent pattern was seen 
across all participants with a median 86% [range 60-88%] of labelled folate in 
the hepatic portal vein following a dose of folic acid being unmodified folic acid 
which was significantly higher (p<0.01) than the median 14% for labelled 5-
MTHF. In contrast, following a dose of 5-FTHF, only a median 3% [range 2-6%] 
of labelled folate in the hepatic portal vein was unmodified 5-FTHF which was 
significantly lower (p<0.001) than the median 97% for labelled 5-MTHF. 
Between oral treatments, the proportion of unmodified folic acid in the hepatic 
portal vein was significantly greater (p<0.0001) than unmodified 5-FTHF 
(Figure 26).  Additionally, at the 15 minute time point the median concentration 
of labelled 5-MTHF (0.965 nmol/L) derived from folic acid was only 3.7%, and 
significantly lower (p<0.01), than the median concentration of labelled 5-MTHF 
(25.776 nmol/L) derived from 5-FTHF. 
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Figure 26: Percentage of the dose of folic acid and 5-FTHF crossing into the 
portal circulation in an unmodified form after dosing with each in the cross-over 
study. Data are presented for 15 minutes following folate dosing; the first 
sampling time point. Plots delineate the median, max and min and inter-quartile 
range value 
 
3.4.4 Adverse events 
No adverse events were reported in participants taking part in the study. All 
patients found the study acceptable and indeed two thirds consented to the 
cross over study. 
3.4.5 Comparison of survival in patients with uncovered and covered TIPS 
45 of the 323 (11% 95%CI 8%-15%) who had a TIPS procedure at our centre 
were transplanted after a median of 13 months (Range 1-129 mths). Over a 
median follow up period of 6 years (IQR 2-9 yrs), 205 of the 278 (74% 95%CI 
68%-79%) patients who did not receive a transplant died and 73 (26% 95%CI 
21%-32%) were alive. (Figure 27)  
 
P<0.0001 
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Figure 27: Flowchart representing the outcome of patients treated with TIPS at 
the Freeman Hospital Newcastle upon Tyne 
 
Overall transplant free survival in patients who had TIPS at our centre was 21 
months (95%CI 14-28 months). This is shown in Figure 28. There was no 
significant difference in the transplant free survival between patients with 
uncovered TIPS or covered TIPS (p=0.647, log rank test; Figure 29).  
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Figure 28: Transplant free survival in all patients who had a TIPS between 
1992 and 2009 
 
Figure 29: Kaplan Meier curves comparing transplant free survival between 
patients with covered and uncovered TIPS 
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3.5 Discussion 
3.5.1 The site of biotransformation of folates in humans 
This study elegantly and unambiguously demonstrates that the majority of a 
physiological oral dose of folic acid passes into the portal venous circulation in 
an unmodified form. Almost 90% of labelled folic acid administered orally 
passes into the portal vein unmodified in humans and definitively proves that 
folic acid is not metabolised by the small intestinal epithelium in humans. In 
contrast to folic acid, the physiological dietary folate 5-formyltetrahydrofolic acid 
is very nearly completely methylated, appearing in the portal venous circulation 
almost entirely as 5-methyltetrahydrofolic acid; an observation which confirms 
normal gut wall function in terms of both gut permeability and folate methylation 
capacity and that the small intestinal mucosa simply re arranges the one carbon 
moiety in dietary folates to the active 5 methyl tetrahydrofolate form. These 
findings fundamentally challenge the accepted model of folic acid uptake, in 
which folic acid is proposed to be fully reduced and methylated in the gut wall 
as previously suggested by high quality rodent studies (Tani and Iwai, 1983) 
and instead suggests that, whilst human methylation capacity is adequate, 
reduction capacity in the form of dihydrofolate reductase activity is strictly 
limited.  
3.5.2 The effect of portosystemic shunting on the study results  
The appearance of unmodified folic acid after dosing in the peripheral 
circulation reflects the shunt-based experimental model which causes, by its 
nature, significant by-passing of first-pass liver metabolism and therefore limited 
any conclusions that could be drawn about the actual capacity of the liver to bio-
transform folic acid. 
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3.5.3 Different folates have different rates of entry into the portal vein 
Folate excretion out of gut absorptive cells into the hepatic portal vein is 
undertaken by ‘multidrug resistance protein MRP-3’. (R. Zhao et al., 2009) 
Since MRP-3 excretes folic acid with much lower efficiency than the reduced 
tetrahydrofolate form, (Zeng et al., 2001) it is not surprising that after an oral 
dose of folic acid the rate of total labelled folate (folic acid + 5-MTHF) entering 
the human portal vein is significantly lower than the total labelled folate (5-FTHF 
+ 5-MTHF) after an oral dose of 5-FTHF.  
3.5.4 In vivo studies are superior to animal model or in vitro studies 
Our findings disagree with currently held beliefs and assumptions about the 
exact site of biotransformation of folic acid. The most obvious explanation for 
the discrepancy between our findings and those of studies, on which the 
consensus of full gut reduction and methylation of folic acid metabolism was 
based, is their use of rodent models (most typically rat) and human cell lines 
because of the difficulty of doing in vivo human studies. Both of these 
approaches have inherent weaknesses. Rats have significantly higher levels of 
DHFR than humans, (S. W. Bailey and Ayling, 2009) making them a poor model 
for human biology. Human cell lines also exhibit elevated levels of DHFR 
activity, potentially as a consequence of the traditional use of high levels of folic 
acid in tissue culture medium. (Kamen et al., 1985) Although this study  is 
complex and resource intensive, it demonstrates that directly studying gut 
uptake of folic acid (and potentially other nutrients in the future) is feasible in 
human subjects, safe (no adverse events were reported) and highly acceptable 
(all approached patients volunteered for re-dosing and all found the procedure 
fully acceptable). In vivo human studies are, of course, the most relevant for the 
understanding of human biology. Interestingly, our findings confirm and extend 
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those of even earlier human studies published in the 1960s and 1970s. 
(Whitehead and Cooper, 1967; Melikian et al., 1971) These studies were, at the 
time, criticised for administering large, non-physiological, doses of folic acid and 
were subsequently largely disregarded. In the light of our findings, however, the 
fact that no dose-derived 5-MTHF was initially detected in hepatic portal vein 
plasma was a pertinent finding, albeit one overlooked by later researchers.  
3.5.5 Limitations of the study 
Due consideration must be made of the fact that although the study subjects 
were as normal as was feasible, no healthy person has a shunt into their portal 
circulation allowing access to the portal circulation for sampling. The 
characteristics of the study participants, which allowed them to be participants, 
also, therefore, represented a potential limitation of the study. Care was taken in 
selecting study subjects, however, to minimise confounding biological 
processes. All subjects had inactive liver disease and normal liver synthetic 
function and all were abstinent from alcohol. The major confounding factor, that 
of increased gut permeability, was eliminated by determining – as part of the 
study – complete methylation of natural folate implying the passage of all 
labelled folate through enterocytes. Given the principal measurements were gut 
transport into the hepatic portal vein (i.e. “upstream” of the liver) and gut 
permeability was normal, we believe our observations are robust. More caution 
needs to be applied to systemic circulation data given the capacity for peri-
portal shunting effects. When single physiological doses of stable-isotope-
labelled folic acid have been given to normal human volunteers who were 
neither exposed to mandatory fortification nor self-supplementation, no 
unmetabolised labelled folic acid was seen in the systemic circulation, only 
labelled 5-MTHF. (Wright et al., 2005)  If folic acid is mainly transferred to the 
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hepatic portal vein un-metabolised, one may now conclude that under those 
experimental conditions all folic acid entering the hepatic portal vein must have 
been removed on ‘first-pass’ metabolism by the liver (by the ‘proton-coupled 
folate transporter’), (R. Zhao et al., 2009) which exhibits a slightly greater affinity 
for folic acid  than for reduced folates, and biotransformed to 5-MTHF prior to 
enterohepatic recirculation. As human liver has recently been shown to have 
not only low but highly variable DHFR activity, (S. W. Bailey and Ayling, 2009) 
then arguably, chronic exposure to folic acid even in physiological doses (as 
would be the case with mandatory fortification) may induce saturation and 
explain the observed systemic circulation of unmetabolised folic acid. (Regan L. 
Bailey et al., 2010)  
3.5.6 Biological patterns of systemic response to FA and dietary folates 
 The key finding of this study is that the biological patterns following 
supplementation with folic acid (as would be the case with supplements and/or 
food fortification containing folic acid) and folate (as would happen with 
increased dietary intake) are very different. One potential explanation for the 
apparent paradox of risk associated with folic acid supplementation, despite the 
obvious benefits associated by reversing low body folate levels, would that the 
adverse effects are a direct consequence of the presence of unnatural 
circulating concentrations of unmetabolised folic acid following prolonged 
exposure to this artificial entity. That the risk is not associated with elevated 
folate exposure in general is suggested by the Danish population study 
(Roswall et al., 2012) which showed that, in contrast to patients taking folic acid 
supplements in whom increased mortality rates were seen, patients consuming 
a naturally high folate diet had no increased risk.  
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3.5.7 TIPS can be used safely for portal venous sampling in humans 
There were no adverse effects noted in the study both at the time of venous 
sampling and on follow up. Portal venous sampling at the time of venography 
was acceptable to patients and almost all screening clinic invitees agreed to 
take part, with further consent to take part in the cross over phase.  
  
162 
 
3.6 Conclusion 
In conclusion, low enzyme activity of dihydrofolate reductase (DHFR) may 
compromise both mucosal and liver biotransformation of folic acid in humans. 
For dietary supplement capsules, it is suggested that folic acid could be 
partially, or completely, replaced with 6S-5-MTHF (the normal systemically-
circulating folate form), the multiple advantages of which have been noted 
previously. (Wright et al., 2010) It is also suggested that effort is made to 
microencapsulate 5-MTHF so that losses from manufacture and use in 
voluntary fortified foods (e.g. breakfast cereals) and subsequent processing 
(e.g. heat) of products following UK proposals for mandatorily-fortified flour (if 
implemented), are minimised. 
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GENERAL DISCUSSION 
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The work carried out during this project aimed to rise up to the clinical challenge 
of predicting the presence of portal hypertension in patients with PBC and to 
utilise the opportunity for portal venous sampling presented at routine TIPS 
venography to answer important questions about the actual role of the human 
small intestine and liver in the metabolism of folic acid.  
We have shown that in PBC, GOV are common even in early disease and that 
the presence of varices is a poor prognostic marker in these patients. The NVP 
and NVP-S scores are inexpensive bed side tools which can be used to predict 
the presence of varices in patients with PBC, including those with early disease, 
with high accuracy and can be used at different probability cut offs to suit 
differing health economic locales. We have also shown that patients with PBC 
who develop GOV have a poorer prognosis than those who do not. Therefore, 
the NVP and the NVP-S scores are also prognostic scores which can be used 
to identify PBC patients with a poorer prognosis. Unlike the Mayo Score, they 
do not contain subjective variables such as the presence of peripheral oedema. 
Further studies to evaluate their use in this setting should be the focus of further 
research in this setting. 
Our work has demonstrated that portal venous sampling through TIPS is 
feasible and safe and can be used to study metabolic pathways in humans. 
Though the effect of shunting on the interpretations poses a limitation, this can 
be adjusted for in future studies by studying absorptive pharmacokinetics in 
patients with TIPS and healthy matched controls. This factor however did not 
limit the interpretation of our study which specifically aimed to find the exact site 
of biotransformation of folates. We have found that synthetic folic acid, the form 
taken in folic acid supplements bought over the counter, is not processed by the 
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body in the same way as natural folates, the form found in nature. This can lead 
to unprocessed folic acid circulating in the blood stream, with unknown potential 
health effects. With the UK government considering adding folic acid to all 
bread flour (to reduce the 900 neural tube defect births thought to be related to 
low maternal folate levels in the UK every year) our study suggests a need to 
think about using a different folate form for the fortification, or better understand 
the implications of excess folic acid. Fortification can also be done with natural 
forms of folate. These are already licensed for use, under the names Metafolin® 
(Merck KGaA, Darmstadt, Germany) and Quatrefolic ® (Gnosis S.P.A, Milan). 
These have been approved for use as a food supplement and are metabolised 
in the same way as natural folates, and so avoid the problem identified in this 
study. If these can be adapted for use in food fortification, they present a way of 
improving the folate status of the population, reducing the risk from 
unmetabolised folic acid in the blood and any possible risks to health. 
 “A pessimist sees the difficulty in every opportunity; an optimist sees the 
opportunity in every difficulty” said Winston Churchill.  
We have risen to the challenge of non invasive prediction of portal hypertension 
in patients with PBC and optimised the opportunity presented in the 
management of portal hypertension to study the exact site of biotransformation 
of folic acid in humans.  
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How is Folic Acid Metabolised in People? 
Information for Participants  
We would like to invite you to take part in a research study. Before you decide 
you need to understand why the research is being done and what it would 
involve for you. Please take time to read the following information carefully and 
discuss it with others if you wish. The summary section briefly outlines the 
studies and the implications that taking part in it would have for you. Part 1 tells 
you the purpose of the study and what will happen to you if you take part in 
more detail. Part 2 gives you more detailed information about the conduct of the 
study. If you have any questions or would like more explanation, please ask. 
You can choose not to take part in the study. If you do decide to take part, you 
can change your mind at any time. Your decision will not affect the standard of 
care you receive in any way. 
SUMMARY 
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This study will answer important questions about how the vitamin folic acid is 
taken up by the body which are very relevant given government plans to add 
folic acid to food in the UK. The study is possible because in TIPSS patients we 
have the unique opportunity to take blood samples through the TIPSS from the 
portal vein. This will be done immediately after a normal TIPSS check 
venogram. If you are willing to participate in the study, and our tests suggest 
you are suitable, 3 things will happen to you over and above what would 
normally happen at a TIPSS check 
1) The tube used to check the TIPSS will not be removed immediately, 
instead it will be left in place for a maximum of 4 hours (after which it will 
be removed as normal) 
2) We will ask you to take a single dose of one of two types of folic acid 
(similar in dose to a normal supplement tablet but modified to have a 
safe “label” contained within it to allow us to measure it) 
3) Once you have taken the folic acid tablet we will take a series of small 
blood samples both from the tube into the TIPSS and from a vein to 
measure the levels of folic acid  
4) We will ask you if you wish to take part in a “cross over” study, with your 
next annual TIPSS check-up venogram. This would involve the same 
procedure as above but on this occasion you will be given another type 
of folic acid supplement again similar in dose to a normal supplement 
and modified to have a safe “label” contained within it to allow us to 
measure it. 
 
PART 1 
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What is this study about? 
There is a lot of information available now which suggests that increasing the 
amount of folic acid in our diet may have health benefits. These include 
reducing serious conditions in babies developing in the womb such as spina 
bifida.  It has also been suggested that folic acid may be helpful in reducing the 
risk of heart disease and stroke. Based on this information many people elect to 
increase the amount of folic acid in their diet through the use of vitamin 
supplements which are available in all UK pharmacies and supermarkets. Folic 
acid supplements are also recommended for all women trying to become 
pregnant and who are already pregnant in the UK. 
Given its health benefits the government is considering adding folic acid to flour 
in the UK meaning that anyone who eats bread (or any other type of food made 
from flour) will automatically receive an increased dose. A number of countries 
(including the USA and Canada) have already introduced folic acid “fortification” 
of flour and have seen significant reductions in conditions such as spina bifida. 
The plans to fortify flour with folic acid in the UK are, however, currently on hold. 
The reason for this is that concerns have emerged about some potential health 
risks associated with long term high level exposure to folic acid (as might 
happen in someone eating fortified flour in addition to an otherwise healthy diet 
and who was also taking folic acid containing vitamin supplements). Amongst 
the concerns is the possibility of an  increased risk of bowel cancer. One of the 
potential reasons for this may be that, unlike animals, humans appear to have 
only a limited capacity to metabolise folic acid meaning that too much in the diet 
may result in too much getting into the body. It is thought that in animals this 
risk of harm is prevented by folic acid being changed, partly by the bowel wall 
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and partly by the liver, into a modified form, with both components of this 
metabolism system having significant spare capacity. We already know that 
humans have much lower capacity to modify folic acid within the liver. Up until 
now, however, it has not been possible to study folic acid breakdown in the 
bowel wall.  Were humans to have a high capacity to modify folic acid in the 
bowel wall then this would provide significant reassurance about the benefits of 
folic acid fortification of food. In contrast, were humans to lack this capacity (as 
they lack it in the liver) it would raise concerns about the proposed policy 
because of its potential risk.  
Why have I been asked to take part? 
The reason why we have, until now, not been able to answer the question as to 
whether folic acid is modified by the bowel wall is that it is normally not possible 
to take blood samples from the portal vein (the blood vessel which takes blood 
from the bowel to the liver and which carries all the nutrients (including folic 
acid) to the liver). You are being asked to participate in this study because you 
are one of a small but unique group of people in whom, because you have a 
TIPSS in place, it is possible to take blood samples from the portal vein via the 
TIPSS at the time of a TIPSS-check procedure. 
Do I have to take part?     
It is up to you to decide. We will describe the study and go through this 
information sheet, which we will then give to you. We will then ask you to sign a 
consent form to show you have agreed to take part. You are free to withdraw at 
any time, without giving a reason. This would not affect the standard of care you 
receive. 
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What would it involve? 
First, the doctor will ask you some basic questions about your health, and make 
a note of your recent hospital blood tests.  If your answers suggest that you 
would be a suitable participant for the study, the first stage will involve a test to 
make sure that you absorb dietary contents normally. This will involve taking a 
urine (water) sample following an oral dose of two agents which are safe and 
widely used in medical practice (Lactulose and Mannitol) which shouldn’t be 
absorbed from the diet. If, based on this screening test, you are thought to be 
suitable then the test itself would involve taking some blood samples from the 
portal vein through the tube which is used to carry out a normal TIPSS check 
procedure (an x-ray procedure used to check whether the TIPSS remains open 
and which is one of the tests used to answer this question on an annual basis 
within the Freeman hospital in all TIPSS patients). We will also take blood 
samples from an arm vain trough a normal drip). Prior to the blood sampling you 
will be asked to take a single dose of either folic acid or a modified form of 
folate.  You will then be asked if you would like to take part in a repeat study 
with your next annual TIPSS check up. If you are happy to take part, then the 
procedure will be repeated using modified folate (if you were given folic acid in 
the first study) or folic acid (if you were given modified folate in the first study). 
Why will I be asked to have to have it repeated? 
We want to make sure that the differences we hope to see in the way the body 
changes folic acid is because of the inability of the bowel wall to do so rather 
than our own individual differences to do so. This can best be answered if were 
able to repeat the test with both folic acid and the modified folate and compare 
the results. 
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Do I have to take part in the repeat study? 
Again, it is up to you to decide. We will describe the repeat study and go 
through this information sheet again when we request your willingness to take 
part in the repeat study. We will then ask you to sign another consent form to 
show you have agreed to take part in the repeat study. You are free to withdraw 
at any time, without giving any reasons. This would not affect the standard of 
care you receive. 
Are there any risks associated with taking part? 
The study has been designed to make it as low risk as possible but there are 3 
things which you should consider.  
 
We will ask you to take a dose of folic acid. The folic acid dose we will be asking 
you to take is the same as would be present in a single folic acid supplement 
tablet available in all chemists and supermarkets in the UK and the folate dose 
would be the equivalent to single days green vegetables in somebody following 
the UK’s “five a day” recommendation for fruit and vegetables intake in the diet. 
The only difference between this folic acid and the type which you would buy in 
a supermarket is that it has been modified to include a harmless “label” which 
allows the tablet form to be identified in your blood. 
We will be taking blood samples. The total volume of blood which will be taken 
over the course of the 4 hour study will be approximately 30mls (this is 
equivalent to about 3 times the volume taken in a normal clinic visit for a TIPSS 
patient and about one tenth the volume that would be taken from a blood donor 
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in a single donation). Taking this amount of blood of blood over a period of 4 
hours is thought to be completely safe.    
In order to carry out the study we will need to leave the tube used to carry out 
the TIPSS check procedure in place for longer than would normally be the case 
(to allow us to take the blood samples) giving rise to theoretical risks of infection 
and clotting. The investigators will take the utmost care to keep this risk to a 
minimum. The approach of leaving the tube in place in the portal vein after a 
TIPSS check to allow blood sampling has been used safely before in the UK. At 
the end of the study the tube will be removed in the exactly the same way as 
would happen normally in the X-ray department. 
If you agree to repeat this study with your next annual TIPSS check up, you will 
be taking an extra dose of folic acid or folate. Taking an extra dose is again 
thought to be completely safe. The repeat study will be carried out in an entirely 
similar way to the first study as explained above.  
What will happen to the blood samples? 
The blood samples will be used to measure the level of folic acid and its 
modified forms.  The measurements will be performed at the University of 
Nottingham.  The samples will all be destroyed during the course of the study.  
If you decide to withdraw from the study following the taking of the blood 
samples but before the analysis the samples cannot be returned to you but can 
be destroyed at your request 
PART 2 
What will happen if I don’t want to carry on with the study? 
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You are free to withdraw from the study at any time and the blood samples 
obtained to that point destroyed. 
What will happen if I don’t want to carry on with the repeat study? 
You are free not to take part in the repeat study, or withdraw from the whole 
study at any time it and the blood samples obtained to that point will be 
destroyed. 
What if there is a problem? 
If you have a concern about any aspect of the this study you should ask to 
speak to the researchers (Professor David Jones and Dr Mark Hudson who can 
be contacted via 0191 233 6161) who will do their best to answer your 
questions. If you remain unhappy and wish to complain formally you can do this 
through the normal NHS complaints procedure. Details can be obtained form 
the hospital. In the event that something does go wrong and you are harmed 
during the research, and this is due to someone’s negligence, then you may 
have grounds for legal action for compensation against Newcastle-upon-Tyne 
NHS Foundation Trust who are sponsoring the study.  
Will my taking part in the study be kept confidential? 
If you join the study some parts of your medical records and the data collected 
for the study will be looked at by authorised persons from Newcastle University. 
They may also be looked at by representatives from the regulatory authorities 
and by authorised people to check that the study is being carried out correctly. 
All will have a duty of confidentiality to you as a research participant and we will 
do our best to meet this duty. Any information about you which leaves the 
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hospital will have your name and address removed so that you cannot be 
recognised. 
 
 
Who is organising and funding the research? 
The research will be sponsored by Newcastle-upon-Tyne NHS Foundation 
Trust and carried out by members of staff from this Trust and Newcastle 
University. The research is being funded by the Biotechnology and Biological 
Sciences Research Council (BBSRC), a UK government funded research 
council established to support scientific research. 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called 
a Research Ethics Committee, to protect your safety, rights wellbeing and 
dignity. This study has been reviewed and given a favourable opinion by 
Newcastle and North Tyneside 1 Research Ethics Committee. The research 
has also been independently reviewed by 4 outside experts on behalf of the 
BBSRC as part of its normal assessment process before deciding to pay for it. 
What if I have questions later? 
Please contact: 
Dr Mark Hudson or Professor David EJ Jones  
via the hospital switchboard (Tel 0191 2336161). 
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APPENDIX – SCREENING QUESTIONNAIRE 
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